Sch@@ iz@@ op@@ hr@@ en@@ ia - in a long term 5@@ 2-@@ week controlled trial , ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients had an over@@ all-@@ lower inci@@ dence ( 25.@@ 8 % ) of EP@@ S including par@@ kin@@ son@@ ism , ak@@ ath@@ is@@ ia , d@@ yst@@ onia and dy@@ sk@@ in@@ esia compared with those treated with hal@@ op@@ eri@@ do@@ l ( 5@@ 7.@@ 3 % ) .
In a long term 26@@ -@@ week plac@@ eb@@ o-@@ controlled trial , the inci@@ dence of EP@@ S was 19 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 13@@ .1 % for plac@@ eb@@ o-@@ treated patients .
In another long-term 26@@ -@@ week controlled trial , the inci@@ dence of EP@@ S was 14.@@ 8 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 15@@ .1 % for ol@@ anz@@ ap@@ ine-@@ treated patients .
Man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order - in a 12-@@ week controlled trial , the inci@@ dence of EP@@ S was 2@@ 3.5 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 5@@ 3.3 % for hal@@ op@@ eri@@ dol@@ -@@ treated patients .
In another 12-@@ week trial , the inci@@ dence of EP@@ S was 26.@@ 6 % for patients treated with ari@@ pip@@ ra@@ z@@ ole and 17.@@ 6 % for those treated with li@@ th@@ ium .
In the long term 26@@ -@@ week maintenance phase of a plac@@ eb@@ o-@@ controlled trial , the inci@@ dence of EP@@ S was 18.@@ 2 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 15.@@ 7 % for plac@@ eb@@ o-@@ treated patients .
In plac@@ eb@@ o-@@ controlled trials , the inci@@ dence of ak@@ ath@@ is@@ ia in bi@@ pol@@ ar patients was 12.@@ 1 % with ari@@ pip@@ ra@@ z@@ ole and 3.2 % with plac@@ eb@@ o .
In sch@@ iz@@ op@@ hr@@ en@@ ia patients the inci@@ dence of ak@@ ath@@ is@@ ia was 6.2 % with ari@@ pip@@ ra@@ z@@ ole and 3.0 % with plac@@ eb@@ o .
Compar@@ is@@ ons between ari@@ pip@@ ra@@ z@@ ole and plac@@ eb@@ o in the propor@@ tions of patients experiencing potentially clin@@ ically significant changes in routine laboratory parameters revealed no medi@@ cally important differences .
Elev@@ ations of CP@@ K ( Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ ase ) , generally transi@@ ent and asy@@ mpt@@ omati@@ c , were observed in 3.5 % of ari@@ pip@@ ra@@ z@@ ole treated patients as compared to 2.0 % of patients who received plac@@ eb@@ o .
Other findings :
Un@@ des@@ irable effects known to be associated with anti@@ psycho@@ tic therapy and also reported during treatment with ari@@ pip@@ ra@@ z@@ ole include neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ drome , tar@@ dive dy@@ sk@@ in@@ esia , sei@@ z@@ ure , cer@@ eb@@ rov@@ as@@ cular ad@@ verse events and increased mort@@ ality in elderly dem@@ ented patients , hyper@@ gly@@ ca@@ emia and diabetes mel@@ lit@@ us ( see section 4.4 ) .
Po@@ st-@@ Marketing :
The following ad@@ verse events have been reported during post-@@ marketing surveillance .
The frequency of these events is considered not known ( cannot be estimated from the available data ) .
Inves@@ tig@@ ations :
increased Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ ase , blood glu@@ c@@ ose increased , blood glu@@ c@@ ose flu@@ c@@ tu@@ ation , gly@@ cos@@ yl@@ ated ha@@ em@@ og@@ lob@@ in increased
Cardi@@ ac disorders :
Q@@ T pro@@ long@@ ation , v@@ entri@@ cular ar@@ rhyth@@ mi@@ as , sudden un@@ explained death , cardi@@ ac arrest , tor@@ sa@@ des de poin@@ tes , bra@@ dy@@ car@@ dia
Blood and the ly@@ m@@ ph@@ atic system disorders :
leu@@ kop@@ en@@ ia , neut@@ rop@@ en@@ ia , thro@@ mbo@@ cy@@ top@@ en@@ ia
63 N@@ erv@@ ous system disorders :
speech dis@@ order , Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome ( N@@ MS ) , grand mal conv@@ ul@@ sion
Resp@@ ir@@ atory , thor@@ ac@@ ic and medi@@ ast@@ inal disorders :
or@@ op@@ har@@ yn@@ ge@@ al sp@@ as@@ m , lar@@ yn@@ g@@ osp@@ as@@ m , asp@@ ir@@ ation pneum@@ onia
Gast@@ ro@@ int@@ est@@ inal disorders :
pan@@ cre@@ ati@@ tis , dy@@ sph@@ ag@@ ia , ab@@ dom@@ inal dis@@ comfort , stomach dis@@ comfort , di@@ ar@@ r@@ ho@@ ea
Ren@@ al and ur@@ inary disorders :
ur@@ inary in@@ contin@@ ence , ur@@ inary re@@ tention
Skin and sub@@ cut@@ aneous tissue disorders :
r@@ ash , phot@@ os@@ ensi@@ tivity reaction , al@@ op@@ eci@@ a , hyper@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ etal and connec@@ tive tissue disorders :
r@@ hab@@ dom@@ y@@ oly@@ sis , my@@ al@@ gia , sti@@ ff@@ ness
En@@ doc@@ r@@ ine disorders :
hyper@@ gly@@ ca@@ emia , diabetes mel@@ lit@@ us , di@@ ab@@ etic k@@ eto@@ aci@@ do@@ sis , di@@ ab@@ etic hyper@@ os@@ mol@@ ar com@@ a
Met@@ aboli@@ sm and nutrition disorders :
weight gain , weight decreased , an@@ or@@ ex@@ ia , h@@ yp@@ on@@ at@@ rem@@ ia
Vas@@ cular disorders :
syn@@ cope , hyper@@ tension , thro@@ mbo@@ em@@ bo@@ lic events
General disorders and administration site conditions :
temperature regulation dis@@ order ( e. g. hypo@@ ther@@ m@@ ia , py@@ re@@ x@@ ia ) , chest pain , periph@@ eral o@@ e@@ de@@ ma
Im@@ m@@ une system disorders :
aller@@ gic reaction ( e. g. an@@ ap@@ hy@@ lac@@ tic reaction , an@@ gi@@ o@@ e@@ de@@ ma including sw@@ ollen tongue , tongue o@@ e@@ de@@ ma , face o@@ e@@ de@@ ma , pr@@ ur@@ it@@ us , or ur@@ tic@@ aria )
H@@ ep@@ at@@ o@@ bili@@ ary disorders :
j@@ a@@ un@@ dice , h@@ ep@@ ati@@ tis , increased Al@@ an@@ ine Amin@@ ot@@ ran@@ s@@ fer@@ ase ( AL@@ T ) , increased A@@ spart@@ ate Amin@@ ot@@ ran@@ s@@ fer@@ ase ( AS@@ T ) , increased G@@ amma Gl@@ ut@@ am@@ yl Transfer@@ ase ( G@@ GT ) , increased al@@ kal@@ ine phosph@@ at@@ ase
Re@@ productive system and breast disorders :
pri@@ ap@@ ism
Psych@@ iat@@ ric disorders :
ag@@ itation , ner@@ v@@ ousness ; suicide attempt , su@@ ic@@ id@@ al ide@@ ation , and completed suicide ( see section 4.4 )
4.@@ 9 Over@@ dose
In clinical trials and post-@@ marketing experience , acci@@ dental or inten@@ tional ac@@ ute over@@ dos@@ age of ari@@ pip@@ ra@@ z@@ ole alone was identified in adult patients with reported estimated d@@ oses up to 1,@@ 260 mg with no fat@@ alities .
The potentially medi@@ cally important signs and symptoms observed included le@@ th@@ ar@@ gy , increased blood pressure , som@@ n@@ ol@@ ence , t@@ ach@@ y@@ car@@ dia , nau@@ sea , v@@ om@@ iting and di@@ ar@@ r@@ ho@@ ea .
In addition , reports of acci@@ dental over@@ dose with ari@@ pip@@ ra@@ z@@ ole alone ( up to 195 mg ) in children have been received with no fat@@ alities .
The potentially medi@@ cally serious signs and symptoms reported included som@@ n@@ ol@@ ence , transi@@ ent loss of consciousness and extra@@ py@@ ram@@ id@@ al symptoms .
Management of over@@ dose should concentrate on sup@@ por@@ tive therapy , maintaining an adequate air@@ way , oxy@@ gen@@ ation and ventil@@ ation , and management of symptoms .
The possibility of multiple medic@@ inal product involvement should be considered .
Therefore cardi@@ ov@@ as@@ cular monitoring should be started immediately and should include continuous electro@@ cardi@@ ographic monitoring to detect possible ar@@ rhyth@@ mi@@ as .
Following any confirmed or susp@@ ected over@@ dose with ari@@ pip@@ ra@@ z@@ ole , close medical supervision and monitoring should continue until the patient re@@ covers .
64 Activ@@ ated char@@ coal ( 50 g ) , administ@@ ered one hour after ari@@ pip@@ ra@@ z@@ ole , decreased ari@@ pip@@ ra@@ z@@ ole C@@ max by about 41 % and AU@@ C by about 51 % , suggest@@ ing that char@@ coal may be effective in the treatment of over@@ dose .
Although there is no information on the effect of ha@@ emo@@ di@@ aly@@ sis in tre@@ ating an over@@ dose with ari@@ pip@@ ra@@ z@@ ole , ha@@ emo@@ di@@ aly@@ sis is un@@ likely to be useful in over@@ dose management since ari@@ pip@@ ra@@ z@@ ole is highly bound to plas@@ ma proteins .
5 .
PH@@ AR@@ MA@@ CO@@ LO@@ G@@ IC@@ AL PRO@@ PER@@ TI@@ ES
5.1 Ph@@ armac@@ o@@ dynamic properties
Ph@@ armac@@ o@@ therapeutic group : anti@@ psycho@@ tics , AT@@ C code :
N@@ 05@@ AX@@ 12
It has been proposed that ari@@ pip@@ ra@@ z@@ ole ’ s eff@@ ic@@ acy in sch@@ iz@@ op@@ hr@@ en@@ ia and Bi@@ pol@@ ar I Dis@@ order is medi@@ ated through a combination of partial agon@@ ism at d@@ op@@ am@@ ine D@@ 2 and ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ a rec@@ ept@@ ors and ant@@ agon@@ ism of ser@@ ot@@ on@@ in 5@@ HT@@ 2@@ a rec@@ ept@@ ors .
A@@ rip@@ ip@@ ra@@ z@@ ole exhib@@ ited ant@@ agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ ergi@@ c hyper@@ activity and agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ ergi@@ c hypo@@ activity .
A@@ rip@@ ip@@ ra@@ z@@ ole exhib@@ ited high binding aff@@ inity in vit@@ ro for d@@ op@@ am@@ ine D@@ 2 and D@@ 3 , ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ a and 5@@ HT@@ 2@@ a rec@@ ept@@ ors and moderate aff@@ inity for d@@ op@@ am@@ ine D@@ 4 , ser@@ ot@@ on@@ in 5@@ HT@@ 2@@ c and 5@@ HT@@ 7 , alp@@ ha@@ -1 ad@@ ren@@ ergi@@ c and hist@@ am@@ ine H@@ 1 rec@@ ept@@ ors .
A@@ rip@@ ip@@ ra@@ z@@ ole also exhib@@ ited moderate binding aff@@ inity for the ser@@ ot@@ on@@ in re@@ up@@ take site and no appreci@@ able aff@@ inity for mus@@ car@@ in@@ ic rec@@ ept@@ ors .
Inter@@ action with rec@@ ept@@ ors other than d@@ op@@ am@@ ine and ser@@ ot@@ on@@ in sub@@ types may explain some of the other clinical effects of ari@@ pip@@ ra@@ z@@ ole .
A@@ rip@@ ip@@ ra@@ z@@ ole d@@ oses ranging from 0.5 to 30 mg administ@@ ered once a day to healthy subjects for 2 weeks produced a dos@@ e-@@ dependent reduction in the binding of 11@@ C-@@ rac@@ lo@@ pride , a D@@ 2 / D@@ 3 recep@@ tor lig@@ and , to the cau@@ date and put@@ amen detected by pos@@ it@@ ron emission tom@@ ography .
Further information on clinical trials :
Sch@@ iz@@ op@@ hr@@ en@@ ia :
In three short-@@ term ( 4 to 6 weeks ) plac@@ eb@@ o-@@ controlled trials involving 1,@@ 2@@ 28 sch@@ iz@@ op@@ hr@@ en@@ ic patients , presenting with positive or negative symptoms , ari@@ pip@@ ra@@ z@@ ole was associated with statisti@@ cally significantly greater improvements in psycho@@ tic symptoms compared to plac@@ eb@@ o .
AB@@ IL@@ IF@@ Y is effective in maintaining the clinical improvement during continu@@ ation therapy in patients who have shown an initial treatment response .
In a hal@@ op@@ eri@@ dol@@ -@@ controlled trial , the proportion of respon@@ der patients maintaining response to medic@@ inal product at 5@@ 2-@@ weeks was similar in both groups ( ari@@ pip@@ ra@@ z@@ ole 77 % and hal@@ op@@ eri@@ do@@ l 73 % ) .
The overall completion rate was significantly higher for patients on ari@@ pip@@ ra@@ z@@ ole ( 43 % ) than for hal@@ op@@ eri@@ do@@ l ( 30 % ) .
Ac@@ tual scores in rating sc@@ ales used as secondary end@@ points , including P@@ AN@@ SS and the Mont@@ g@@ om@@ er@@ y-@@ As@@ berg Depression Rating Sc@@ ale showed a significant improvement over hal@@ op@@ eri@@ do@@ l .
In a 26@@ -@@ week , plac@@ eb@@ o-@@ controlled trial in stabili@@ sed patients with chronic sch@@ iz@@ op@@ hr@@ en@@ ia , ari@@ pip@@ ra@@ z@@ ole had significantly greater reduction in rel@@ ap@@ se rate , 34 % in ari@@ pip@@ ra@@ z@@ ole group and 57 % in plac@@ eb@@ o .
Weight gain : in clinical trials ari@@ pip@@ ra@@ z@@ ole has not been shown to in@@ duce clin@@ ically relevant weight gain .
In a 26@@ -@@ week , ol@@ anz@@ ap@@ ine-@@ controlled , double-@@ blind , multi-@@ national study of sch@@ iz@@ op@@ hr@@ en@@ ia which included 3@@ 14 patients and where the primary end-@@ point was weight gain , significantly less patients had at least 7 % weight gain over bas@@ eline ( i@@ . e. a gain of at least 5.@@ 6 kg for a mean bas@@ eline weight of ~ 8@@ 0.5 kg ) on ari@@ pip@@ ra@@ z@@ ole ( N = 18 , or 13 % of evalu@@ able patients ) , compared to ol@@ anz@@ ap@@ ine ( N = 45 , or 33 % of evalu@@ able patients ) .
Man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order :
In two 3-@@ week , flexi@@ b@@ le-@@ dose , plac@@ eb@@ o-@@ controlled mon@@ o@@ therapy trials involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , ari@@ pip@@ ra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to plac@@ eb@@ o in
These trials included patients with or without psycho@@ tic features and with or without a rap@@ id-@@ cycling course .
In one 3-@@ week , fix@@ ed-@@ dose , plac@@ eb@@ o-@@ controlled mon@@ o@@ therapy trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , ari@@ pip@@ ra@@ z@@ ole failed to demonstrate superior eff@@ ic@@ acy to plac@@ eb@@ o .
In two 12-@@ week , plac@@ ebo@@ - and activ@@ e-@@ controlled mon@@ o@@ therapy trials in patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , with or without psycho@@ tic features , ari@@ pip@@ ra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to plac@@ eb@@ o at week 3 and a maintenance of effect comparable to li@@ th@@ ium or hal@@ op@@ eri@@ do@@ l at week 12 .
A@@ rip@@ ip@@ ra@@ z@@ ole also demonstrated a comparable proportion of patients in sympt@@ omati@@ c re@@ mission from man@@ ia as li@@ th@@ ium or hal@@ op@@ eri@@ do@@ l at week 12 .
In a 6-@@ week , plac@@ eb@@ o-@@ controlled trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , with or without psycho@@ tic features , who were partially non-@@ respon@@ sive to li@@ th@@ ium or val@@ pro@@ ate mon@@ o@@ therapy for 2 weeks at therapeutic ser@@ um levels , the addition of ari@@ pip@@ ra@@ z@@ ole as adj@@ unc@@ tive therapy resulted in superior eff@@ ic@@ acy in reduction of man@@ ic symptoms than li@@ th@@ ium or val@@ pro@@ ate mon@@ o@@ therapy .
In a 26@@ -@@ week , plac@@ eb@@ o-@@ controlled trial , followed by a 7@@ 4-@@ week extension , in man@@ ic patients who achieved re@@ mission on ari@@ pip@@ ra@@ z@@ ole during a stabili@@ zation phase prior to random@@ ization , ari@@ pip@@ ra@@ z@@ ole demonstrated su@@ peri@@ ority over plac@@ eb@@ o in preventing bi@@ pol@@ ar rec@@ ur@@ r@@ ence , primarily in preventing rec@@ ur@@ r@@ ence into man@@ ia but failed to demonstrate su@@ peri@@ ority over plac@@ eb@@ o in preventing rec@@ ur@@ r@@ ence into depression .
5.2 Ph@@ armac@@ ok@@ ine@@ tic properties
A@@ rip@@ ip@@ ra@@ z@@ ole or@@ o@@ disp@@ er@@ sible tablet is bio@@ equivalent to ari@@ pip@@ ra@@ z@@ ole tablets , with a similar rate and extent of absor@@ ption .
A@@ rip@@ ip@@ ra@@ z@@ ole or@@ o@@ disp@@ er@@ sible tablets may be used as an alternative to ari@@ pip@@ ra@@ z@@ ole tablets .
Ab@@ sor@@ ption :
A@@ rip@@ ip@@ ra@@ z@@ ole is well absor@@ bed , with peak plas@@ ma concentr@@ ations occurr@@ ing within 3-5 hours after d@@ osing .
A@@ rip@@ ip@@ ra@@ z@@ ole under@@ goes minimal pre-@@ system@@ ic metabolism .
The absolute oral bio@@ availability of the tablet form@@ ulation is 87 % .
There is no effect of a high fat meal on the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole .
Distribution :
A@@ rip@@ ip@@ ra@@ z@@ ole is widely distributed throughout the body with an apparent volume of distribution of 4.@@ 9 l / kg , indic@@ ating extensive ex@@ trav@@ as@@ cular distribution .
At therapeutic concentr@@ ations , ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole are greater than 99 % bound to ser@@ um proteins , binding primarily to alb@@ um@@ in .
Met@@ aboli@@ sm :
A@@ rip@@ ip@@ ra@@ z@@ ole is exten@@ sively metaboli@@ sed by the liver primarily by three bi@@ ot@@ ran@@ s@@ formation path@@ ways : de@@ hydro@@ gen@@ ation , hydro@@ x@@ yl@@ ation , and N-@@ deal@@ k@@ yl@@ ation .
Based on in vit@@ ro studies , C@@ Y@@ P@@ 3@@ A4 and C@@ Y@@ P@@ 2@@ D@@ 6 enz@@ y@@ mes are responsible for de@@ hydro@@ gen@@ ation and hydro@@ x@@ yl@@ ation of ari@@ pip@@ ra@@ z@@ ole , and N-@@ deal@@ k@@ yl@@ ation is cat@@ aly@@ sed by C@@ Y@@ P@@ 3@@ A4 .
A@@ rip@@ ip@@ ra@@ z@@ ole is the pre@@ dominant medic@@ inal product mo@@ i@@ ety in system@@ ic circulation .
At ste@@ ady state , de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole , the active metaboli@@ te , represents about 40 % of ari@@ pip@@ ra@@ z@@ ole AU@@ C in plas@@ ma .
Eli@@ min@@ ation :
The mean elim@@ ination half-@@ lives for ari@@ pip@@ ra@@ z@@ ole are approximately 75 hours in extensive metaboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 and approximately 14@@ 6 hours in poor metaboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 .
The total body clear@@ ance of ari@@ pip@@ ra@@ z@@ ole is 0.@@ 7 ml / min / kg , which is primarily h@@ ep@@ atic .
Following a single oral dose of &#91; 14@@ C &#93; -@@ lab@@ elled ari@@ pip@@ ra@@ z@@ ole , approximately 27 % of the administ@@ ered radio@@ activity was recovered in the ur@@ ine and approximately 60 % in the fa@@ eces .
Less than 1 % of un@@ changed ari@@ pip@@ ra@@ z@@ ole was ex@@ cre@@ ted in the ur@@ ine and approximately 18 % was recovered un@@ changed in the fa@@ eces .
66 Ph@@ armac@@ ok@@ ine@@ tics in special patient groups
El@@ derly :
There are no differences in the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole between healthy elderly and younger adult subjects , nor is there any det@@ ec@@ table effect of age in a population ph@@ armac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hr@@ en@@ ic patients .
Gender :
There are no differences in the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole between healthy male and female subjects nor is there any det@@ ec@@ table effect of gender in a population ph@@ armac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hr@@ en@@ ic patients .
Smoking and Race :
Population ph@@ armac@@ ok@@ ine@@ tic evaluation has revealed no evidence of clin@@ ically significant rac@@ e-@@ related differences or effects from smoking upon the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole .
Ren@@ al Dis@@ ease :
The ph@@ armac@@ ok@@ ine@@ tic characteristics of ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole were found to be similar in patients with severe ren@@ al disease compared to young healthy subjects .
H@@ ep@@ atic Dis@@ ease :
A single-@@ dose study in subjects with var@@ ying degrees of liver cir@@ r@@ ho@@ sis ( Chil@@ d-@@ Pu@@ gh Cl@@ asses A , B , and C ) did not reveal a significant effect of h@@ ep@@ atic imp@@ air@@ ment on the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole , but the study included only 3 patients with Class C liver cir@@ r@@ ho@@ sis , which is in@@ sufficient to draw conclusions on their metaboli@@ c capacity .
5.@@ 3 Prec@@ lin@@ ical safety data
Non-@@ clinical safety data revealed no special haz@@ ard for humans based on conventional studies of safety ph@@ armac@@ ology , repe@@ at-@@ dose tox@@ ic@@ ity , gen@@ ot@@ ox@@ ic@@ ity , car@@ cin@@ ogen@@ ic potential , and tox@@ ic@@ ity to reproduction .
To@@ x@@ ic@@ ologically significant effects were observed only at d@@ oses or expos@@ ures that were sufficiently in excess of the maximum human dose or exposure , indic@@ ating that these effects were limited or of no relev@@ ance to clinical use .
These included : dos@@ e-@@ dependent ad@@ ren@@ oc@@ or@@ tical tox@@ ic@@ ity ( li@@ po@@ f@@ us@@ c@@ in pig@@ ment accum@@ ulation and / or par@@ ench@@ y@@ mal cell loss ) in rats after 104 weeks at 20 to 60 mg / kg / day ( 3 to 10 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended human dose ) and increased ad@@ ren@@ oc@@ or@@ tical car@@ cin@@ omas and combined ad@@ ren@@ oc@@ or@@ tical aden@@ omas / car@@ cin@@ omas in female rats at 60 mg / kg / day ( 10 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended human dose ) .
The highest n@@ ont@@ um@@ orig@@ en@@ ic exposure in female rats was 7 times the human exposure at the recommended dose .
An additional finding was chol@@ eli@@ thi@@ asis as a consequence of precipitation of sul@@ ph@@ ate con@@ jug@@ ates of hydro@@ xy metaboli@@ tes of ari@@ pip@@ ra@@ z@@ ole in the b@@ ile of mon@@ keys after repeated oral d@@ osing at 25 to 125 mg / kg / day ( 1 to 3 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg / m2 ) .
However , the concentr@@ ations of the sul@@ ph@@ ate con@@ jug@@ ates of hydro@@ xy ari@@ pip@@ ra@@ z@@ ole in human b@@ ile at the highest dose proposed , 30 mg per day , were no more than 6 % of the b@@ ile concentr@@ ations found in the mon@@ keys in the 3@@ 9-@@ week study and are well below ( 6 % ) their limits of in vit@@ ro sol@@ u@@ bility .
Based on results of a full range of standard gen@@ ot@@ ox@@ ic@@ ity tests , ari@@ pip@@ ra@@ z@@ ole was considered non-@@ gen@@ ot@@ ox@@ ic .
A@@ rip@@ ip@@ ra@@ z@@ ole did not imp@@ air fer@@ tility in re@@ productive tox@@ ic@@ ity studies .
Develop@@ mental tox@@ ic@@ ity , including dos@@ e-@@ dependent del@@ ayed fo@@ etal ossi@@ fication and possible ter@@ at@@ ogen@@ ic effects , were observed in rats at d@@ oses resulting in sub@@ therapeutic expos@@ ures ( based on AU@@ C ) and in rab@@ bits at d@@ oses resulting in expos@@ ures 3 and 11 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended clinical dose .
Mat@@ ern@@ al tox@@ ic@@ ity occurred at d@@ oses similar to those el@@ ic@@ iting develop@@ mental tox@@ ic@@ ity .
67 6 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL P@@ ART@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
Cal@@ cium si@@ lic@@ ate Cro@@ sc@@ arm@@ ell@@ ose so@@ dium Cro@@ spo@@ vi@@ done Sili@@ con dioxide X@@ y@@ li@@ to@@ l Micro@@ cryst@@ all@@ ine cell@@ ul@@ ose A@@ spart@@ ame ( E@@ 9@@ 51 ) Ac@@ es@@ ul@@ f@@ ame pot@@ assi@@ um Van@@ illa flav@@ our ( including van@@ ill@@ in and eth@@ yl van@@ ill@@ in ) T@@ art@@ ari@@ c acid Magn@@ esium st@@ ear@@ ate
Yellow iron oxide ( E@@ 17@@ 2 )
6.2 In@@ compati@@ bilities
Not applicable .
6.@@ 3 Shel@@ f life
3 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store in the original package in order to protect from moisture .
6.5 Nature and contents of container
Cart@@ on of 14 x 1 tablets in col@@ d-@@ formed aluminium per@@ for@@ ated unit dose bli@@ sters .
Cart@@ on of 28 x 1 tablets in col@@ d-@@ formed aluminium per@@ for@@ ated unit dose bli@@ sters .
Cart@@ on of 49 x 1 tablets in col@@ d-@@ formed aluminium per@@ for@@ ated unit dose bli@@ sters .
Not all pack sizes may be mark@@ eted .
6.@@ 6 Special prec@@ au@@ tions for disposal and other handling
Any un@@ used product or waste material should be dispos@@ ed of in accordance with local requirements .
7 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
8 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION N@@ UM@@ BER ( S )
EU / 1 / 04 / 27@@ 6 / 0@@ 2@@ 7-@@ 0@@ 29
9 .
D@@ ATE OF F@@ IR@@ ST AU@@ TH@@ OR@@ IS@@ ATION / R@@ EN@@ EW@@ AL OF THE AU@@ TH@@ OR@@ IS@@ ATION
68 Date of first author@@ isation :
4 June 2004
10 .
D@@ ATE OF RE@@ V@@ IS@@ ION OF THE TE@@ XT
{ M@@ M / Y@@ Y@@ Y@@ Y }
Detailed information on this product is available on the website of the European Medic@@ ines Agency ( EM@@ EA ) http : / / ww@@ w. em@@ e@@ a. europ@@ a. eu /
69 1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 30 mg or@@ o@@ disp@@ er@@ sible tablets
2 .
QU@@ AL@@ IT@@ AT@@ IVE AND QU@@ AN@@ T@@ IT@@ AT@@ IVE COMP@@ OS@@ IT@@ ION
Each or@@ o@@ disp@@ er@@ sible tablet contains 30 mg of ari@@ pip@@ ra@@ z@@ ole .
Ex@@ cip@@ i@@ ent :
6 mg as@@ part@@ ame ( E@@ 9@@ 51 ) per or@@ o@@ disp@@ er@@ sible tablet
For a full list of ex@@ cip@@ i@@ ents , see section 6.@@ 1 .
3 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL FOR@@ M
O@@ ro@@ disp@@ er@@ sible tablet Round and pink , marked with &quot; A &quot; over &quot; 6@@ 43 &quot; on one side and &quot; 30 &quot; on the other .
4 .
CL@@ IN@@ IC@@ AL P@@ ART@@ IC@@ UL@@ AR@@ S
4.1 Therap@@ eu@@ tic indic@@ ations
AB@@ IL@@ IF@@ Y is indicated for the treatment of sch@@ iz@@ op@@ hr@@ en@@ ia .
AB@@ IL@@ IF@@ Y is indicated for the treatment of moderate to severe man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order and for the prevention of a new man@@ ic episode in patients who experienced pre@@ domin@@ antly man@@ ic episodes and whose man@@ ic episodes responded to ari@@ pip@@ ra@@ z@@ ole treatment ( see section 5.1 ) .
4.2 Pos@@ ology and method of administration
Or@@ al use .
Sch@@ iz@@ op@@ hr@@ en@@ ia :
The recommended starting dose for AB@@ IL@@ IF@@ Y is 10 or 15 mg / day with a maintenance dose of 15 mg / day administ@@ ered on a on@@ ce-@@ a-@@ day schedule without regard to meals .
AB@@ IL@@ IF@@ Y is effective in a dose range of 10 to 30 mg / day .
Enh@@ anced eff@@ ic@@ acy at d@@ oses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose .
The maximum daily dose should not exceed 30 mg .
Man@@ ic episodes :
The recommended starting dose for AB@@ IL@@ IF@@ Y is 15 mg administ@@ ered on a on@@ ce-@@ a-@@ day schedule without regard to meals as mon@@ o@@ therapy or combination therapy ( see section 5.1 ) .
Some patients may benefit from a higher dose .
The maximum daily dose should not exceed 30 mg .
Rec@@ ur@@ r@@ ence prevention of man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order :
For preventing rec@@ ur@@ r@@ ence of man@@ ic episodes in patients who have been receiving ari@@ pip@@ ra@@ z@@ ole , continue therapy at the same dose .
Ad@@ just@@ ments of daily dos@@ age , including dose reduction should be considered on the basis of clinical status .
The or@@ o@@ disp@@ er@@ sible tablet should be placed in the mouth on the tongue , where it will rapidly disp@@ er@@ se in s@@ ali@@ va .
It can be taken with or without liquid .
Rem@@ oval of the int@@ act or@@ o@@ disp@@ er@@ sible tablet from the mouth is difficult .
Since the or@@ o@@ disp@@ er@@ sible tablet is frag@@ ile , it should be taken immediately on opening the bli@@ ster .
Altern@@ atively , disp@@ er@@ se the tablet in water and drink the resulting suspension .
70 The or@@ o@@ disp@@ er@@ sible tablets may be used as an alternative to AB@@ IL@@ IF@@ Y tablets for patients who have difficulty to swal@@ low AB@@ IL@@ IF@@ Y tablets ( see also section 5.2 ) .
Children and ad@@ ol@@ esc@@ ents : there is no experience in children and ad@@ ol@@ esc@@ ents under 18 years of age .
Pati@@ ents with h@@ ep@@ atic imp@@ air@@ ment : no dos@@ age adjustment is required for patients with mild to moderate h@@ ep@@ atic imp@@ air@@ ment .
In patients with severe h@@ ep@@ atic imp@@ air@@ ment , the data available are in@@ sufficient to establish recommendations .
In these patients d@@ osing should be managed cau@@ ti@@ ously .
However , the maximum daily dose of 30 mg should be used with cau@@ tion in patients with severe h@@ ep@@ atic imp@@ air@@ ment ( see section 5.2 ) .
Pati@@ ents with ren@@ al imp@@ air@@ ment : no dos@@ age adjustment is required in patients with ren@@ al imp@@ air@@ ment .
El@@ derly : the effectiveness of AB@@ IL@@ IF@@ Y in the treatment of sch@@ iz@@ op@@ hr@@ en@@ ia and Bi@@ pol@@ ar I Dis@@ order in patients 65 years of age or older has not been established .
O@@ wing to the greater sensitivity of this population , a lower starting dose should be considered when clinical factors war@@ rant ( see section 4.4 ) .
Gender : no dos@@ age adjustment is required for female patients as compared to male patients ( see section 5.2 ) .
Smoking status : according to the metaboli@@ c path@@ way of ari@@ pip@@ ra@@ z@@ ole no dos@@ age adjustment is required for smo@@ kers ( see section 4.5 ) .
When con@@ com@@ it@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hib@@ itors with ari@@ pip@@ ra@@ z@@ ole occurs , the ari@@ pip@@ ra@@ z@@ ole dose should be reduced .
When the C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hib@@ itor is with@@ drawn from the combination therapy , ari@@ pip@@ ra@@ z@@ ole dose should then be increased ( see section 4.5 ) .
When con@@ com@@ it@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers with ari@@ pip@@ ra@@ z@@ ole occurs , the ari@@ pip@@ ra@@ z@@ ole dose should be increased .
When the C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ er is with@@ drawn from the combination therapy , the ari@@ pip@@ ra@@ z@@ ole dose should then be reduced to the recommended dose ( see section 4.5 ) .
4.3 Con@@ tra@@ indic@@ ations
Hyper@@ sensitivity to the active substance or to any of the ex@@ cip@@ i@@ ents .
4.4 Special war@@ nings and prec@@ au@@ tions for use
During anti@@ psycho@@ tic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
Pati@@ ents should be closely monitored throughout this period .
The occurr@@ ence of su@@ ic@@ id@@ al behaviour is inher@@ ent in psycho@@ tic ill@@ nesses and mood disorders and in some cases has been reported early after initi@@ ation or switch of anti@@ psycho@@ tic therapy , including treatment with ari@@ pip@@ ra@@ z@@ ole ( see section 4.@@ 8 ) .
Close supervision of high-@@ risk patients should accompany anti@@ psycho@@ tic therapy .
Results of an epide@@ mi@@ ological study found that there was no increased risk of su@@ ic@@ id@@ ality with ari@@ pip@@ ra@@ z@@ ole compared to other anti@@ psycho@@ tics among patients with bi@@ pol@@ ar dis@@ order .
Cardi@@ ov@@ as@@ cular disorders :
A@@ rip@@ ip@@ ra@@ z@@ ole should be used with cau@@ tion in patients with known cardi@@ ov@@ as@@ cular disease ( history of my@@ oc@@ ardi@@ al inf@@ ar@@ ction or isch@@ a@@ em@@ ic heart disease , heart failure , or conduc@@ tion ab@@ norm@@ alities ) , cer@@ eb@@ rov@@ as@@ cular disease , conditions which would pre@@ disp@@ ose patients to h@@ yp@@ ot@@ en@@ sion ( de@@ hydr@@ ation , hypo@@ vol@@ emia , and treatment with anti@@ hyper@@ ten@@ sive medic@@ ations ) or hyper@@ tension , including acceler@@ ated or mal@@ ign@@ ant .
Con@@ duction ab@@ norm@@ alities :
In clinical trials of ari@@ pip@@ ra@@ z@@ ole , the inci@@ dence of Q@@ T pro@@ long@@ ation was comparable to plac@@ eb@@ o .
As with other anti@@ psycho@@ tics , ari@@ pip@@ ra@@ z@@ ole should be used with cau@@ tion in patients with a family history of Q@@ T pro@@ long@@ ation .
71 Tar@@ dive Dy@@ sk@@ in@@ esia : in clinical trials of one year or less duration , there were un@@ common reports of treatment emerg@@ ent dy@@ sk@@ in@@ esia during treatment with ari@@ pip@@ ra@@ z@@ ole .
If signs and symptoms of tar@@ dive dy@@ sk@@ in@@ esia appear in a patient on AB@@ IL@@ IF@@ Y , dose reduction or dis@@ continu@@ ation should be considered .
These symptoms can tempor@@ ally deteri@@ or@@ ate or can even arise after dis@@ continu@@ ation of treatment .
Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome ( N@@ MS ) :
N@@ MS is a potentially fat@@ al sy@@ mp@@ tom complex associated with anti@@ psycho@@ tic medic@@ inal products .
In clinical trials , rare cases of N@@ MS were reported during treatment with ari@@ pip@@ ra@@ z@@ ole .
Clin@@ ical manifest@@ ations of N@@ MS are hyper@@ py@@ re@@ x@@ ia , muscle rigi@@ dity , alter@@ ed mental status and evidence of autonom@@ ic inst@@ ability ( ir@@ regular pul@@ se or blood pressure , t@@ ach@@ y@@ car@@ dia , di@@ ap@@ hor@@ esis and cardi@@ ac d@@ ys@@ rhyth@@ m@@ ia ) .
Additional signs may include elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase , my@@ og@@ lo@@ bin@@ ur@@ ia ( r@@ hab@@ dom@@ y@@ oly@@ sis ) , and ac@@ ute ren@@ al failure .
However , elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase and r@@ hab@@ dom@@ y@@ oly@@ sis , not necessarily in association with N@@ MS , have also been reported .
If a patient develops signs and symptoms indic@@ ative of N@@ MS , or presents with un@@ explained high f@@ ever without additional clinical manifest@@ ations of N@@ MS , all anti@@ psycho@@ tic medic@@ inal products , including AB@@ IL@@ IF@@ Y , must be dis@@ continued .
Sei@@ z@@ ure : in clinical trials , un@@ common cases of sei@@ z@@ ure were reported during treatment with ari@@ pip@@ ra@@ z@@ ole .
Therefore , ari@@ pip@@ ra@@ z@@ ole should be used with cau@@ tion in patients who have a history of sei@@ z@@ ure dis@@ order or have conditions associated with sei@@ zur@@ es .
El@@ derly patients with de@@ men@@ ti@@ a-@@ related psycho@@ sis :
Incre@@ ased mort@@ ality : in three plac@@ eb@@ o-@@ controlled trials ( n = 9@@ 38 ; mean age :
8@@ 2.4 years ; range :
5@@ 6-@@ 99 years ) of ari@@ pip@@ ra@@ z@@ ole in elderly patients with psycho@@ sis associated with Alz@@ heimer &apos;s disease , patients treated with ari@@ pip@@ ra@@ z@@ ole were at increased risk of death compared to plac@@ eb@@ o .
The rate of death in ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients was 3.5 % compared to 1.7 % in the plac@@ eb@@ o group .
Although the causes of deaths were varied , most of the deaths appeared to be either cardi@@ ov@@ as@@ cular ( e. g. heart failure , sudden death ) or inf@@ ec@@ tious ( e. g. pneum@@ onia ) in nature .
Cer@@ eb@@ rov@@ as@@ cular ad@@ verse events : in the same trials , cer@@ eb@@ rov@@ as@@ cular ad@@ verse events ( e. g. stroke , transi@@ ent isch@@ a@@ em@@ ic attack ) , including fat@@ alities , were reported in patients ( mean age :
84 years ; range :
7@@ 8-@@ 88 years ) .
Overall , 1.3 % of ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients reported cer@@ eb@@ rov@@ as@@ cular ad@@ verse events compared with 0.@@ 6 % of plac@@ eb@@ o-@@ treated patients in these trials .
This difference was not statisti@@ cally significant .
However , in one of these trials , a fix@@ ed-@@ dose trial , there was a significant dose response relationship for cer@@ eb@@ rov@@ as@@ cular ad@@ verse events in patients treated with ari@@ pip@@ ra@@ z@@ ole .
AB@@ IL@@ IF@@ Y is not approved for the treatment of de@@ men@@ ti@@ a-@@ related psycho@@ sis .
Hyper@@ gly@@ ca@@ emia and Diabetes M@@ elli@@ tus : hyper@@ gly@@ ca@@ emia , in some cases extreme and associated with k@@ eto@@ aci@@ do@@ sis or hyper@@ os@@ mol@@ ar com@@ a or death , has been reported in patients treated with at@@ yp@@ ical anti@@ psycho@@ tic agents , including AB@@ IL@@ IF@@ Y .
Risk factors that may pre@@ disp@@ ose patients to severe complic@@ ations include o@@ bes@@ ity and family history of diabetes .
In clinical trials with ari@@ pip@@ ra@@ z@@ ole , there were no significant differences in the inci@@ dence rates of hyper@@ gly@@ ca@@ em@@ i@@ a-@@ related ad@@ verse events ( including diabetes ) or in ab@@ normal gly@@ ca@@ emia laboratory values compared to plac@@ eb@@ o .
Prec@@ ise risk estimates for hyper@@ gly@@ ca@@ em@@ i@@ a-@@ related ad@@ verse events in patients treated with AB@@ IL@@ IF@@ Y and with other at@@ yp@@ ical anti@@ psycho@@ tic agents are not available to allow direct comparis@@ ons .
Pati@@ ents treated with any anti@@ psycho@@ tic agents , including AB@@ IL@@ IF@@ Y , should be observed for signs and symptoms of hyper@@ gly@@ ca@@ emia ( such as poly@@ di@@ p@@ sia , poly@@ ur@@ ia , poly@@ ph@@ ag@@ ia and weak@@ ness ) and patients with diabetes mel@@ lit@@ us or with risk factors for diabetes mel@@ lit@@ us should be monitored regularly for wor@@ sen@@ ing of glu@@ c@@ ose control .
Weight gain : weight gain is commonly seen in sch@@ iz@@ op@@ hr@@ en@@ ic and bi@@ pol@@ ar man@@ ia patients due to co@@ - mor@@ bi@@ di@@ ties , use of anti@@ psycho@@ tics known to cause weight gain , poor@@ ly managed life-@@ style , and might lead to severe complic@@ ations .
Weight gain has been reported post-@@ marketing among patients prescri@@ bed AB@@ IL@@ IF@@ Y .
When seen , it is usually in those with significant risk factors such as history of diabetes , th@@ y@@ ro@@ id dis@@ order or p@@ itu@@ itary aden@@ oma .
In clinical trials ari@@ pip@@ ra@@ z@@ ole has not been shown to in@@ duce clin@@ ically relevant weight gain ( see section 5.1 ) .
72 Dy@@ sph@@ ag@@ ia : o@@ es@@ op@@ ha@@ ge@@ al d@@ ys@@ mo@@ tility and asp@@ ir@@ ation have been associated with anti@@ psycho@@ tic drug use , including AB@@ IL@@ IF@@ Y .
A@@ rip@@ ip@@ ra@@ z@@ ole and other anti@@ psycho@@ tic drugs should be used cau@@ ti@@ ously in patients at risk for asp@@ ir@@ ation pneum@@ onia .
Ph@@ en@@ yl@@ k@@ et@@ on@@ ur@@ ics :
AB@@ IL@@ IF@@ Y or@@ o@@ disp@@ er@@ sible tablets contain as@@ part@@ ame , a source of phen@@ yl@@ al@@ an@@ ine which may be harmful for people with phen@@ yl@@ k@@ et@@ on@@ ur@@ ia .
Hyper@@ sensitivity : as with other medic@@ ations hyper@@ sensitivity reactions , characterised by aller@@ gic symptoms , may occur with ari@@ pip@@ ra@@ z@@ ole ( see section 4.@@ 8 ) .
4.5 Inter@@ action with other medic@@ inal products and other forms of interaction
Due to its α 1-@@ ad@@ ren@@ ergi@@ c recep@@ tor ant@@ agon@@ ism , ari@@ pip@@ ra@@ z@@ ole has the potential to enhance the effect of certain anti@@ hyper@@ ten@@ sive agents .
Given the primary CN@@ S effects of ari@@ pip@@ ra@@ z@@ ole , cau@@ tion should be used when ari@@ pip@@ ra@@ z@@ ole is taken in combination with alcohol or other CN@@ S medic@@ inal products with over@@ l@@ apping undes@@ irable effects such as se@@ dation ( see section 4.@@ 8 ) .
If ari@@ pip@@ ra@@ z@@ ole is administ@@ ered con@@ com@@ it@@ antly with medicines known to cause Q@@ T pro@@ long@@ ation or elec@@ trol@@ yte im@@ balance , cau@@ tion should be used .
Potential for other medic@@ inal products to affect AB@@ IL@@ IF@@ Y :
A ga@@ stri@@ c acid blo@@ cker , the H@@ 2 ant@@ agon@@ ist fam@@ oti@@ d@@ ine , reduces ari@@ pip@@ ra@@ z@@ ole rate of absor@@ ption but this effect is deemed not clin@@ ically relevant .
A@@ rip@@ ip@@ ra@@ z@@ ole is metaboli@@ sed by multiple path@@ ways involving the C@@ Y@@ P@@ 2@@ D@@ 6 and C@@ Y@@ P@@ 3@@ A4 enz@@ y@@ mes but not C@@ Y@@ P@@ 1@@ A enz@@ y@@ mes .
Thus , no dos@@ age adjustment is required for smo@@ kers .
In a clinical trial in healthy subjects , a pot@@ ent in@@ hib@@ itor of C@@ Y@@ P@@ 2@@ D@@ 6 ( qu@@ in@@ id@@ ine ) increased ari@@ pip@@ ra@@ z@@ ole AU@@ C by 107 % , while C@@ max was un@@ changed .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole , the active metaboli@@ te , decreased by 32 % and 47 % .
AB@@ IL@@ IF@@ Y dose should be reduced to approximately one-@@ half of its prescri@@ bed dose when con@@ com@@ it@@ ant administration of AB@@ IL@@ IF@@ Y with qu@@ in@@ id@@ ine occurs .
Other pot@@ ent in@@ hib@@ itors of C@@ Y@@ P@@ 2@@ D@@ 6 , such as flu@@ ox@@ et@@ ine and par@@ ox@@ et@@ ine , may be expected to have similar effects and similar dose reduc@@ tions should therefore be applied .
In a clinical trial in healthy subjects , a pot@@ ent in@@ hib@@ itor of C@@ Y@@ P@@ 3@@ A4 ( k@@ eto@@ con@@ az@@ ole ) increased ari@@ pip@@ ra@@ z@@ ole AU@@ C and C@@ max by 63 % and 37 % , respectively .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole increased by 77 % and 43 % , respectively .
In C@@ Y@@ P@@ 2@@ D@@ 6 poor metaboli@@ sers , con@@ com@@ it@@ ant use of pot@@ ent in@@ hib@@ itors of C@@ Y@@ P@@ 3@@ A4 may result in higher plas@@ ma concentr@@ ations of ari@@ pip@@ ra@@ z@@ ole compared to that in C@@ Y@@ P@@ 2@@ D@@ 6 extensive metaboli@@ z@@ ers .
When considering con@@ com@@ it@@ ant administration of k@@ eto@@ con@@ az@@ ole or other pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hib@@ itors with AB@@ IL@@ IF@@ Y , potential benefits should out@@ wei@@ gh the potential risks to the patient .
When con@@ com@@ it@@ ant administration of k@@ eto@@ con@@ o@@ z@@ ole with AB@@ IL@@ IF@@ Y occurs , AB@@ IL@@ IF@@ Y dose should be reduced to approximately one-@@ half of its prescri@@ bed dose .
Other pot@@ ent in@@ hib@@ itors of C@@ Y@@ P@@ 3@@ A4 , such as it@@ ra@@ con@@ az@@ ole and HIV pro@@ tease in@@ hib@@ itors , may be expected to have similar effects and similar dose reduc@@ tions should therefore be applied .
Upon dis@@ continu@@ ation of the C@@ Y@@ P@@ 2@@ D@@ 6 or 3@@ A4 in@@ hib@@ itor , the dos@@ age of AB@@ IL@@ IF@@ Y should be increased to the level prior to the initi@@ ation of the con@@ com@@ it@@ ant therapy .
When weak in@@ hib@@ itors of C@@ Y@@ P@@ 3@@ A4 ( e. g . , dil@@ ti@@ az@@ em or esc@@ it@@ al@@ op@@ ram ) or C@@ Y@@ P@@ 2@@ D@@ 6 are used con@@ com@@ it@@ antly with AB@@ IL@@ IF@@ Y , mod@@ est increases in ari@@ pip@@ ra@@ z@@ ole concentr@@ ations might be expected .
Following con@@ com@@ it@@ ant administration of carb@@ amaz@@ ep@@ ine , a pot@@ ent in@@ duc@@ er of C@@ Y@@ P@@ 3@@ A4 , the geomet@@ ric means of C@@ max and AU@@ C for ari@@ pip@@ ra@@ z@@ ole were 68 % and 73 % lower , respectively , compared to when ari@@ pip@@ ra@@ z@@ ole ( 30 mg ) was administ@@ ered alone .
Simil@@ arly , for de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole the geomet@@ ric means
73 of C@@ max and AU@@ C after carb@@ amaz@@ ep@@ ine co-@@ administration were 69 % and 71 % lower , respectively , than those following treatment with ari@@ pip@@ ra@@ z@@ ole alone .
AB@@ IL@@ IF@@ Y dose should be dou@@ bled when con@@ com@@ it@@ ant administration of AB@@ IL@@ IF@@ Y occurs with carb@@ amaz@@ ep@@ ine .
John &apos;s Wort ) may be expected to have similar effects and similar dose increases should therefore be applied .
Upon dis@@ continu@@ ation of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers , the dos@@ age of AB@@ IL@@ IF@@ Y should be reduced to the recommended dose .
When either val@@ pro@@ ate or li@@ th@@ ium were administ@@ ered con@@ com@@ it@@ antly with ari@@ pip@@ ra@@ z@@ ole , there was no clin@@ ically significant change in ari@@ pip@@ ra@@ z@@ ole concentr@@ ations .
Potential for AB@@ IL@@ IF@@ Y to affect other medic@@ inal products :
In clinical studies , 10-@@ 30 mg / day d@@ oses of ari@@ pip@@ ra@@ z@@ ole had no significant effect on the metabolism of sub@@ str@@ ates of C@@ Y@@ P@@ 2@@ D@@ 6 ( de@@ x@@ tro@@ meth@@ orph@@ an / 3-@@ metho@@ xy@@ mor@@ ph@@ in@@ an ratio ) , 2@@ C@@ 9 ( war@@ far@@ in ) , 2@@ C@@ 19 ( om@@ ep@@ ra@@ z@@ ole ) , and 3@@ A4 ( de@@ x@@ tro@@ meth@@ orph@@ an ) .
Additionally , ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole did not show potential for alter@@ ing C@@ Y@@ P@@ 1@@ A@@ 2-@@ medi@@ ated metabolism in vit@@ ro .
Thus , ari@@ pip@@ ra@@ z@@ ole is un@@ likely to cause clin@@ ically important medic@@ inal product inter@@ actions medi@@ ated by these enz@@ y@@ mes .
When ari@@ pip@@ ra@@ z@@ ole was administ@@ ered con@@ com@@ it@@ antly with either val@@ pro@@ ate or li@@ th@@ ium , there was no clin@@ ically important change in val@@ pro@@ ate or li@@ th@@ ium concentr@@ ations .
4.@@ 6 Pre@@ gn@@ ancy and lac@@ tation
There are no adequate and well-@@ controlled trials of ari@@ pip@@ ra@@ z@@ ole in pregnant women .
Animal studies could not exclu@@ de potential develop@@ mental tox@@ ic@@ ity ( see section 5.@@ 3 ) .
Pati@@ ents should be advised to noti@@ fy their physi@@ cian if they become pregnant or intend to become pregnant during treatment with ari@@ pip@@ ra@@ z@@ ole .
Due to in@@ sufficient safety information in humans and concerns raised by animal re@@ productive studies , this medic@@ inal product should not be used in pregnancy unless the expected benefit clearly justi@@ fies the potential risk to the fo@@ etus .
A@@ rip@@ ip@@ ra@@ z@@ ole was ex@@ cre@@ ted in the milk of treated rats during lac@@ tation .
Pati@@ ents should be advised not to breast feed if they are taking ari@@ pip@@ ra@@ z@@ ole .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No studies on the effect on the ability to drive and use machines have been performed .
However , as with other anti@@ psycho@@ tics , patients should be cau@@ tioned about operating haz@@ ard@@ ous machines , including motor vehicles , until they are reason@@ ably certain that ari@@ pip@@ ra@@ z@@ ole does not affect them ad@@ ver@@ sely .
4.@@ 8 Un@@ des@@ irable effects
The following undes@@ irable effects occurred more often ( ≥ 1 / 100 ) than plac@@ eb@@ o , or were identified as possibly medi@@ cally relevant ad@@ verse reactions ( * ) :
The frequency listed below is defined using the following convention : common ( &gt; 1 / 100 , &lt; 1 / 10 ) and un@@ common ( &gt; 1 / 1 , 000 , &lt; 1 / 100 ) .
74 Cardi@@ ac disorders Un@@ common : t@@ ach@@ y@@ car@@ dia * N@@ erv@@ ous System disorders Common : extra@@ py@@ ram@@ id@@ al dis@@ order , ak@@ ath@@ is@@ ia , tre@@ m@@ or , di@@ zz@@ iness , som@@ n@@ ol@@ ence , se@@ dation , head@@ ache Eye disorders Common : bl@@ urred vision Gast@@ ro@@ int@@ est@@ inal disorders Common : dy@@ sp@@ ep@@ sia , v@@ om@@ iting , nau@@ sea , con@@ sti@@ p@@ ation , s@@ ali@@ vary hy@@ persec@@ re@@ tion Vas@@ cular disorders Un@@ common : or@@ tho@@ static h@@ yp@@ ot@@ en@@ sion * General disorders and administration site conditions Common : f@@ ati@@ gue Psych@@ iat@@ ric disorders Common : rest@@ less@@ ness , in@@ som@@ nia , an@@ xi@@ ety Un@@ common : depression *
Extra@@ py@@ ram@@ id@@ al symptoms ( EP@@ S ) :
Sch@@ iz@@ op@@ hr@@ en@@ ia - in a long term 5@@ 2-@@ week controlled trial , ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients had an over@@ all-@@ lower inci@@ dence ( 25.@@ 8 % ) of EP@@ S including par@@ kin@@ son@@ ism , ak@@ ath@@ is@@ ia , d@@ yst@@ onia and dy@@ sk@@ in@@ esia compared with those treated with hal@@ op@@ eri@@ do@@ l ( 5@@ 7.@@ 3 % ) .
In a long term 26@@ -@@ week plac@@ eb@@ o-@@ controlled trial , the inci@@ dence of EP@@ S was 19 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 13@@ .1 % for plac@@ eb@@ o-@@ treated patients .
In another long-term 26@@ -@@ week controlled trial , the inci@@ dence of EP@@ S was 14.@@ 8 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 15@@ .1 % for ol@@ anz@@ ap@@ ine-@@ treated patients .
Man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order - in a 12-@@ week controlled trial , the inci@@ dence of EP@@ S was 2@@ 3.5 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 5@@ 3.3 % for hal@@ op@@ eri@@ dol@@ -@@ treated patients .
In another 12-@@ week trial , the inci@@ dence of EP@@ S was 26.@@ 6 % for patients treated with ari@@ pip@@ ra@@ z@@ ole and 17.@@ 6 % for those treated with li@@ th@@ ium .
In the long term 26@@ -@@ week maintenance phase of a plac@@ eb@@ o-@@ controlled trial , the inci@@ dence of EP@@ S was 18.@@ 2 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 15.@@ 7 % for plac@@ eb@@ o-@@ treated patients .
In plac@@ eb@@ o-@@ controlled trials , the inci@@ dence of ak@@ ath@@ is@@ ia in bi@@ pol@@ ar patients was 12.@@ 1 % with ari@@ pip@@ ra@@ z@@ ole and 3.2 % with plac@@ eb@@ o .
In sch@@ iz@@ op@@ hr@@ en@@ ia patients the inci@@ dence of ak@@ ath@@ is@@ ia was 6.2 % with ari@@ pip@@ ra@@ z@@ ole and 3.0 % with plac@@ eb@@ o .
Compar@@ is@@ ons between ari@@ pip@@ ra@@ z@@ ole and plac@@ eb@@ o in the propor@@ tions of patients experiencing potentially clin@@ ically significant changes in routine laboratory parameters revealed no medi@@ cally important differences .
Elev@@ ations of CP@@ K ( Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ ase ) , generally transi@@ ent and asy@@ mpt@@ omati@@ c , were observed in 3.5 % of ari@@ pip@@ ra@@ z@@ ole treated patients as compared to 2.0 % of patients who received plac@@ eb@@ o .
Other findings :
Un@@ des@@ irable effects known to be associated with anti@@ psycho@@ tic therapy and also reported during treatment with ari@@ pip@@ ra@@ z@@ ole include neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ drome , tar@@ dive dy@@ sk@@ in@@ esia , sei@@ z@@ ure , cer@@ eb@@ rov@@ as@@ cular ad@@ verse events and increased mort@@ ality in elderly dem@@ ented patients , hyper@@ gly@@ ca@@ emia and diabetes mel@@ lit@@ us ( see section 4.4 ) .
Po@@ st-@@ Marketing :
The following ad@@ verse events have been reported during post-@@ marketing surveillance .
The frequency of these events is considered not known ( cannot be estimated from the available data ) .
Inves@@ tig@@ ations :
increased Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ ase , blood glu@@ c@@ ose increased , blood glu@@ c@@ ose flu@@ c@@ tu@@ ation , gly@@ cos@@ yl@@ ated ha@@ em@@ og@@ lob@@ in increased
Cardi@@ ac disorders :
Q@@ T pro@@ long@@ ation , v@@ entri@@ cular ar@@ rhyth@@ mi@@ as , sudden un@@ explained death , cardi@@ ac arrest , tor@@ sa@@ des de poin@@ tes , bra@@ dy@@ car@@ dia
Blood and the ly@@ m@@ ph@@ atic system disorders :
leu@@ kop@@ en@@ ia , neut@@ rop@@ en@@ ia , thro@@ mbo@@ cy@@ top@@ en@@ ia
75 N@@ erv@@ ous system disorders :
speech dis@@ order , Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome ( N@@ MS ) , grand mal conv@@ ul@@ sion
Resp@@ ir@@ atory , thor@@ ac@@ ic and medi@@ ast@@ inal disorders :
or@@ op@@ har@@ yn@@ ge@@ al sp@@ as@@ m , lar@@ yn@@ g@@ osp@@ as@@ m , asp@@ ir@@ ation pneum@@ onia
Gast@@ ro@@ int@@ est@@ inal disorders :
pan@@ cre@@ ati@@ tis , dy@@ sph@@ ag@@ ia , ab@@ dom@@ inal dis@@ comfort , stomach dis@@ comfort , di@@ ar@@ r@@ ho@@ ea
Ren@@ al and ur@@ inary disorders :
ur@@ inary in@@ contin@@ ence , ur@@ inary re@@ tention
Skin and sub@@ cut@@ aneous tissue disorders :
r@@ ash , phot@@ os@@ ensi@@ tivity reaction , al@@ op@@ eci@@ a , hyper@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ etal and connec@@ tive tissue disorders :
r@@ hab@@ dom@@ y@@ oly@@ sis , my@@ al@@ gia , sti@@ ff@@ ness
En@@ doc@@ r@@ ine disorders :
hyper@@ gly@@ ca@@ emia , diabetes mel@@ lit@@ us , di@@ ab@@ etic k@@ eto@@ aci@@ do@@ sis , di@@ ab@@ etic hyper@@ os@@ mol@@ ar com@@ a
Met@@ aboli@@ sm and nutrition disorders :
weight gain , weight decreased , an@@ or@@ ex@@ ia , h@@ yp@@ on@@ at@@ rem@@ ia
Vas@@ cular disorders :
syn@@ cope , hyper@@ tension , thro@@ mbo@@ em@@ bo@@ lic events
General disorders and administration site conditions :
temperature regulation dis@@ order ( e. g. hypo@@ ther@@ m@@ ia , py@@ re@@ x@@ ia ) , chest pain , periph@@ eral o@@ e@@ de@@ ma
Im@@ m@@ une system disorders :
aller@@ gic reaction ( e. g. an@@ ap@@ hy@@ lac@@ tic reaction , an@@ gi@@ o@@ e@@ de@@ ma including sw@@ ollen tongue , tongue o@@ e@@ de@@ ma , face o@@ e@@ de@@ ma , pr@@ ur@@ it@@ us , or ur@@ tic@@ aria )
H@@ ep@@ at@@ o@@ bili@@ ary disorders :
j@@ a@@ un@@ dice , h@@ ep@@ ati@@ tis , increased Al@@ an@@ ine Amin@@ ot@@ ran@@ s@@ fer@@ ase ( AL@@ T ) , increased A@@ spart@@ ate Amin@@ ot@@ ran@@ s@@ fer@@ ase ( AS@@ T ) , increased G@@ amma Gl@@ ut@@ am@@ yl Transfer@@ ase ( G@@ GT ) , increased al@@ kal@@ ine phosph@@ at@@ ase
Re@@ productive system and breast disorders :
pri@@ ap@@ ism
Psych@@ iat@@ ric disorders :
ag@@ itation , ner@@ v@@ ousness ; suicide attempt , su@@ ic@@ id@@ al ide@@ ation , and completed suicide ( see section 4.4 )
4.@@ 9 Over@@ dose
In clinical trials and post-@@ marketing experience , acci@@ dental or inten@@ tional ac@@ ute over@@ dos@@ age of ari@@ pip@@ ra@@ z@@ ole alone was identified in adult patients with reported estimated d@@ oses up to 1,@@ 260 mg with no fat@@ alities .
The potentially medi@@ cally important signs and symptoms observed included le@@ th@@ ar@@ gy , increased blood pressure , som@@ n@@ ol@@ ence , t@@ ach@@ y@@ car@@ dia , nau@@ sea , v@@ om@@ iting and di@@ ar@@ r@@ ho@@ ea .
In addition , reports of acci@@ dental over@@ dose with ari@@ pip@@ ra@@ z@@ ole alone ( up to 195 mg ) in children have been received with no fat@@ alities .
The potentially medi@@ cally serious signs and symptoms reported included som@@ n@@ ol@@ ence , transi@@ ent loss of consciousness and extra@@ py@@ ram@@ id@@ al symptoms .
Management of over@@ dose should concentrate on sup@@ por@@ tive therapy , maintaining an adequate air@@ way , oxy@@ gen@@ ation and ventil@@ ation , and management of symptoms .
The possibility of multiple medic@@ inal product involvement should be considered .
Therefore cardi@@ ov@@ as@@ cular monitoring should be started immediately and should include continuous electro@@ cardi@@ ographic monitoring to detect possible ar@@ rhyth@@ mi@@ as .
Following any confirmed or susp@@ ected over@@ dose with ari@@ pip@@ ra@@ z@@ ole , close medical supervision and monitoring should continue until the patient re@@ covers .
76 Activ@@ ated char@@ coal ( 50 g ) , administ@@ ered one hour after ari@@ pip@@ ra@@ z@@ ole , decreased ari@@ pip@@ ra@@ z@@ ole C@@ max by about 41 % and AU@@ C by about 51 % , suggest@@ ing that char@@ coal may be effective in the treatment of over@@ dose .
Although there is no information on the effect of ha@@ emo@@ di@@ aly@@ sis in tre@@ ating an over@@ dose with ari@@ pip@@ ra@@ z@@ ole , ha@@ emo@@ di@@ aly@@ sis is un@@ likely to be useful in over@@ dose management since ari@@ pip@@ ra@@ z@@ ole is highly bound to plas@@ ma proteins .
5 .
PH@@ AR@@ MA@@ CO@@ LO@@ G@@ IC@@ AL PRO@@ PER@@ TI@@ ES
5.1 Ph@@ armac@@ o@@ dynamic properties
Ph@@ armac@@ o@@ therapeutic group : anti@@ psycho@@ tics , AT@@ C code :
N@@ 05@@ AX@@ 12
It has been proposed that ari@@ pip@@ ra@@ z@@ ole ’ s eff@@ ic@@ acy in sch@@ iz@@ op@@ hr@@ en@@ ia and Bi@@ pol@@ ar I Dis@@ order is medi@@ ated through a combination of partial agon@@ ism at d@@ op@@ am@@ ine D@@ 2 and ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ a rec@@ ept@@ ors and ant@@ agon@@ ism of ser@@ ot@@ on@@ in 5@@ HT@@ 2@@ a rec@@ ept@@ ors .
A@@ rip@@ ip@@ ra@@ z@@ ole exhib@@ ited ant@@ agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ ergi@@ c hyper@@ activity and agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ ergi@@ c hypo@@ activity .
A@@ rip@@ ip@@ ra@@ z@@ ole exhib@@ ited high binding aff@@ inity in vit@@ ro for d@@ op@@ am@@ ine D@@ 2 and D@@ 3 , ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ a and 5@@ HT@@ 2@@ a rec@@ ept@@ ors and moderate aff@@ inity for d@@ op@@ am@@ ine D@@ 4 , ser@@ ot@@ on@@ in 5@@ HT@@ 2@@ c and 5@@ HT@@ 7 , alp@@ ha@@ -1 ad@@ ren@@ ergi@@ c and hist@@ am@@ ine H@@ 1 rec@@ ept@@ ors .
A@@ rip@@ ip@@ ra@@ z@@ ole also exhib@@ ited moderate binding aff@@ inity for the ser@@ ot@@ on@@ in re@@ up@@ take site and no appreci@@ able aff@@ inity for mus@@ car@@ in@@ ic rec@@ ept@@ ors .
Inter@@ action with rec@@ ept@@ ors other than d@@ op@@ am@@ ine and ser@@ ot@@ on@@ in sub@@ types may explain some of the other clinical effects of ari@@ pip@@ ra@@ z@@ ole .
A@@ rip@@ ip@@ ra@@ z@@ ole d@@ oses ranging from 0.5 to 30 mg administ@@ ered once a day to healthy subjects for 2 weeks produced a dos@@ e-@@ dependent reduction in the binding of 11@@ C-@@ rac@@ lo@@ pride , a D@@ 2 / D@@ 3 recep@@ tor lig@@ and , to the cau@@ date and put@@ amen detected by pos@@ it@@ ron emission tom@@ ography .
Further information on clinical trials :
Sch@@ iz@@ op@@ hr@@ en@@ ia :
In three short-@@ term ( 4 to 6 weeks ) plac@@ eb@@ o-@@ controlled trials involving 1,@@ 2@@ 28 sch@@ iz@@ op@@ hr@@ en@@ ic patients , presenting with positive or negative symptoms , ari@@ pip@@ ra@@ z@@ ole was associated with statisti@@ cally significantly greater improvements in psycho@@ tic symptoms compared to plac@@ eb@@ o .
AB@@ IL@@ IF@@ Y is effective in maintaining the clinical improvement during continu@@ ation therapy in patients who have shown an initial treatment response .
In a hal@@ op@@ eri@@ dol@@ -@@ controlled trial , the proportion of respon@@ der patients maintaining response to medic@@ inal product at 5@@ 2-@@ weeks was similar in both groups ( ari@@ pip@@ ra@@ z@@ ole 77 % and hal@@ op@@ eri@@ do@@ l 73 % ) .
The overall completion rate was significantly higher for patients on ari@@ pip@@ ra@@ z@@ ole ( 43 % ) than for hal@@ op@@ eri@@ do@@ l ( 30 % ) .
Ac@@ tual scores in rating sc@@ ales used as secondary end@@ points , including P@@ AN@@ SS and the Mont@@ g@@ om@@ er@@ y-@@ As@@ berg Depression Rating Sc@@ ale showed a significant improvement over hal@@ op@@ eri@@ do@@ l .
In a 26@@ -@@ week , plac@@ eb@@ o-@@ controlled trial in stabili@@ sed patients with chronic sch@@ iz@@ op@@ hr@@ en@@ ia , ari@@ pip@@ ra@@ z@@ ole had significantly greater reduction in rel@@ ap@@ se rate , 34 % in ari@@ pip@@ ra@@ z@@ ole group and 57 % in plac@@ eb@@ o .
Weight gain : in clinical trials ari@@ pip@@ ra@@ z@@ ole has not been shown to in@@ duce clin@@ ically relevant weight gain .
In a 26@@ -@@ week , ol@@ anz@@ ap@@ ine-@@ controlled , double-@@ blind , multi-@@ national study of sch@@ iz@@ op@@ hr@@ en@@ ia which included 3@@ 14 patients and where the primary end-@@ point was weight gain , significantly less patients had at least 7 % weight gain over bas@@ eline ( i@@ . e. a gain of at least 5.@@ 6 kg for a mean bas@@ eline weight of ~ 8@@ 0.5 kg ) on ari@@ pip@@ ra@@ z@@ ole ( N = 18 , or 13 % of evalu@@ able patients ) , compared to ol@@ anz@@ ap@@ ine ( N = 45 , or 33 % of evalu@@ able patients ) .
Man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order :
In two 3-@@ week , flexi@@ b@@ le-@@ dose , plac@@ eb@@ o-@@ controlled mon@@ o@@ therapy trials involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , ari@@ pip@@ ra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to plac@@ eb@@ o in
These trials included patients with or without psycho@@ tic features and with or without a rap@@ id-@@ cycling course .
In one 3-@@ week , fix@@ ed-@@ dose , plac@@ eb@@ o-@@ controlled mon@@ o@@ therapy trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , ari@@ pip@@ ra@@ z@@ ole failed to demonstrate superior eff@@ ic@@ acy to plac@@ eb@@ o .
In two 12-@@ week , plac@@ ebo@@ - and activ@@ e-@@ controlled mon@@ o@@ therapy trials in patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , with or without psycho@@ tic features , ari@@ pip@@ ra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to plac@@ eb@@ o at week 3 and a maintenance of effect comparable to li@@ th@@ ium or hal@@ op@@ eri@@ do@@ l at week 12 .
A@@ rip@@ ip@@ ra@@ z@@ ole also demonstrated a comparable proportion of patients in sympt@@ omati@@ c re@@ mission from man@@ ia as li@@ th@@ ium or hal@@ op@@ eri@@ do@@ l at week 12 .
In a 6-@@ week , plac@@ eb@@ o-@@ controlled trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , with or without psycho@@ tic features , who were partially non-@@ respon@@ sive to li@@ th@@ ium or val@@ pro@@ ate mon@@ o@@ therapy for 2 weeks at therapeutic ser@@ um levels , the addition of ari@@ pip@@ ra@@ z@@ ole as adj@@ unc@@ tive therapy resulted in superior eff@@ ic@@ acy in reduction of man@@ ic symptoms than li@@ th@@ ium or val@@ pro@@ ate mon@@ o@@ therapy .
In a 26@@ -@@ week , plac@@ eb@@ o-@@ controlled trial , followed by a 7@@ 4-@@ week extension , in man@@ ic patients who achieved re@@ mission on ari@@ pip@@ ra@@ z@@ ole during a stabili@@ zation phase prior to random@@ ization , ari@@ pip@@ ra@@ z@@ ole demonstrated su@@ peri@@ ority over plac@@ eb@@ o in preventing bi@@ pol@@ ar rec@@ ur@@ r@@ ence , primarily in preventing rec@@ ur@@ r@@ ence into man@@ ia but failed to demonstrate su@@ peri@@ ority over plac@@ eb@@ o in preventing rec@@ ur@@ r@@ ence into depression .
5.2 Ph@@ armac@@ ok@@ ine@@ tic properties
A@@ rip@@ ip@@ ra@@ z@@ ole or@@ o@@ disp@@ er@@ sible tablet is bio@@ equivalent to ari@@ pip@@ ra@@ z@@ ole tablets , with a similar rate and extent of absor@@ ption .
A@@ rip@@ ip@@ ra@@ z@@ ole or@@ o@@ disp@@ er@@ sible tablets may be used as an alternative to ari@@ pip@@ ra@@ z@@ ole tablets .
Ab@@ sor@@ ption :
A@@ rip@@ ip@@ ra@@ z@@ ole is well absor@@ bed , with peak plas@@ ma concentr@@ ations occurr@@ ing within 3-5 hours after d@@ osing .
A@@ rip@@ ip@@ ra@@ z@@ ole under@@ goes minimal pre-@@ system@@ ic metabolism .
The absolute oral bio@@ availability of the tablet form@@ ulation is 87 % .
There is no effect of a high fat meal on the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole .
Distribution :
A@@ rip@@ ip@@ ra@@ z@@ ole is widely distributed throughout the body with an apparent volume of distribution of 4.@@ 9 l / kg , indic@@ ating extensive ex@@ trav@@ as@@ cular distribution .
At therapeutic concentr@@ ations , ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole are greater than 99 % bound to ser@@ um proteins , binding primarily to alb@@ um@@ in .
Met@@ aboli@@ sm :
A@@ rip@@ ip@@ ra@@ z@@ ole is exten@@ sively metaboli@@ sed by the liver primarily by three bi@@ ot@@ ran@@ s@@ formation path@@ ways : de@@ hydro@@ gen@@ ation , hydro@@ x@@ yl@@ ation , and N-@@ deal@@ k@@ yl@@ ation .
Based on in vit@@ ro studies , C@@ Y@@ P@@ 3@@ A4 and C@@ Y@@ P@@ 2@@ D@@ 6 enz@@ y@@ mes are responsible for de@@ hydro@@ gen@@ ation and hydro@@ x@@ yl@@ ation of ari@@ pip@@ ra@@ z@@ ole , and N-@@ deal@@ k@@ yl@@ ation is cat@@ aly@@ sed by C@@ Y@@ P@@ 3@@ A4 .
A@@ rip@@ ip@@ ra@@ z@@ ole is the pre@@ dominant medic@@ inal product mo@@ i@@ ety in system@@ ic circulation .
At ste@@ ady state , de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole , the active metaboli@@ te , represents about 40 % of ari@@ pip@@ ra@@ z@@ ole AU@@ C in plas@@ ma .
Eli@@ min@@ ation :
The mean elim@@ ination half-@@ lives for ari@@ pip@@ ra@@ z@@ ole are approximately 75 hours in extensive metaboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 and approximately 14@@ 6 hours in poor metaboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 .
The total body clear@@ ance of ari@@ pip@@ ra@@ z@@ ole is 0.@@ 7 ml / min / kg , which is primarily h@@ ep@@ atic .
Following a single oral dose of &#91; 14@@ C &#93; -@@ lab@@ elled ari@@ pip@@ ra@@ z@@ ole , approximately 27 % of the administ@@ ered radio@@ activity was recovered in the ur@@ ine and approximately 60 % in the fa@@ eces .
Less than 1 % of un@@ changed ari@@ pip@@ ra@@ z@@ ole was ex@@ cre@@ ted in the ur@@ ine and approximately 18 % was recovered un@@ changed in the fa@@ eces .
78 Ph@@ armac@@ ok@@ ine@@ tics in special patient groups
El@@ derly :
There are no differences in the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole between healthy elderly and younger adult subjects , nor is there any det@@ ec@@ table effect of age in a population ph@@ armac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hr@@ en@@ ic patients .
Gender :
There are no differences in the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole between healthy male and female subjects nor is there any det@@ ec@@ table effect of gender in a population ph@@ armac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hr@@ en@@ ic patients .
Smoking and Race :
Population ph@@ armac@@ ok@@ ine@@ tic evaluation has revealed no evidence of clin@@ ically significant rac@@ e-@@ related differences or effects from smoking upon the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole .
Ren@@ al Dis@@ ease :
The ph@@ armac@@ ok@@ ine@@ tic characteristics of ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole were found to be similar in patients with severe ren@@ al disease compared to young healthy subjects .
H@@ ep@@ atic Dis@@ ease :
A single-@@ dose study in subjects with var@@ ying degrees of liver cir@@ r@@ ho@@ sis ( Chil@@ d-@@ Pu@@ gh Cl@@ asses A , B , and C ) did not reveal a significant effect of h@@ ep@@ atic imp@@ air@@ ment on the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole , but the study included only 3 patients with Class C liver cir@@ r@@ ho@@ sis , which is in@@ sufficient to draw conclusions on their metaboli@@ c capacity .
5.@@ 3 Prec@@ lin@@ ical safety data
Non-@@ clinical safety data revealed no special haz@@ ard for humans based on conventional studies of safety ph@@ armac@@ ology , repe@@ at-@@ dose tox@@ ic@@ ity , gen@@ ot@@ ox@@ ic@@ ity , car@@ cin@@ ogen@@ ic potential , and tox@@ ic@@ ity to reproduction .
To@@ x@@ ic@@ ologically significant effects were observed only at d@@ oses or expos@@ ures that were sufficiently in excess of the maximum human dose or exposure , indic@@ ating that these effects were limited or of no relev@@ ance to clinical use .
These included : dos@@ e-@@ dependent ad@@ ren@@ oc@@ or@@ tical tox@@ ic@@ ity ( li@@ po@@ f@@ us@@ c@@ in pig@@ ment accum@@ ulation and / or par@@ ench@@ y@@ mal cell loss ) in rats after 104 weeks at 20 to 60 mg / kg / day ( 3 to 10 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended human dose ) and increased ad@@ ren@@ oc@@ or@@ tical car@@ cin@@ omas and combined ad@@ ren@@ oc@@ or@@ tical aden@@ omas / car@@ cin@@ omas in female rats at 60 mg / kg / day ( 10 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended human dose ) .
The highest n@@ ont@@ um@@ orig@@ en@@ ic exposure in female rats was 7 times the human exposure at the recommended dose .
An additional finding was chol@@ eli@@ thi@@ asis as a consequence of precipitation of sul@@ ph@@ ate con@@ jug@@ ates of hydro@@ xy metaboli@@ tes of ari@@ pip@@ ra@@ z@@ ole in the b@@ ile of mon@@ keys after repeated oral d@@ osing at 25 to 125 mg / kg / day ( 1 to 3 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg / m2 ) .
However , the concentr@@ ations of the sul@@ ph@@ ate con@@ jug@@ ates of hydro@@ xy ari@@ pip@@ ra@@ z@@ ole in human b@@ ile at the highest dose proposed , 30 mg per day , were no more than 6 % of the b@@ ile concentr@@ ations found in the mon@@ keys in the 3@@ 9-@@ week study and are well below ( 6 % ) their limits of in vit@@ ro sol@@ u@@ bility .
Based on results of a full range of standard gen@@ ot@@ ox@@ ic@@ ity tests , ari@@ pip@@ ra@@ z@@ ole was considered non-@@ gen@@ ot@@ ox@@ ic .
A@@ rip@@ ip@@ ra@@ z@@ ole did not imp@@ air fer@@ tility in re@@ productive tox@@ ic@@ ity studies .
Develop@@ mental tox@@ ic@@ ity , including dos@@ e-@@ dependent del@@ ayed fo@@ etal ossi@@ fication and possible ter@@ at@@ ogen@@ ic effects , were observed in rats at d@@ oses resulting in sub@@ therapeutic expos@@ ures ( based on AU@@ C ) and in rab@@ bits at d@@ oses resulting in expos@@ ures 3 and 11 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended clinical dose .
Mat@@ ern@@ al tox@@ ic@@ ity occurred at d@@ oses similar to those el@@ ic@@ iting develop@@ mental tox@@ ic@@ ity .
79 6 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL P@@ ART@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
Cal@@ cium si@@ lic@@ ate Cro@@ sc@@ arm@@ ell@@ ose so@@ dium Cro@@ spo@@ vi@@ done Sili@@ con dioxide X@@ y@@ li@@ to@@ l Micro@@ cryst@@ all@@ ine cell@@ ul@@ ose A@@ spart@@ ame ( E@@ 9@@ 51 ) Ac@@ es@@ ul@@ f@@ ame pot@@ assi@@ um Van@@ illa flav@@ our ( including van@@ ill@@ in and eth@@ yl van@@ ill@@ in ) T@@ art@@ ari@@ c acid Magn@@ esium st@@ ear@@ ate
Red iron oxide ( E@@ 17@@ 2 )
6.2 In@@ compati@@ bilities
Not applicable .
6.@@ 3 Shel@@ f life
3 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store in the original package in order to protect from moisture .
6.5 Nature and contents of container
Cart@@ on of 14 x 1 tablets in col@@ d-@@ formed aluminium per@@ for@@ ated unit dose bli@@ sters .
Cart@@ on of 28 x 1 tablets in col@@ d-@@ formed aluminium per@@ for@@ ated unit dose bli@@ sters .
Cart@@ on of 49 x 1 tablets in col@@ d-@@ formed aluminium per@@ for@@ ated unit dose bli@@ sters .
Not all pack sizes may be mark@@ eted .
6.@@ 6 Special prec@@ au@@ tions for disposal and other handling
Any un@@ used product or waste material should be dispos@@ ed of in accordance with local requirements .
7 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
8 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION N@@ UM@@ BER ( S )
EU / 1 / 04 / 27@@ 6 / 0@@ 30-@@ 0@@ 32
9 .
D@@ ATE OF F@@ IR@@ ST AU@@ TH@@ OR@@ IS@@ ATION / R@@ EN@@ EW@@ AL OF THE AU@@ TH@@ OR@@ IS@@ ATION
80 Date of first author@@ isation :
4 June 2004
10 .
D@@ ATE OF RE@@ V@@ IS@@ ION OF THE TE@@ XT
{ M@@ M / Y@@ Y@@ Y@@ Y }
Detailed information on this product is available on the website of the European Medic@@ ines Agency ( EM@@ EA ) http : / / ww@@ w. em@@ e@@ a. europ@@ a. eu /
81 1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 1 mg / ml oral solution
2 .
QU@@ AL@@ IT@@ AT@@ IVE AND QU@@ AN@@ T@@ IT@@ AT@@ IVE COMP@@ OS@@ IT@@ ION
Each ml contains 1 mg of ari@@ pip@@ ra@@ z@@ ole .
Ex@@ cip@@ i@@ ents :
200 mg fru@@ c@@ t@@ ose per ml 400 mg su@@ c@@ rose per ml 1.8 mg meth@@ yl par@@ ah@@ y@@ dro@@ xy@@ ben@@ zo@@ ate ( E@@ 2@@ 18 ) per ml 0.2 mg prop@@ yl par@@ ah@@ y@@ dro@@ xy@@ ben@@ zo@@ ate ( E@@ 2@@ 16 ) per ml
For a full list of ex@@ cip@@ i@@ ents , see section 6.@@ 1 .
3 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL FOR@@ M
Or@@ al solution Clear , colour@@ less to light yellow liquid .
4 .
CL@@ IN@@ IC@@ AL P@@ ART@@ IC@@ UL@@ AR@@ S
4.1 Therap@@ eu@@ tic indic@@ ations
AB@@ IL@@ IF@@ Y is indicated for the treatment of sch@@ iz@@ op@@ hr@@ en@@ ia .
AB@@ IL@@ IF@@ Y is indicated for the treatment of moderate to severe man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order and for the prevention of a new man@@ ic episode in patients who experienced pre@@ domin@@ antly man@@ ic episodes and whose man@@ ic episodes responded to ari@@ pip@@ ra@@ z@@ ole treatment ( see section 5.1 ) .
4.2 Pos@@ ology and method of administration
Or@@ al use .
AB@@ IL@@ IF@@ Y oral solution may be used as an alternative to AB@@ IL@@ IF@@ Y tablets for patients who have difficulty swal@@ lowing AB@@ IL@@ IF@@ Y tablets ( see section 5.2 ) .
Sch@@ iz@@ op@@ hr@@ en@@ ia :
The recommended starting dose for AB@@ IL@@ IF@@ Y is 10 or 15 mg / day ( i@@ . e .
10 or 15 ml solution / day ) with a maintenance dose of 15 mg / day administ@@ ered on a on@@ ce-@@ a-@@ day schedule without regard to meals .
A calibr@@ ated measuring cup and a 2 ml calibr@@ ated drop@@ per are included in the cart@@ on .
AB@@ IL@@ IF@@ Y is effective in a dose range of 10 to 30 mg / day ( i@@ . e .
10 to 30 ml solution / day ) .
Enh@@ anced eff@@ ic@@ acy at d@@ oses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose .
The maximum daily dose should not exceed 30 mg .
Man@@ ic episodes :
15 ml solution / day ) administ@@ ered on a on@@ ce-@@ a-@@ day schedule without regard to meals as mon@@ o@@ therapy or combination therapy ( see section 5.1 ) .
Some patients may benefit from a higher dose .
30 ml solution / day ) .
Rec@@ ur@@ r@@ ence prevention of man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order :
82 For preventing rec@@ ur@@ r@@ ence of man@@ ic episodes in patients who have been receiving ari@@ pip@@ ra@@ z@@ ole , continue therapy at the same dose .
Ad@@ just@@ ments of daily dos@@ age , including dose reduction should be considered on the basis of clinical status .
Children and ad@@ ol@@ esc@@ ents : there is no experience in children and ad@@ ol@@ esc@@ ents under 18 years of age .
Pati@@ ents with h@@ ep@@ atic imp@@ air@@ ment : no dos@@ age adjustment is required for patients with mild to moderate h@@ ep@@ atic imp@@ air@@ ment .
In patients with severe h@@ ep@@ atic imp@@ air@@ ment , the data available are in@@ sufficient to establish recommendations .
In these patients d@@ osing should be managed cau@@ ti@@ ously .
However , the maximum daily dose of 30 mg should be used with cau@@ tion in patients with severe h@@ ep@@ atic imp@@ air@@ ment ( see section 5.2 ) .
Pati@@ ents with ren@@ al imp@@ air@@ ment : no dos@@ age adjustment is required in patients with ren@@ al imp@@ air@@ ment .
El@@ derly : the effectiveness of AB@@ IL@@ IF@@ Y in the treatment of sch@@ iz@@ op@@ hr@@ en@@ ia and Bi@@ pol@@ ar I Dis@@ order in patients 65 years of age or older has not been established .
O@@ wing to the greater sensitivity of this population , a lower starting dose should be considered when clinical factors war@@ rant ( see section 4.4 ) .
Gender : no dos@@ age adjustment is required for female patients as compared to male patients ( see sections 4.4 and 5.2 ) .
Smoking status : according to the metaboli@@ c path@@ way of AB@@ IL@@ IF@@ Y no dos@@ age adjustment is required for smo@@ kers ( see section 4.5 ) .
When con@@ com@@ it@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hib@@ itors with ari@@ pip@@ ra@@ z@@ ole occurs , the ari@@ pip@@ ra@@ z@@ ole dose should be reduced .
When the C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hib@@ itor is with@@ drawn from the combination therapy , ari@@ pip@@ ra@@ z@@ ole dose should then be increased ( see section 4.5 ) .
When con@@ com@@ it@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers with ari@@ pip@@ ra@@ z@@ ole occurs , the ari@@ pip@@ ra@@ z@@ ole dose should be increased .
When the C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ er is with@@ drawn from the combination therapy , the ari@@ pip@@ ra@@ z@@ ole dose should then be reduced to the recommended dose ( see section 4.5 ) .
4.3 Con@@ tra@@ indic@@ ations
Hyper@@ sensitivity to the active substance or to any of the ex@@ cip@@ i@@ ents .
4.4 Special war@@ nings and prec@@ au@@ tions for use
During anti@@ psycho@@ tic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
Pati@@ ents should be closely monitored throughout this period .
The occurr@@ ence of su@@ ic@@ id@@ al behaviour is inher@@ ent in psycho@@ tic ill@@ nesses and mood disorders and in some cases has been reported early after initi@@ ation or switch of anti@@ psycho@@ tic therapy , including treatment with ari@@ pip@@ ra@@ z@@ ole ( see section 4.@@ 8 ) .
Close supervision of high-@@ risk patients should accompany anti@@ psycho@@ tic therapy .
Results of an epide@@ mi@@ ological study found that there was no increased risk of su@@ ic@@ id@@ ality with ari@@ pip@@ ra@@ z@@ ole compared to other anti@@ psycho@@ tics among patients with bi@@ pol@@ ar dis@@ order .
Cardi@@ ov@@ as@@ cular disorders :
A@@ rip@@ ip@@ ra@@ z@@ ole should be used with cau@@ tion in patients with known cardi@@ ov@@ as@@ cular disease ( history of my@@ oc@@ ardi@@ al inf@@ ar@@ ction or isch@@ a@@ em@@ ic heart disease , heart failure , or conduc@@ tion ab@@ norm@@ alities ) , cer@@ eb@@ rov@@ as@@ cular disease , conditions which would pre@@ disp@@ ose patients to h@@ yp@@ ot@@ en@@ sion ( de@@ hydr@@ ation , hypo@@ vol@@ emia , and treatment with anti@@ hyper@@ ten@@ sive medic@@ ations ) or hyper@@ tension , including acceler@@ ated or mal@@ ign@@ ant .
Con@@ duction ab@@ norm@@ alities :
In clinical trials of ari@@ pip@@ ra@@ z@@ ole , the inci@@ dence of Q@@ T pro@@ long@@ ation was comparable to plac@@ eb@@ o .
As with other anti@@ psycho@@ tics , ari@@ pip@@ ra@@ z@@ ole should be used with cau@@ tion in patients with a family history of Q@@ T pro@@ long@@ ation .
83 Tar@@ dive dy@@ sk@@ in@@ esia : in clinical trials of one year or less duration , there were un@@ common reports of treatment emerg@@ ent dy@@ sk@@ in@@ esia during treatment with ari@@ pip@@ ra@@ z@@ ole .
If signs and symptoms of tar@@ dive dy@@ sk@@ in@@ esia appear in a patient on AB@@ IL@@ IF@@ Y , dose reduction or dis@@ continu@@ ation should be considered .
These symptoms can tempor@@ ally deteri@@ or@@ ate or can even arise after dis@@ continu@@ ation of treatment .
Neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ drome ( N@@ MS ) :
N@@ MS is a potentially fat@@ al sy@@ mp@@ tom complex associated with anti@@ psycho@@ tic medic@@ inal products .
In clinical trials , rare cases of N@@ MS were reported during treatment with ari@@ pip@@ ra@@ z@@ ole .
Clin@@ ical manifest@@ ations of N@@ MS are hyper@@ py@@ re@@ x@@ ia , muscle rigi@@ dity , alter@@ ed mental status and evidence of autonom@@ ic inst@@ ability ( ir@@ regular pul@@ se or blood pressure , t@@ ach@@ y@@ car@@ dia , di@@ ap@@ hor@@ esis and cardi@@ ac d@@ ys@@ rhyth@@ m@@ ia ) .
Additional signs may include elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase , my@@ og@@ lo@@ bin@@ ur@@ ia ( r@@ hab@@ dom@@ y@@ oly@@ sis ) , and ac@@ ute ren@@ al failure .
However , elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase and r@@ hab@@ dom@@ y@@ oly@@ sis , not necessarily in association with N@@ MS , have also been reported .
If a patient develops signs and symptoms indic@@ ative of N@@ MS , or presents with un@@ explained high f@@ ever without additional clinical manifest@@ ations of N@@ MS , all anti@@ psycho@@ tic medic@@ inal products , including AB@@ IL@@ IF@@ Y , must be dis@@ continued .
Sei@@ z@@ ure : in clinical trials , un@@ common cases of sei@@ z@@ ure were reported during treatment with ari@@ pip@@ ra@@ z@@ ole .
Therefore , ari@@ pip@@ ra@@ z@@ ole should be used with cau@@ tion in patients who have a history of sei@@ z@@ ure dis@@ order or have conditions associated with sei@@ zur@@ es .
El@@ derly patients with de@@ men@@ ti@@ a-@@ related psycho@@ sis :
Incre@@ ased mort@@ ality : in three plac@@ eb@@ o-@@ controlled trials ( n = 9@@ 38 ; mean age :
8@@ 2.4 years ; range :
5@@ 6-@@ 99 years ) of ari@@ pip@@ ra@@ z@@ ole in elderly patients with psycho@@ sis associated with Alz@@ heimer &apos;s disease , patients treated with ari@@ pip@@ ra@@ z@@ ole were at increased risk of death compared to plac@@ eb@@ o .
The rate of death in ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients was 3.5 % compared to 1.7 % in the plac@@ eb@@ o group .
Although the causes of deaths were varied , most of the deaths appeared to be either cardi@@ ov@@ as@@ cular ( e. g. heart failure , sudden death ) or inf@@ ec@@ tious ( e. g. pneum@@ onia ) in nature .
Cer@@ eb@@ rov@@ as@@ cular ad@@ verse events : in the same trials , cer@@ eb@@ rov@@ as@@ cular ad@@ verse events ( e. g. stroke , transi@@ ent isch@@ a@@ em@@ ic attack ) , including fat@@ alities , were reported in patients ( mean age :
84 years ; range :
7@@ 8-@@ 88 years ) .
Overall , 1.3 % of ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients reported cer@@ eb@@ rov@@ as@@ cular ad@@ verse events compared with 0.@@ 6 % of plac@@ eb@@ o-@@ treated patients in these trials .
This difference was not statisti@@ cally significant .
However , in one of these trials , a fix@@ ed-@@ dose trial , there was a significant dose response relationship for cer@@ eb@@ rov@@ as@@ cular ad@@ verse events in patients treated with ari@@ pip@@ ra@@ z@@ ole .
AB@@ IL@@ IF@@ Y is not approved for the treatment of de@@ men@@ ti@@ a-@@ related psycho@@ sis .
Hyper@@ gly@@ ca@@ emia and diabetes mel@@ lit@@ us : hyper@@ gly@@ ca@@ emia , in some cases extreme and associated with k@@ eto@@ aci@@ do@@ sis or hyper@@ os@@ mol@@ ar com@@ a or death , has been reported in patients treated with at@@ yp@@ ical anti@@ psycho@@ tic agents , including AB@@ IL@@ IF@@ Y .
Risk factors that may pre@@ disp@@ ose patients to severe complic@@ ations include o@@ bes@@ ity and family history of diabetes .
In clinical trials with ari@@ pip@@ ra@@ z@@ ole , there were no significant differences in the inci@@ dence rates of hyper@@ gly@@ ca@@ em@@ i@@ a-@@ related ad@@ verse events ( including diabetes ) or in ab@@ normal gly@@ ca@@ emia laboratory values compared to plac@@ eb@@ o .
Prec@@ ise risk estimates for hyper@@ gly@@ ca@@ em@@ i@@ a-@@ related ad@@ verse events in patients treated with AB@@ IL@@ IF@@ Y and with other at@@ yp@@ ical anti@@ psycho@@ tic agents are not available to allow direct comparis@@ ons .
Pati@@ ents treated with any anti@@ psycho@@ tic agents , including AB@@ IL@@ IF@@ Y , should be observed for signs and symptoms of hyper@@ gly@@ ca@@ emia ( such as poly@@ di@@ p@@ sia , poly@@ ur@@ ia , poly@@ ph@@ ag@@ ia and weak@@ ness ) and patients with diabetes mel@@ lit@@ us or with risk factors for diabetes mel@@ lit@@ us should be monitored regularly for wor@@ sen@@ ing of glu@@ c@@ ose control .
Weight gain : weight gain is commonly seen in sch@@ iz@@ op@@ hr@@ en@@ ic and bi@@ pol@@ ar man@@ ia patients due to co@@ - mor@@ bi@@ di@@ ties , use of anti@@ psycho@@ tics known to cause weight gain , poor@@ ly managed life-@@ style , and might lead to severe complic@@ ations .
Weight gain has been reported post-@@ marketing among patients prescri@@ bed AB@@ IL@@ IF@@ Y .
When seen , it is usually in those with significant risk factors such as history of diabetes , th@@ y@@ ro@@ id dis@@ order or p@@ itu@@ itary aden@@ oma .
In clinical trials ari@@ pip@@ ra@@ z@@ ole has not been shown to in@@ duce clin@@ ically relevant weight gain ( see section 5.1 ) .
84 Dy@@ sph@@ ag@@ ia : o@@ es@@ op@@ ha@@ ge@@ al d@@ ys@@ mo@@ tility and asp@@ ir@@ ation have been associated with anti@@ psycho@@ tic drug use , including AB@@ IL@@ IF@@ Y .
A@@ rip@@ ip@@ ra@@ z@@ ole and other anti@@ psycho@@ tic drugs should be used cau@@ ti@@ ously in patients at risk for asp@@ ir@@ ation pneum@@ onia .
Int@@ oler@@ ance :
The oral solution contains fru@@ c@@ t@@ ose .
Pati@@ ents with rare her@@ edit@@ ary problems of fru@@ c@@ t@@ ose int@@ oler@@ ance should not take this medic@@ inal product .
The oral solution contains meth@@ yl par@@ ah@@ y@@ dro@@ xy@@ ben@@ zo@@ ate and prop@@ yl par@@ ah@@ y@@ dro@@ xy@@ ben@@ zo@@ ate which may cause aller@@ gic reactions ( possibly del@@ ayed ) .
The oral solution contains su@@ c@@ rose .
Pati@@ ents with rare her@@ edit@@ ary problems of fru@@ c@@ t@@ ose int@@ oler@@ ance , glu@@ cos@@ e-@@ gal@@ act@@ ose mal@@ absor@@ ption or su@@ cr@@ as@@ e-@@ is@@ om@@ alt@@ ase in@@ suffici@@ ency should not take the oral solution .
Hyper@@ sensitivity : as with other medic@@ ations hyper@@ sensitivity reactions , characterised by aller@@ gic symptoms , may occur with ari@@ pip@@ ra@@ z@@ ole ( see section 4.@@ 8 ) .
4.5 Inter@@ action with other medic@@ inal products and other forms of interaction
Due to its α 1-@@ ad@@ ren@@ ergi@@ c recep@@ tor ant@@ agon@@ ism , ari@@ pip@@ ra@@ z@@ ole has the potential to enhance the effect of certain anti@@ hyper@@ ten@@ sive agents .
Given the primary CN@@ S effects of ari@@ pip@@ ra@@ z@@ ole , cau@@ tion should be used when ari@@ pip@@ ra@@ z@@ ole is taken in combination with alcohol or other CN@@ S medic@@ inal products with over@@ l@@ apping undes@@ irable effects such as se@@ dation ( see section 4.@@ 8 ) .
If ari@@ pip@@ ra@@ z@@ ole is administ@@ ered con@@ com@@ it@@ antly with medicines known to cause Q@@ T pro@@ long@@ ation or elec@@ trol@@ yte im@@ balance , cau@@ tion should be used .
Potential for other medic@@ inal products to affect AB@@ IL@@ IF@@ Y :
A ga@@ stri@@ c acid blo@@ cker , the H@@ 2 ant@@ agon@@ ist fam@@ oti@@ d@@ ine , reduces ari@@ pip@@ ra@@ z@@ ole rate of absor@@ ption but this effect is deemed not clin@@ ically relevant .
A@@ rip@@ ip@@ ra@@ z@@ ole is metaboli@@ sed by multiple path@@ ways involving the C@@ Y@@ P@@ 2@@ D@@ 6 and C@@ Y@@ P@@ 3@@ A4 enz@@ y@@ mes but not C@@ Y@@ P@@ 1@@ A enz@@ y@@ mes .
Thus , no dos@@ age adjustment is required for smo@@ kers .
In a clinical trial in healthy subjects , a pot@@ ent in@@ hib@@ itor of C@@ Y@@ P@@ 2@@ D@@ 6 ( qu@@ in@@ id@@ ine ) increased ari@@ pip@@ ra@@ z@@ ole AU@@ C by 107 % , while C@@ max was un@@ changed .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole , the active metaboli@@ te , decreased by 32 % and 47 % .
AB@@ IL@@ IF@@ Y dose should be reduced to approximately one-@@ half of its prescri@@ bed dose when con@@ com@@ it@@ ant administration of AB@@ IL@@ IF@@ Y with qu@@ in@@ id@@ ine occurs .
Other pot@@ ent in@@ hib@@ itors of C@@ Y@@ P@@ 2@@ D@@ 6 , such as flu@@ ox@@ et@@ ine and par@@ ox@@ et@@ ine , may be expected to have similar effects and similar dose reduc@@ tions should therefore be applied .
In a clinical trial in healthy subjects , a pot@@ ent in@@ hib@@ itor of C@@ Y@@ P@@ 3@@ A4 ( k@@ eto@@ con@@ az@@ ole ) increased ari@@ pip@@ ra@@ z@@ ole AU@@ C and C@@ max by 63 % and 37 % , respectively .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole increased by 77 % and 43 % , respectively .
In C@@ Y@@ P@@ 2@@ D@@ 6 poor metaboli@@ sers , con@@ com@@ it@@ ant use of pot@@ ent in@@ hib@@ itors of C@@ Y@@ P@@ 3@@ A4 may result in higher plas@@ ma concentr@@ ations of ari@@ pip@@ ra@@ z@@ ole compared to that in C@@ Y@@ P@@ 2@@ D@@ 6 extensive metaboli@@ z@@ ers .
When considering con@@ com@@ it@@ ant administration of k@@ eto@@ con@@ az@@ ole or other pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hib@@ itors with AB@@ IL@@ IF@@ Y , potential benefits should out@@ wei@@ gh the potential risks to the patient .
When con@@ com@@ it@@ ant administration of k@@ eto@@ con@@ o@@ z@@ ole with AB@@ IL@@ IF@@ Y occurs , AB@@ IL@@ IF@@ Y dose should be reduced to approximately one-@@ half of its prescri@@ bed dose .
Other pot@@ ent in@@ hib@@ itors of C@@ Y@@ P@@ 3@@ A4 , such as it@@ ra@@ con@@ az@@ ole and HIV pro@@ tease in@@ hib@@ itors , may be expected to have similar effects and similar dose reduc@@ tions should therefore be applied .
Upon dis@@ continu@@ ation of the C@@ Y@@ P@@ 2@@ D@@ 6 or 3@@ A4 in@@ hib@@ itor , the dos@@ age of AB@@ IL@@ IF@@ Y should be increased to the level prior to the initi@@ ation of the con@@ com@@ it@@ ant therapy .
85 When weak in@@ hib@@ itors of C@@ Y@@ P@@ 3@@ A4 ( e. g . , dil@@ ti@@ az@@ em or esc@@ it@@ al@@ op@@ ram ) or C@@ Y@@ P@@ 2@@ D@@ 6 are used con@@ com@@ it@@ antly with AB@@ IL@@ IF@@ Y , mod@@ est increases in ari@@ pip@@ ra@@ z@@ ole concentr@@ ations might be expected .
Following con@@ com@@ it@@ ant administration of carb@@ amaz@@ ep@@ ine , a pot@@ ent in@@ duc@@ er of C@@ Y@@ P@@ 3@@ A4 , the geomet@@ ric means of C@@ max and AU@@ C for ari@@ pip@@ ra@@ z@@ ole were 68 % and 73 % lower , respectively , compared to when ari@@ pip@@ ra@@ z@@ ole ( 30 mg ) was administ@@ ered alone .
Simil@@ arly , for de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole the geomet@@ ric means of C@@ max and AU@@ C after carb@@ amaz@@ ep@@ ine co-@@ administration were 69 % and 71 % lower , respectively , than those following treatment with ari@@ pip@@ ra@@ z@@ ole alone .
AB@@ IL@@ IF@@ Y dose should be dou@@ bled when con@@ com@@ it@@ ant administration of AB@@ IL@@ IF@@ Y occurs with carb@@ amaz@@ ep@@ ine .
John &apos;s Wort ) may be expected to have similar effects and similar dose increases should therefore be applied .
Upon dis@@ continu@@ ation of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers , the dos@@ age of AB@@ IL@@ IF@@ Y should be reduced to the recommended dose .
When either val@@ pro@@ ate or li@@ th@@ ium were administ@@ ered con@@ com@@ it@@ antly with ari@@ pip@@ ra@@ z@@ ole , there was no clin@@ ically significant change in ari@@ pip@@ ra@@ z@@ ole concentr@@ ations .
Potential for AB@@ IL@@ IF@@ Y to affect other medic@@ inal products :
In clinical studies , 10-@@ 30 mg / day d@@ oses of ari@@ pip@@ ra@@ z@@ ole had no significant effect on the metabolism of sub@@ str@@ ates of C@@ Y@@ P@@ 2@@ D@@ 6 ( de@@ x@@ tro@@ meth@@ orph@@ an / 3-@@ metho@@ xy@@ mor@@ ph@@ in@@ an ratio ) , 2@@ C@@ 9 ( war@@ far@@ in ) , 2@@ C@@ 19 ( om@@ ep@@ ra@@ z@@ ole ) , and 3@@ A4 ( de@@ x@@ tro@@ meth@@ orph@@ an ) .
Additionally , ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole did not show potential for alter@@ ing C@@ Y@@ P@@ 1@@ A@@ 2-@@ medi@@ ated metabolism in vit@@ ro .
Thus , ari@@ pip@@ ra@@ z@@ ole is un@@ likely to cause clin@@ ically important medic@@ inal product inter@@ actions medi@@ ated by these enz@@ y@@ mes .
When ari@@ pip@@ ra@@ z@@ ole was administ@@ ered con@@ com@@ it@@ antly with either val@@ pro@@ ate or li@@ th@@ ium , there was no clin@@ ically important change in val@@ pro@@ ate or li@@ th@@ ium concentr@@ ations .
4.@@ 6 Pre@@ gn@@ ancy and lac@@ tation
There are no adequate and well-@@ controlled trials of ari@@ pip@@ ra@@ z@@ ole in pregnant women .
Animal studies could not exclu@@ de potential develop@@ mental tox@@ ic@@ ity ( see section 5.@@ 3 ) .
Pati@@ ents should be advised to noti@@ fy their physi@@ cian if they become pregnant or intend to become pregnant during treatment with ari@@ pip@@ ra@@ z@@ ole .
Due to in@@ sufficient safety information in humans and concerns raised by animal re@@ productive studies , this medic@@ inal product should not be used in pregnancy unless the expected benefit clearly justi@@ fies the potential risk to the fo@@ etus .
A@@ rip@@ ip@@ ra@@ z@@ ole was ex@@ cre@@ ted in the milk of treated rats during lac@@ tation .
Pati@@ ents should be advised not to breast feed if they are taking ari@@ pip@@ ra@@ z@@ ole .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No studies on the effect on the ability to drive and use machines have been performed .
However , as with other anti@@ psycho@@ tics , patients should be cau@@ tioned about operating haz@@ ard@@ ous machines , including motor vehicles , until they are reason@@ ably certain that ari@@ pip@@ ra@@ z@@ ole does not affect them ad@@ ver@@ sely .
4.@@ 8 Un@@ des@@ irable effects
The following undes@@ irable effects occurred more often ( ≥ 1 / 100 ) than plac@@ eb@@ o , or were identified as possibly medi@@ cally relevant ad@@ verse reactions ( * ) :
The frequency listed below is defined using the following convention : common ( &gt; 1 / 100 , &lt; 1 / 10 ) and un@@ common ( &gt; 1 / 1 , 000 , &lt; 1 / 100 ) .
86 Cardi@@ ac disorders Un@@ common : t@@ ach@@ y@@ car@@ dia * N@@ erv@@ ous System disorders Common : extra@@ py@@ ram@@ id@@ al dis@@ order , ak@@ ath@@ is@@ ia , tre@@ m@@ or , di@@ zz@@ iness , som@@ n@@ ol@@ ence , se@@ dation , head@@ ache Eye disorders Common : bl@@ urred vision Gast@@ ro@@ int@@ est@@ inal disorders Common : dy@@ sp@@ ep@@ sia , v@@ om@@ iting , nau@@ sea , con@@ sti@@ p@@ ation , s@@ ali@@ vary hy@@ persec@@ re@@ tion Vas@@ cular disorders Un@@ common : or@@ tho@@ static h@@ yp@@ ot@@ en@@ sion * General disorders and administration site conditions Common : f@@ ati@@ gue Psych@@ iat@@ ric disorders Common : rest@@ less@@ ness , in@@ som@@ nia , an@@ xi@@ ety Un@@ common : depression *
Extra@@ py@@ ram@@ id@@ al symptoms ( EP@@ S ) :
Sch@@ iz@@ op@@ hr@@ en@@ ia - in a long term 5@@ 2-@@ week controlled trial , ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients had an over@@ all-@@ lower inci@@ dence ( 25.@@ 8 % ) of EP@@ S including par@@ kin@@ son@@ ism , ak@@ ath@@ is@@ ia , d@@ yst@@ onia and dy@@ sk@@ in@@ esia compared with those treated with hal@@ op@@ eri@@ do@@ l ( 5@@ 7.@@ 3 % ) .
In a long term 26@@ -@@ week plac@@ eb@@ o-@@ controlled trial , the inci@@ dence of EP@@ S was 19 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 13@@ .1 % for plac@@ eb@@ o-@@ treated patients .
In another long-term 26@@ -@@ week controlled trial , the inci@@ dence of EP@@ S was 14.@@ 8 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 15@@ .1 % for ol@@ anz@@ ap@@ ine-@@ treated patients .
Man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order - in a 12-@@ week controlled trial , the inci@@ dence of EP@@ S was 2@@ 3.5 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 5@@ 3.3 % for hal@@ op@@ eri@@ dol@@ -@@ treated patients .
In another 12-@@ week trial , the inci@@ dence of EP@@ S was 26.@@ 6 % for patients treated with ari@@ pip@@ ra@@ z@@ ole and 17.@@ 6 % for those treated with li@@ th@@ ium .
In the long term 26@@ -@@ week maintenance phase of a plac@@ eb@@ o-@@ controlled trial , the inci@@ dence of EP@@ S was 18.@@ 2 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 15.@@ 7 % for plac@@ eb@@ o-@@ treated patients .
In plac@@ eb@@ o-@@ controlled trials , the inci@@ dence of ak@@ ath@@ is@@ ia in bi@@ pol@@ ar patients was 12.@@ 1 % with ari@@ pip@@ ra@@ z@@ ole and 3.2 % with plac@@ eb@@ o .
In sch@@ iz@@ op@@ hr@@ en@@ ia patients the inci@@ dence of ak@@ ath@@ is@@ ia was 6.2 % with ari@@ pip@@ ra@@ z@@ ole and 3.0 % with plac@@ eb@@ o .
Compar@@ is@@ ons between ari@@ pip@@ ra@@ z@@ ole and plac@@ eb@@ o in the propor@@ tions of patients experiencing potentially clin@@ ically significant changes in routine laboratory parameters revealed no medi@@ cally important differences .
Elev@@ ations of CP@@ K ( Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ ase ) , generally transi@@ ent and asy@@ mpt@@ omati@@ c , were observed in 3.5 % of ari@@ pip@@ ra@@ z@@ ole treated patients as compared to 2.0 % of patients who received plac@@ eb@@ o .
Other findings :
Un@@ des@@ irable effects known to be associated with anti@@ psycho@@ tic therapy and also reported during treatment with ari@@ pip@@ ra@@ z@@ ole include neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ drome , tar@@ dive dy@@ sk@@ in@@ esia , sei@@ z@@ ure , cer@@ eb@@ rov@@ as@@ cular ad@@ verse events and increased mort@@ ality in elderly dem@@ ented patients , hyper@@ gly@@ ca@@ emia and diabetes mel@@ lit@@ us ( see section 4.4 ) .
Po@@ st-@@ Marketing :
The frequency of these events is considered not known ( cannot be estimated from the available data ) .
Inves@@ tig@@ ations :
increased Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ ase , blood glu@@ c@@ ose increased , blood glu@@ c@@ ose flu@@ c@@ tu@@ ation , gly@@ cos@@ yl@@ ated ha@@ em@@ og@@ lob@@ in increased
Cardi@@ ac disorders :
Q@@ T pro@@ long@@ ation , v@@ entri@@ cular ar@@ rhyth@@ mi@@ as , sudden un@@ explained death , cardi@@ ac arrest , tor@@ sa@@ des de poin@@ tes , bra@@ dy@@ car@@ dia
Blood and the ly@@ m@@ ph@@ atic system disorders :
leu@@ kop@@ en@@ ia , neut@@ rop@@ en@@ ia , thro@@ mbo@@ cy@@ top@@ en@@ ia
87 N@@ erv@@ ous system disorders :
speech dis@@ order , Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome ( N@@ MS ) , grand mal conv@@ ul@@ sion
Resp@@ ir@@ atory , thor@@ ac@@ ic and medi@@ ast@@ inal disorders :
or@@ op@@ har@@ yn@@ ge@@ al sp@@ as@@ m , lar@@ yn@@ g@@ osp@@ as@@ m , asp@@ ir@@ ation pneum@@ onia
Gast@@ ro@@ int@@ est@@ inal disorders :
pan@@ cre@@ ati@@ tis , dy@@ sph@@ ag@@ ia , ab@@ dom@@ inal dis@@ comfort , stomach dis@@ comfort , di@@ ar@@ r@@ ho@@ ea
Ren@@ al and ur@@ inary disorders :
ur@@ inary in@@ contin@@ ence , ur@@ inary re@@ tention
Skin and sub@@ cut@@ aneous tissue disorders :
r@@ ash , phot@@ os@@ ensi@@ tivity reaction , al@@ op@@ eci@@ a , hyper@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ etal and connec@@ tive tissue disorders :
r@@ hab@@ dom@@ y@@ oly@@ sis , my@@ al@@ gia , sti@@ ff@@ ness
En@@ doc@@ r@@ ine disorders :
hyper@@ gly@@ ca@@ emia , diabetes mel@@ lit@@ us , di@@ ab@@ etic k@@ eto@@ aci@@ do@@ sis , di@@ ab@@ etic hyper@@ os@@ mol@@ ar com@@ a
Met@@ aboli@@ sm and nutrition disorders :
weight gain , weight decreased , an@@ or@@ ex@@ ia , h@@ yp@@ on@@ at@@ rem@@ ia
Vas@@ cular disorders :
syn@@ cope , hyper@@ tension , thro@@ mbo@@ em@@ bo@@ lic events
General disorders and administration site conditions :
temperature regulation dis@@ order ( e. g. hypo@@ ther@@ m@@ ia , py@@ re@@ x@@ ia ) , chest pain , periph@@ eral o@@ e@@ de@@ ma
Im@@ m@@ une system disorders :
aller@@ gic reaction ( e. g. an@@ ap@@ hy@@ lac@@ tic reaction , an@@ gi@@ o@@ e@@ de@@ ma including sw@@ ollen tongue , tongue o@@ e@@ de@@ ma , face o@@ e@@ de@@ ma , pr@@ ur@@ it@@ us , or ur@@ tic@@ aria )
H@@ ep@@ at@@ o@@ bili@@ ary disorders :
j@@ a@@ un@@ dice , h@@ ep@@ ati@@ tis , increased Al@@ an@@ ine Amin@@ ot@@ ran@@ s@@ fer@@ ase ( AL@@ T ) , increased A@@ spart@@ ate Amin@@ ot@@ ran@@ s@@ fer@@ ase ( AS@@ T ) , increased G@@ amma Gl@@ ut@@ am@@ yl Transfer@@ ase ( G@@ GT ) , increased al@@ kal@@ ine phosph@@ at@@ ase
Re@@ productive system and breast disorders :
pri@@ ap@@ ism
Psych@@ iat@@ ric disorders :
ag@@ itation , ner@@ v@@ ousness ; suicide attempt , su@@ ic@@ id@@ al ide@@ ation , and completed suicide ( see section 4.4 )
4.@@ 9 Over@@ dose
In clinical trials and post-@@ marketing experience , acci@@ dental or inten@@ tional ac@@ ute over@@ dos@@ age of ari@@ pip@@ ra@@ z@@ ole alone was identified in adult patients with reported estimated d@@ oses up to 1,@@ 260 mg with no fat@@ alities .
The potentially medi@@ cally important signs and symptoms observed included le@@ th@@ ar@@ gy , increased blood pressure , som@@ n@@ ol@@ ence , t@@ ach@@ y@@ car@@ dia , nau@@ sea , v@@ om@@ iting and di@@ ar@@ r@@ ho@@ ea .
In addition , reports of acci@@ dental over@@ dose with ari@@ pip@@ ra@@ z@@ ole alone ( up to 195 mg ) in children have been received with no fat@@ alities .
The potentially medi@@ cally serious signs and symptoms reported included som@@ n@@ ol@@ ence , transi@@ ent loss of consciousness and extra@@ py@@ ram@@ id@@ al symptoms .
Management of over@@ dose should concentrate on sup@@ por@@ tive therapy , maintaining an adequate air@@ way , oxy@@ gen@@ ation and ventil@@ ation , and management of symptoms .
The possibility of multiple medic@@ inal product involvement should be considered .
Therefore cardi@@ ov@@ as@@ cular monitoring should be started immediately and should include continuous electro@@ cardi@@ ographic monitoring to detect possible ar@@ rhyth@@ mi@@ as .
Following any confirmed or susp@@ ected over@@ dose with ari@@ pip@@ ra@@ z@@ ole , close medical supervision and monitoring should continue until the patient re@@ covers .
88 Activ@@ ated char@@ coal ( 50 g ) , administ@@ ered one hour after ari@@ pip@@ ra@@ z@@ ole , decreased ari@@ pip@@ ra@@ z@@ ole C@@ max by about 41 % and AU@@ C by about 51 % , suggest@@ ing that char@@ coal may be effective in the treatment of over@@ dose .
Although there is no information on the effect of ha@@ emo@@ di@@ aly@@ sis in tre@@ ating an over@@ dose with ari@@ pip@@ ra@@ z@@ ole , ha@@ emo@@ di@@ aly@@ sis is un@@ likely to be useful in over@@ dose management since ari@@ pip@@ ra@@ z@@ ole is highly bound to plas@@ ma proteins .
5 .
PH@@ AR@@ MA@@ CO@@ LO@@ G@@ IC@@ AL PRO@@ PER@@ TI@@ ES
5.1 Ph@@ armac@@ o@@ dynamic properties
Ph@@ armac@@ o@@ therapeutic group : anti@@ psycho@@ tics , AT@@ C code :
N@@ 05@@ AX@@ 12
It has been proposed that ari@@ pip@@ ra@@ z@@ ole ’ s eff@@ ic@@ acy in sch@@ iz@@ op@@ hr@@ en@@ ia and Bi@@ pol@@ ar I Dis@@ order is medi@@ ated through a combination of partial agon@@ ism at d@@ op@@ am@@ ine D@@ 2 and ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ a rec@@ ept@@ ors and ant@@ agon@@ ism of ser@@ ot@@ on@@ in 5@@ HT@@ 2@@ a rec@@ ept@@ ors .
A@@ rip@@ ip@@ ra@@ z@@ ole exhib@@ ited ant@@ agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ ergi@@ c hyper@@ activity and agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ ergi@@ c hypo@@ activity .
A@@ rip@@ ip@@ ra@@ z@@ ole exhib@@ ited high binding aff@@ inity in vit@@ ro for d@@ op@@ am@@ ine D@@ 2 and D@@ 3 , ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ a and 5@@ HT@@ 2@@ a rec@@ ept@@ ors and moderate aff@@ inity for d@@ op@@ am@@ ine D@@ 4 , ser@@ ot@@ on@@ in 5@@ HT@@ 2@@ c and 5@@ HT@@ 7 , alp@@ ha@@ -1 ad@@ ren@@ ergi@@ c and hist@@ am@@ ine H@@ 1 rec@@ ept@@ ors .
A@@ rip@@ ip@@ ra@@ z@@ ole also exhib@@ ited moderate binding aff@@ inity for the ser@@ ot@@ on@@ in re@@ up@@ take site and no appreci@@ able aff@@ inity for mus@@ car@@ in@@ ic rec@@ ept@@ ors .
Inter@@ action with rec@@ ept@@ ors other than d@@ op@@ am@@ ine and ser@@ ot@@ on@@ in sub@@ types may explain some of the other clinical effects of ari@@ pip@@ ra@@ z@@ ole .
A@@ rip@@ ip@@ ra@@ z@@ ole d@@ oses ranging from 0.5 to 30 mg administ@@ ered once a day to healthy subjects for 2 weeks produced a dos@@ e-@@ dependent reduction in the binding of 11@@ C-@@ rac@@ lo@@ pride , a D@@ 2 / D@@ 3 recep@@ tor lig@@ and , to the cau@@ date and put@@ amen detected by pos@@ it@@ ron emission tom@@ ography .
Further information on clinical trials :
Sch@@ iz@@ op@@ hr@@ en@@ ia :
In three short-@@ term ( 4 to 6 weeks ) plac@@ eb@@ o-@@ controlled trials involving 1,@@ 2@@ 28 sch@@ iz@@ op@@ hr@@ en@@ ic patients , presenting with positive or negative symptoms , ari@@ pip@@ ra@@ z@@ ole was associated with statisti@@ cally significantly greater improvements in psycho@@ tic symptoms compared to plac@@ eb@@ o .
AB@@ IL@@ IF@@ Y is effective in maintaining the clinical improvement during continu@@ ation therapy in patients who have shown an initial treatment response .
In a hal@@ op@@ eri@@ dol@@ -@@ controlled trial , the proportion of respon@@ der patients maintaining response to medic@@ inal product at 5@@ 2-@@ weeks was similar in both groups ( ari@@ pip@@ ra@@ z@@ ole 77 % and hal@@ op@@ eri@@ do@@ l 73 % ) .
The overall completion rate was significantly higher for patients on ari@@ pip@@ ra@@ z@@ ole ( 43 % ) than for hal@@ op@@ eri@@ do@@ l ( 30 % ) .
Ac@@ tual scores in rating sc@@ ales used as secondary end@@ points , including P@@ AN@@ SS and the Mont@@ g@@ om@@ er@@ y-@@ As@@ berg Depression Rating Sc@@ ale showed a significant improvement over hal@@ op@@ eri@@ do@@ l .
In a 26@@ -@@ week , plac@@ eb@@ o-@@ controlled trial in stabili@@ sed patients with chronic sch@@ iz@@ op@@ hr@@ en@@ ia , ari@@ pip@@ ra@@ z@@ ole had significantly greater reduction in rel@@ ap@@ se rate , 34 % in ari@@ pip@@ ra@@ z@@ ole group and 57 % in plac@@ eb@@ o .
Weight gain : in clinical trials ari@@ pip@@ ra@@ z@@ ole has not been shown to in@@ duce clin@@ ically relevant weight gain .
In a 26@@ -@@ week , ol@@ anz@@ ap@@ ine-@@ controlled , double-@@ blind , multi-@@ national study of sch@@ iz@@ op@@ hr@@ en@@ ia which included 3@@ 14 patients and where the primary end-@@ point was weight gain , significantly less patients had at least 7 % weight gain over bas@@ eline ( i@@ . e. a gain of at least 5.@@ 6 kg for a mean bas@@ eline weight of ~ 8@@ 0.5 kg ) on ari@@ pip@@ ra@@ z@@ ole ( N = 18 , or 13 % of evalu@@ able patients ) , compared to ol@@ anz@@ ap@@ ine ( N = 45 , or 33 % of evalu@@ able patients ) .
Man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order :
In two 3-@@ week , flexi@@ b@@ le-@@ dose , plac@@ eb@@ o-@@ controlled mon@@ o@@ therapy trials involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , ari@@ pip@@ ra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to plac@@ eb@@ o in
These trials included patients with or without psycho@@ tic features and with or without a rap@@ id-@@ cycling course .
In one 3-@@ week , fix@@ ed-@@ dose , plac@@ eb@@ o-@@ controlled mon@@ o@@ therapy trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , ari@@ pip@@ ra@@ z@@ ole failed to demonstrate superior eff@@ ic@@ acy to plac@@ eb@@ o .
In two 12-@@ week , plac@@ ebo@@ - and activ@@ e-@@ controlled mon@@ o@@ therapy trials in patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , with or without psycho@@ tic features , ari@@ pip@@ ra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to plac@@ eb@@ o at week 3 and a maintenance of effect comparable to li@@ th@@ ium or hal@@ op@@ eri@@ do@@ l at week 12 .
A@@ rip@@ ip@@ ra@@ z@@ ole also demonstrated a comparable proportion of patients in sympt@@ omati@@ c re@@ mission from man@@ ia as li@@ th@@ ium or hal@@ op@@ eri@@ do@@ l at week 12 .
In a 6-@@ week , plac@@ eb@@ o-@@ controlled trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , with or without psycho@@ tic features , who were partially non-@@ respon@@ sive to li@@ th@@ ium or val@@ pro@@ ate mon@@ o@@ therapy for 2 weeks at therapeutic ser@@ um levels , the addition of ari@@ pip@@ ra@@ z@@ ole as adj@@ unc@@ tive therapy resulted in superior eff@@ ic@@ acy in reduction of man@@ ic symptoms than li@@ th@@ ium or val@@ pro@@ ate mon@@ o@@ therapy .
In a 26@@ -@@ week , plac@@ eb@@ o-@@ controlled trial , followed by a 7@@ 4-@@ week extension , in man@@ ic patients who achieved re@@ mission on ari@@ pip@@ ra@@ z@@ ole during a stabili@@ zation phase prior to random@@ ization , ari@@ pip@@ ra@@ z@@ ole demonstrated su@@ peri@@ ority over plac@@ eb@@ o in preventing bi@@ pol@@ ar rec@@ ur@@ r@@ ence , primarily in preventing rec@@ ur@@ r@@ ence into man@@ ia but failed to demonstrate su@@ peri@@ ority over plac@@ eb@@ o in preventing rec@@ ur@@ r@@ ence into depression .
5.2 Ph@@ armac@@ ok@@ ine@@ tic properties
Ab@@ sor@@ ption :
A@@ rip@@ ip@@ ra@@ z@@ ole is well absor@@ bed , with peak plas@@ ma concentr@@ ations occurr@@ ing within 3-5 hours after d@@ osing .
A@@ rip@@ ip@@ ra@@ z@@ ole under@@ goes minimal pre-@@ system@@ ic metabolism .
The absolute oral bio@@ availability of the tablet form@@ ulation is 87 % .
There is no effect of a high fat meal on the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole .
Distribution :
A@@ rip@@ ip@@ ra@@ z@@ ole is widely distributed throughout the body with an apparent volume of distribution of 4.@@ 9 l / kg , indic@@ ating extensive ex@@ trav@@ as@@ cular distribution .
At therapeutic concentr@@ ations , ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole are greater than 99 % bound to ser@@ um proteins , binding primarily to alb@@ um@@ in .
Met@@ aboli@@ sm :
A@@ rip@@ ip@@ ra@@ z@@ ole is exten@@ sively metaboli@@ sed by the liver primarily by three bi@@ ot@@ ran@@ s@@ formation path@@ ways : de@@ hydro@@ gen@@ ation , hydro@@ x@@ yl@@ ation , and N-@@ deal@@ k@@ yl@@ ation .
Based on in vit@@ ro studies , C@@ Y@@ P@@ 3@@ A4 and C@@ Y@@ P@@ 2@@ D@@ 6 enz@@ y@@ mes are responsible for de@@ hydro@@ gen@@ ation and hydro@@ x@@ yl@@ ation of ari@@ pip@@ ra@@ z@@ ole , and N-@@ deal@@ k@@ yl@@ ation is cat@@ aly@@ sed by C@@ Y@@ P@@ 3@@ A4 .
A@@ rip@@ ip@@ ra@@ z@@ ole is the pre@@ dominant medic@@ inal product mo@@ i@@ ety in system@@ ic circulation .
At ste@@ ady state , de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole , the active metaboli@@ te , represents about 40 % of ari@@ pip@@ ra@@ z@@ ole AU@@ C in plas@@ ma .
Eli@@ min@@ ation :
The mean elim@@ ination half-@@ lives for ari@@ pip@@ ra@@ z@@ ole are approximately 75 hours in extensive metaboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 and approximately 14@@ 6 hours in poor metaboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 .
The total body clear@@ ance of ari@@ pip@@ ra@@ z@@ ole is 0.@@ 7 ml / min / kg , which is primarily h@@ ep@@ atic .
Following a single oral dose of &#91; 14@@ C &#93; -@@ lab@@ elled ari@@ pip@@ ra@@ z@@ ole , approximately 27 % of the administ@@ ered radio@@ activity was recovered in the ur@@ ine and approximately 60 % in the fa@@ eces .
Less than 1 % of un@@ changed ari@@ pip@@ ra@@ z@@ ole was ex@@ cre@@ ted in the ur@@ ine and approximately 18 % was recovered un@@ changed in the fa@@ eces .
A@@ rip@@ ip@@ ra@@ z@@ ole is well absor@@ bed when administ@@ ered or@@ ally as the solution .
At equivalent d@@ oses , the peak plas@@ ma concentr@@ ations of ari@@ pip@@ ra@@ z@@ ole ( C@@ max ) from the solution were somewhat higher but the system@@ ic
90 exposure ( AU@@ C ) was equivalent to tablets .
In a relative bio@@ availability study compar@@ ing the ph@@ armac@@ ok@@ ine@@ tics of 30 mg ari@@ pip@@ ra@@ z@@ ole as the oral solution to 30 mg ari@@ pip@@ ra@@ z@@ ole tablets in healthy subjects , the solution to the tablet ratio of geomet@@ ric mean C@@ max values was 122 % ( N = 30 ) .
The sing@@ le@@ - dose ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole were linear and dos@@ e-@@ propor@@ tional .
Ph@@ armac@@ ok@@ ine@@ tics in special patient groups
El@@ derly :
There are no differences in the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole between healthy elderly and younger adult subjects , nor is there any det@@ ec@@ table effect of age in a population ph@@ armac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hr@@ en@@ ic patients .
Gender :
There are no differences in the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole between healthy male and female subjects nor is there any det@@ ec@@ table effect of gender in a population ph@@ armac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hr@@ en@@ ic patients .
Smoking and Race :
Population ph@@ armac@@ ok@@ ine@@ tic evaluation has revealed no evidence of clin@@ ically significant rac@@ e-@@ related differences or effects from smoking upon the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole .
Ren@@ al Dis@@ ease :
The ph@@ armac@@ ok@@ ine@@ tic characteristics of ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole were found to be similar in patients with severe ren@@ al disease compared to young healthy subjects .
H@@ ep@@ atic Dis@@ ease :
A single-@@ dose study in subjects with var@@ ying degrees of liver cir@@ r@@ ho@@ sis ( Chil@@ d-@@ Pu@@ gh Cl@@ asses A , B , and C ) did not reveal a significant effect of h@@ ep@@ atic imp@@ air@@ ment on the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole , but the study included only 3 patients with Class C liver cir@@ r@@ ho@@ sis , which is in@@ sufficient to draw conclusions on their metaboli@@ c capacity .
5.@@ 3 Prec@@ lin@@ ical safety data
Non-@@ clinical safety data revealed no special haz@@ ard for humans based on conventional studies of safety ph@@ armac@@ ology , repe@@ at-@@ dose tox@@ ic@@ ity , gen@@ ot@@ ox@@ ic@@ ity , car@@ cin@@ ogen@@ ic potential , and tox@@ ic@@ ity to reproduction .
To@@ x@@ ic@@ ologically significant effects were observed only at d@@ oses or expos@@ ures that were sufficiently in excess of the maximum human dose or exposure , indic@@ ating that these effects were limited or of no relev@@ ance to clinical use .
These included : dos@@ e-@@ dependent ad@@ ren@@ oc@@ or@@ tical tox@@ ic@@ ity ( li@@ po@@ f@@ us@@ c@@ in pig@@ ment accum@@ ulation and / or par@@ ench@@ y@@ mal cell loss ) in rats after 104 weeks at 20 to 60 mg / kg / day ( 3 to 10 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended human dose ) and increased ad@@ ren@@ oc@@ or@@ tical car@@ cin@@ omas and combined ad@@ ren@@ oc@@ or@@ tical aden@@ omas / car@@ cin@@ omas in female rats at 60 mg / kg / day ( 10 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended human dose ) .
The highest n@@ ont@@ um@@ orig@@ en@@ ic exposure in female rats was 7 times the human exposure at the recommended dose .
An additional finding was chol@@ eli@@ thi@@ asis as a consequence of precipitation of sul@@ ph@@ ate con@@ jug@@ ates of hydro@@ xy metaboli@@ tes of ari@@ pip@@ ra@@ z@@ ole in the b@@ ile of mon@@ keys after repeated oral d@@ osing at 25 to 125 mg / kg / day ( 1 to 3 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg / m2 ) .
However , the concentr@@ ations of the sul@@ ph@@ ate con@@ jug@@ ates of hydro@@ xy ari@@ pip@@ ra@@ z@@ ole in human b@@ ile at the highest dose proposed , 30 mg per day , were no more than 6 % of the b@@ ile concentr@@ ations found in the mon@@ keys in the 3@@ 9-@@ week study and are well below ( 6 % ) their limits of in vit@@ ro sol@@ u@@ bility .
Based on results of a full range of standard gen@@ ot@@ ox@@ ic@@ ity tests , ari@@ pip@@ ra@@ z@@ ole was considered non-@@ gen@@ ot@@ ox@@ ic .
A@@ rip@@ ip@@ ra@@ z@@ ole did not imp@@ air fer@@ tility in re@@ productive tox@@ ic@@ ity studies .
Develop@@ mental tox@@ ic@@ ity , including dos@@ e-@@ dependent del@@ ayed fo@@ etal ossi@@ fication and possible ter@@ at@@ ogen@@ ic effects , were
91 observed in rats at d@@ oses resulting in sub@@ therapeutic expos@@ ures ( based on AU@@ C ) and in rab@@ bits at d@@ oses resulting in expos@@ ures 3 and 11 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended clinical dose .
Mat@@ ern@@ al tox@@ ic@@ ity occurred at d@@ oses similar to those el@@ ic@@ iting develop@@ mental tox@@ ic@@ ity .
6 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL P@@ ART@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
Dis@@ o@@ dium ed@@ et@@ ate Fru@@ c@@ t@@ ose Gl@@ y@@ cer@@ in Lac@@ tic acid Meth@@ yl par@@ ah@@ y@@ dro@@ xy@@ ben@@ zo@@ ate ( E@@ 2@@ 18 ) Pro@@ p@@ ylene gly@@ col Pro@@ p@@ yl par@@ ah@@ y@@ dro@@ xy@@ ben@@ zo@@ ate ( E@@ 2@@ 16 ) So@@ dium hydro@@ x@@ ide Su@@ c@@ rose Pur@@ i@@ fied water
Natural orange cream with other natural flav@@ ours
6.2 In@@ compati@@ bilities
The oral solution should not be dil@@ uted with other liqu@@ ids or mixed with any food prior to administration .
6.@@ 3 Shel@@ f life
3 years After first opening :
6 months .
6.@@ 4 Special prec@@ au@@ tions for storage
This medic@@ inal product does not require any special storage conditions .
6.5 Nature and contents of container
P@@ ET@@ -@@ bottles with poly@@ prop@@ ylene chil@@ d-@@ resistant closure containing 50 , 150 or 4@@ 80 ml per bottle .
Each cart@@ on contains 1 bottle and both a calibr@@ ated poly@@ prop@@ ylene measuring cup and a calibr@@ ated poly@@ prop@@ ylene low-@@ density poly@@ eth@@ ylene drop@@ per .
Not all pack sizes may be mark@@ eted .
6.@@ 6 Special prec@@ au@@ tions for disposal and other handling
Any un@@ used product or waste material should be dispos@@ ed of in accordance with local requirements .
7 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
92 8 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION N@@ UM@@ BER ( S )
EU / 1 / 04 / 27@@ 6 / 03@@ 3-@@ 0@@ 35
9 .
D@@ ATE OF F@@ IR@@ ST AU@@ TH@@ OR@@ IS@@ ATION / R@@ EN@@ EW@@ AL OF THE AU@@ TH@@ OR@@ IS@@ ATION
Date of first author@@ isation :
4 June 2004
10 .
D@@ ATE OF RE@@ V@@ IS@@ ION OF THE TE@@ XT
{ M@@ M / Y@@ Y@@ Y@@ Y }
Detailed information on this product is available on the website of the European Medic@@ ines Agency ( EM@@ EA ) http : / / ww@@ w. em@@ e@@ a. europ@@ a. eu /
93 1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 7.5 mg / ml solution for injection
2 .
QU@@ AL@@ IT@@ AT@@ IVE AND QU@@ AN@@ T@@ IT@@ AT@@ IVE COMP@@ OS@@ IT@@ ION
Each ml contains 7.5 mg of ari@@ pip@@ ra@@ z@@ ole .
A vi@@ al contains 9.@@ 75 mg ari@@ pip@@ ra@@ z@@ ole .
For a full list of ex@@ cip@@ i@@ ents , see section 6.@@ 1 .
3 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL FOR@@ M
Solution for injection Clear , colour@@ less , aqu@@ e@@ ous solution .
4 .
CL@@ IN@@ IC@@ AL P@@ ART@@ IC@@ UL@@ AR@@ S
4.1 Therap@@ eu@@ tic indic@@ ations
AB@@ IL@@ IF@@ Y solution for injection is indicated for the rapid control of ag@@ itation and distur@@ bed behavi@@ ours in patients with sch@@ iz@@ op@@ hr@@ en@@ ia or in patients with man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order , when oral therapy is not appropriate .
Treat@@ ment with ari@@ pip@@ ra@@ z@@ ole solution for injection should be dis@@ continued as soon as clin@@ ically appropriate and the use of oral ari@@ pip@@ ra@@ z@@ ole should be initiated .
4.2 Pos@@ ology and method of administration
For in@@ tr@@ am@@ us@@ cular use .
To enhance absor@@ ption and minim@@ ise vari@@ ability , injection into the del@@ to@@ id or deep within the gl@@ ut@@ eus maxim@@ us muscle , avo@@ iding adi@@ pose regions , is recommended .
AB@@ IL@@ IF@@ Y solution for injection should not be administ@@ ered in@@ tra@@ ven@@ ously or sub@@ cut@@ ane@@ ously .
AB@@ IL@@ IF@@ Y solution for injection is ready to use and intended for short-@@ term use only ( see section 5.1 ) .
The recommended initial dose for ari@@ pip@@ ra@@ z@@ ole solution for injection is 9.@@ 75 mg ( 1.3 ml ) , administ@@ ered as a single in@@ tr@@ am@@ us@@ cular injection .
The effective dose range of ari@@ pip@@ ra@@ z@@ ole solution for injection is 5.@@ 25-@@ 15 mg as a single injection .
A lower dose of 5.@@ 25 mg ( 0.@@ 7 ml ) may be given , on the basis of individual clinical status , which should also include consideration of medic@@ inal products already administ@@ ered either for maintenance or ac@@ ute treatment ( see section 4.5 ) .
A second injection may be administ@@ ered 2 hours after the first injection , on the basis of individual clinical status and no more than three inj@@ ections should be given in any 24-hour period .
The maximum daily dose of ari@@ pip@@ ra@@ z@@ ole is 30 mg ( including all form@@ ulations of ari@@ pip@@ ra@@ z@@ ole ) .
If continued treatment is indicated with oral ari@@ pip@@ ra@@ z@@ ole , see the Sum@@ mary of Product Charac@@ ter@@ istics for AB@@ IL@@ IF@@ Y tablets , AB@@ IL@@ IF@@ Y or@@ o@@ disp@@ er@@ sible tablets , or AB@@ IL@@ IF@@ Y oral solution .
Children and ad@@ ol@@ esc@@ ents : there is no experience in children and ad@@ ol@@ esc@@ ents under 18 years of age .
Pati@@ ents with h@@ ep@@ atic imp@@ air@@ ment : no dos@@ age adjustment is required for patients with mild to moderate h@@ ep@@ atic imp@@ air@@ ment .
In patients with severe h@@ ep@@ atic imp@@ air@@ ment , the data available are in@@ sufficient to
94 establish recommendations .
In these patients d@@ osing should be managed cau@@ ti@@ ously .
However , the maximum daily dose of 30 mg should be used with cau@@ tion in patients with severe h@@ ep@@ atic imp@@ air@@ ment ( see section 5.2 ) .
Pati@@ ents with ren@@ al imp@@ air@@ ment : no dos@@ age adjustment is required in patients with ren@@ al imp@@ air@@ ment .
El@@ derly : the effectiveness of AB@@ IL@@ IF@@ Y solution for injection in patients who are 65 years of age or older has not been established .
O@@ wing to the greater sensitivity of this population , a lower starting dose should be considered when clinical factors war@@ rant ( see section 4.4 ) .
Gender : no dos@@ age adjustment is required for female patients as compared to male patients ( see section 5.2 ) .
Smoking status : according to the metaboli@@ c path@@ way of AB@@ IL@@ IF@@ Y no dos@@ age adjustment is required for smo@@ kers ( see section 4.5 ) .
When con@@ com@@ it@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hib@@ itors with ari@@ pip@@ ra@@ z@@ ole occurs , the ari@@ pip@@ ra@@ z@@ ole dose should be reduced .
When the C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hib@@ itor is with@@ drawn from the combination therapy , ari@@ pip@@ ra@@ z@@ ole dose should then be increased ( see section 4.5 ) .
When con@@ com@@ it@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers with ari@@ pip@@ ra@@ z@@ ole occurs , the ari@@ pip@@ ra@@ z@@ ole dose should be increased .
When the C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ er is with@@ drawn from the combination therapy , the ari@@ pip@@ ra@@ z@@ ole dose should then be reduced to the recommended dose ( see section 4.5 ) .
4.3 Con@@ tra@@ indic@@ ations
Hyper@@ sensitivity to the active substance or to any of the ex@@ cip@@ i@@ ents .
4.4 Special war@@ nings and prec@@ au@@ tions for use
The eff@@ ic@@ acy of ari@@ pip@@ ra@@ z@@ ole solution for injection in patients with ag@@ itation and distur@@ bed behavi@@ ours has not been established related to conditions other than sch@@ iz@@ op@@ hr@@ en@@ ia and man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order .
Simul@@ tane@@ ous administration of inj@@ ec@@ table anti@@ psycho@@ tics and par@@ enter@@ al ben@@ zo@@ di@@ az@@ ep@@ ine may be associated with excessive se@@ dation and cardi@@ or@@ esp@@ ir@@ atory depression .
If par@@ enter@@ al ben@@ zo@@ di@@ az@@ ep@@ ine therapy is deemed necessary in addition to ari@@ pip@@ ra@@ z@@ ole solution for injection , patients should be monitored for excessive se@@ dation and for or@@ tho@@ static h@@ yp@@ ot@@ en@@ sion ( see section 4.5 ) .
Pati@@ ents receiving ari@@ pip@@ ra@@ z@@ ole solution for injection should be observed for or@@ tho@@ static h@@ yp@@ ot@@ en@@ sion .
Blood pressure , pul@@ se , resp@@ ir@@ atory rate and level of consciousness should be monitored regularly .
The safety and eff@@ ic@@ acy of ari@@ pip@@ ra@@ z@@ ole solution for injection has not been evaluated in patients with alcohol or medic@@ inal product in@@ tox@@ ic@@ ation ( either with prescri@@ bed or il@@ lic@@ it medic@@ inal products ) .
During anti@@ psycho@@ tic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
Pati@@ ents should be closely monitored throughout this period .
The occurr@@ ence of su@@ ic@@ id@@ al behaviour is inher@@ ent in psycho@@ tic ill@@ nesses and mood disorders and in some cases has been reported early after initi@@ ation or switch of anti@@ psycho@@ tic therapy , including treatment with ari@@ pip@@ ra@@ z@@ ole ( see section 4.@@ 8 ) .
Close supervision of high-@@ risk patients should accompany anti@@ psycho@@ tic therapy .
Results of an epide@@ mi@@ ological study found that there was no increased risk of su@@ ic@@ id@@ ality with ari@@ pip@@ ra@@ z@@ ole compared to other anti@@ psycho@@ tics among patients with bi@@ pol@@ ar dis@@ order .
Cardi@@ ov@@ as@@ cular disorders :
95 conduc@@ tion ab@@ norm@@ alities ) , cer@@ eb@@ rov@@ as@@ cular disease , conditions which would pre@@ disp@@ ose patients to h@@ yp@@ ot@@ en@@ sion ( de@@ hydr@@ ation , hypo@@ vol@@ emia , and treatment with anti@@ hyper@@ ten@@ sive medic@@ ations ) or hyper@@ tension , including acceler@@ ated or mal@@ ign@@ ant .
Con@@ duction ab@@ norm@@ alities :
In clinical trials of ari@@ pip@@ ra@@ z@@ ole , the inci@@ dence of Q@@ T pro@@ long@@ ation was comparable to plac@@ eb@@ o .
As with other anti@@ psycho@@ tics , ari@@ pip@@ ra@@ z@@ ole should be used with cau@@ tion in patients with a family history of Q@@ T pro@@ long@@ ation .
Tar@@ dive Dy@@ sk@@ in@@ esia : in clinical trials of one year or less duration , there were un@@ common reports of treatment emerg@@ ent dy@@ sk@@ in@@ esia during treatment with ari@@ pip@@ ra@@ z@@ ole .
If signs and symptoms of tar@@ dive dy@@ sk@@ in@@ esia appear in a patient on AB@@ IL@@ IF@@ Y , dose reduction or dis@@ continu@@ ation should be considered .
These symptoms can tempor@@ ally deteri@@ or@@ ate or can even arise after dis@@ continu@@ ation of treatment .
Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome ( N@@ MS ) :
N@@ MS is a potentially fat@@ al sy@@ mp@@ tom complex associated with anti@@ psycho@@ tic medic@@ inal products .
In clinical trials , rare cases of N@@ MS were reported during treatment with ari@@ pip@@ ra@@ z@@ ole .
Clin@@ ical manifest@@ ations of N@@ MS are hyper@@ py@@ re@@ x@@ ia , muscle rigi@@ dity , alter@@ ed mental status and evidence of autonom@@ ic inst@@ ability ( ir@@ regular pul@@ se or blood pressure , t@@ ach@@ y@@ car@@ dia , di@@ ap@@ hor@@ esis and cardi@@ ac d@@ ys@@ rhyth@@ m@@ ia ) .
Additional signs may include elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase , my@@ og@@ lo@@ bin@@ ur@@ ia ( r@@ hab@@ dom@@ y@@ oly@@ sis ) , and ac@@ ute ren@@ al failure .
However , elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase and r@@ hab@@ dom@@ y@@ oly@@ sis , not necessarily in association with N@@ MS , have also been reported .
If a patient develops signs and symptoms indic@@ ative of N@@ MS , or presents with un@@ explained high f@@ ever without additional clinical manifest@@ ations of N@@ MS , all anti@@ psycho@@ tic medic@@ inal products , including AB@@ IL@@ IF@@ Y , must be dis@@ continued .
Sei@@ z@@ ure : in clinical trials , un@@ common cases of sei@@ z@@ ure were reported during treatment with ari@@ pip@@ ra@@ z@@ ole .
Therefore , ari@@ pip@@ ra@@ z@@ ole should be used with cau@@ tion in patients who have a history of sei@@ z@@ ure dis@@ order or have conditions associated with sei@@ zur@@ es .
El@@ derly patients with de@@ men@@ ti@@ a-@@ related psycho@@ sis :
Incre@@ ased mort@@ ality : in three plac@@ eb@@ o-@@ controlled trials ( n = 9@@ 38 ; mean age :
8@@ 2.4 years ; range :
5@@ 6-@@ 99 years ) of ari@@ pip@@ ra@@ z@@ ole in elderly patients with psycho@@ sis associated with Alz@@ heimer &apos;s disease , patients treated with ari@@ pip@@ ra@@ z@@ ole were at increased risk of death compared to plac@@ eb@@ o .
The rate of death in ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients was 3.5 % compared to 1.7 % in the plac@@ eb@@ o group .
Although the causes of deaths were varied , most of the deaths appeared to be either cardi@@ ov@@ as@@ cular ( e. g. heart failure , sudden death ) or inf@@ ec@@ tious ( e. g. pneum@@ onia ) in nature .
Cer@@ eb@@ rov@@ as@@ cular ad@@ verse events : in the same trials , cer@@ eb@@ rov@@ as@@ cular ad@@ verse events ( e. g. stroke , transi@@ ent isch@@ a@@ em@@ ic attack ) , including fat@@ alities , were reported in patients ( mean age :
84 years ; range :
7@@ 8-@@ 88 years ) .
Overall , 1.3 % of ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients reported cer@@ eb@@ rov@@ as@@ cular ad@@ verse events compared with 0.@@ 6 % of plac@@ eb@@ o-@@ treated patients in these trials .
This difference was not statisti@@ cally significant .
However , in one of these trials , a fix@@ ed-@@ dose trial , there was a significant dose response relationship for cer@@ eb@@ rov@@ as@@ cular ad@@ verse events in patients treated with ari@@ pip@@ ra@@ z@@ ole .
AB@@ IL@@ IF@@ Y is not approved for the treatment of de@@ men@@ ti@@ a-@@ related psycho@@ sis .
Hyper@@ gly@@ ca@@ emia and Diabetes M@@ elli@@ tus : hyper@@ gly@@ ca@@ emia , in some cases extreme and associated with k@@ eto@@ aci@@ do@@ sis or hyper@@ os@@ mol@@ ar com@@ a or death , has been reported in patients treated with at@@ yp@@ ical anti@@ psycho@@ tic agents , including AB@@ IL@@ IF@@ Y .
Risk factors that may pre@@ disp@@ ose patients to severe complic@@ ations include o@@ bes@@ ity and family history of diabetes .
In clinical trials with ari@@ pip@@ ra@@ z@@ ole , there were no significant differences in the inci@@ dence rates of hyper@@ gly@@ ca@@ em@@ i@@ a-@@ related ad@@ verse events ( including diabetes ) or in ab@@ normal gly@@ ca@@ emia laboratory values compared to plac@@ eb@@ o .
Prec@@ ise risk estimates for hyper@@ gly@@ ca@@ em@@ i@@ a-@@ related ad@@ verse events in patients treated with AB@@ IL@@ IF@@ Y and with other at@@ yp@@ ical anti@@ psycho@@ tic agents are not available to allow direct comparis@@ ons .
Pati@@ ents treated with any anti@@ psycho@@ tic agents , including AB@@ IL@@ IF@@ Y , should be observed for signs and symptoms of hyper@@ gly@@ ca@@ emia ( such as poly@@ di@@ p@@ sia , poly@@ ur@@ ia , poly@@ ph@@ ag@@ ia and weak@@ ness ) and patients with diabetes mel@@ lit@@ us or with risk factors for diabetes mel@@ lit@@ us should be monitored regularly for wor@@ sen@@ ing of glu@@ c@@ ose control .
96 Weight gain : weight gain is commonly seen in sch@@ iz@@ op@@ hr@@ en@@ ic and bi@@ pol@@ ar man@@ ia patients due to co@@ - mor@@ bi@@ di@@ ties , use of anti@@ psycho@@ tics known to cause weight gain , poor@@ ly managed life-@@ style , and might lead to severe complic@@ ations .
Weight gain has been reported post-@@ marketing among patients prescri@@ bed AB@@ IL@@ IF@@ Y .
When seen , it is usually in those with significant risk factors such as history of diabetes , th@@ y@@ ro@@ id dis@@ order or p@@ itu@@ itary aden@@ oma .
In clinical trials ari@@ pip@@ ra@@ z@@ ole has not been shown to in@@ duce clin@@ ically relevant weight gain ( see section 5.1 ) .
Dy@@ sph@@ ag@@ ia : o@@ es@@ op@@ ha@@ ge@@ al d@@ ys@@ mo@@ tility and asp@@ ir@@ ation have been associated with anti@@ psycho@@ tic drug use , including AB@@ IL@@ IF@@ Y .
A@@ rip@@ ip@@ ra@@ z@@ ole and other anti@@ psycho@@ tic drugs should be used cau@@ ti@@ ously in patients at risk for asp@@ ir@@ ation pneum@@ onia .
Hyper@@ sensitivity : as with other medic@@ ations hyper@@ sensitivity reactions , characterised by aller@@ gic symptoms , may occur with ari@@ pip@@ ra@@ z@@ ole ( see section 4.@@ 8 ) .
4.5 Inter@@ action with other medic@@ inal products and other forms of interaction
Due to its α 1-@@ ad@@ ren@@ ergi@@ c recep@@ tor ant@@ agon@@ ism , ari@@ pip@@ ra@@ z@@ ole has the potential to enhance the effect of certain anti@@ hyper@@ ten@@ sive agents .
Given the primary CN@@ S effects of ari@@ pip@@ ra@@ z@@ ole , cau@@ tion should be used when ari@@ pip@@ ra@@ z@@ ole is taken in combination with alcohol or other CN@@ S medic@@ inal products with over@@ l@@ apping undes@@ irable effects such as se@@ dation ( see section 4.@@ 8 ) .
If ari@@ pip@@ ra@@ z@@ ole is administ@@ ered con@@ com@@ it@@ antly with medicines known to cause Q@@ T pro@@ long@@ ation or elec@@ trol@@ yte im@@ balance , cau@@ tion should be used .
Potential for other medic@@ inal products to affect AB@@ IL@@ IF@@ Y :
The administration of lor@@ az@@ ep@@ am solution for injection had no effect on the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole solution for injection when administ@@ ered con@@ com@@ it@@ antly .
However , in a single-@@ dose , in@@ tr@@ am@@ us@@ cular study of ari@@ pip@@ ra@@ z@@ ole ( dose 15 mg ) in healthy subjects , administ@@ ered simultaneously with in@@ tr@@ am@@ us@@ cular lor@@ az@@ ep@@ am ( dose 2 mg ) , the intensity of se@@ dation was greater with the combination as compared to that observed with ari@@ pip@@ ra@@ z@@ ole alone .
A ga@@ stri@@ c acid blo@@ cker , the H@@ 2 ant@@ agon@@ ist fam@@ oti@@ d@@ ine , reduces ari@@ pip@@ ra@@ z@@ ole rate of absor@@ ption but this effect is deemed not clin@@ ically relevant .
A@@ rip@@ ip@@ ra@@ z@@ ole is metaboli@@ sed by multiple path@@ ways involving the C@@ Y@@ P@@ 2@@ D@@ 6 and C@@ Y@@ P@@ 3@@ A4 enz@@ y@@ mes but not C@@ Y@@ P@@ 1@@ A enz@@ y@@ mes .
Thus , no dos@@ age adjustment is required for smo@@ kers .
In a clinical trial in healthy subjects , a pot@@ ent in@@ hib@@ itor of C@@ Y@@ P@@ 2@@ D@@ 6 ( qu@@ in@@ id@@ ine ) increased ari@@ pip@@ ra@@ z@@ ole AU@@ C by 107 % , while C@@ max was un@@ changed .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole , the active metaboli@@ te , decreased by 32 % and 47 % .
AB@@ IL@@ IF@@ Y dose should be reduced to approximately one-@@ half of its prescri@@ bed dose when con@@ com@@ it@@ ant administration of AB@@ IL@@ IF@@ Y with qu@@ in@@ id@@ ine occurs .
Other pot@@ ent in@@ hib@@ itors of C@@ Y@@ P@@ 2@@ D@@ 6 , such as flu@@ ox@@ et@@ ine and par@@ ox@@ et@@ ine , may be expected to have similar effects and similar dose reduc@@ tions should therefore be applied .
In a clinical trial in healthy subjects , a pot@@ ent in@@ hib@@ itor of C@@ Y@@ P@@ 3@@ A4 ( k@@ eto@@ con@@ az@@ ole ) increased ari@@ pip@@ ra@@ z@@ ole AU@@ C and C@@ max by 63 % and 37 % , respectively .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole increased by 77 % and 43 % , respectively .
In C@@ Y@@ P@@ 2@@ D@@ 6 poor metaboli@@ sers , con@@ com@@ it@@ ant use of pot@@ ent in@@ hib@@ itors of C@@ Y@@ P@@ 3@@ A4 may result in higher plas@@ ma concentr@@ ations of ari@@ pip@@ ra@@ z@@ ole compared to that in C@@ Y@@ P@@ 2@@ D@@ 6 extensive metaboli@@ z@@ ers .
When considering con@@ com@@ it@@ ant administration of k@@ eto@@ con@@ az@@ ole or other pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hib@@ itors with AB@@ IL@@ IF@@ Y , potential benefits should out@@ wei@@ gh the potential risks to the patient .
When con@@ com@@ it@@ ant administration of k@@ eto@@ con@@ o@@ z@@ ole with AB@@ IL@@ IF@@ Y occurs , AB@@ IL@@ IF@@ Y dose should be reduced to approximately one-@@ half of its prescri@@ bed dose .
Other pot@@ ent in@@ hib@@ itors of C@@ Y@@ P@@ 3@@ A4 , such as it@@ ra@@ con@@ az@@ ole and HIV pro@@ tease in@@ hib@@ itors , may be expected to have similar effects and similar dose reduc@@ tions should therefore be applied .
97 Upon dis@@ continu@@ ation of the C@@ Y@@ P@@ 2@@ D@@ 6 or 3@@ A4 in@@ hib@@ itor , the dos@@ age of AB@@ IL@@ IF@@ Y should be increased to the level prior to the initi@@ ation of the con@@ com@@ it@@ ant therapy .
When weak in@@ hib@@ itors of C@@ Y@@ P@@ 3@@ A4 ( e. g . , dil@@ ti@@ az@@ em or esc@@ it@@ al@@ op@@ ram ) or C@@ Y@@ P@@ 2@@ D@@ 6 are used con@@ com@@ it@@ antly with AB@@ IL@@ IF@@ Y , mod@@ est increases in ari@@ pip@@ ra@@ z@@ ole concentr@@ ations might be expected .
Following con@@ com@@ it@@ ant administration of carb@@ amaz@@ ep@@ ine , a pot@@ ent in@@ duc@@ er of C@@ Y@@ P@@ 3@@ A4 , the geomet@@ ric means of C@@ max and AU@@ C for ari@@ pip@@ ra@@ z@@ ole were 68 % and 73 % lower , respectively , compared to when ari@@ pip@@ ra@@ z@@ ole ( 30 mg ) was administ@@ ered alone .
Simil@@ arly , for de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole the geomet@@ ric means of C@@ max and AU@@ C after carb@@ amaz@@ ep@@ ine co-@@ administration were 69 % and 71 % lower , respectively , than those following treatment with ari@@ pip@@ ra@@ z@@ ole alone .
AB@@ IL@@ IF@@ Y dose should be dou@@ bled when con@@ com@@ it@@ ant administration of AB@@ IL@@ IF@@ Y occurs with carb@@ amaz@@ ep@@ ine .
John &apos;s Wort ) may be expected to have similar effects and similar dose increases should therefore be applied .
Upon dis@@ continu@@ ation of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers , the dos@@ age of AB@@ IL@@ IF@@ Y should be reduced to the recommended dose .
When either val@@ pro@@ ate or li@@ th@@ ium were administ@@ ered con@@ com@@ it@@ antly with ari@@ pip@@ ra@@ z@@ ole , there was no clin@@ ically significant change in ari@@ pip@@ ra@@ z@@ ole concentr@@ ations .
Potential for AB@@ IL@@ IF@@ Y to affect other medic@@ inal products :
The administration of ari@@ pip@@ ra@@ z@@ ole solution for injection had no effect on the ph@@ armac@@ ok@@ ine@@ tics of lor@@ az@@ ep@@ am solution for injection when administ@@ ered con@@ com@@ it@@ antly .
However , in a single-@@ dose , in@@ tr@@ am@@ us@@ cular study of ari@@ pip@@ ra@@ z@@ ole ( dose 15 mg ) in healthy subjects , administ@@ ered simultaneously with in@@ tr@@ am@@ us@@ cular lor@@ az@@ ep@@ am ( dose 2 mg ) , the or@@ tho@@ static h@@ yp@@ ot@@ en@@ sion observed was greater with the combination as compared to that observed with lor@@ az@@ ep@@ am alone .
In clinical studies , 10-@@ 30 mg / day d@@ oses of ari@@ pip@@ ra@@ z@@ ole had no significant effect on the metabolism of sub@@ str@@ ates of C@@ Y@@ P@@ 2@@ D@@ 6 ( de@@ x@@ tro@@ meth@@ orph@@ an / 3-@@ metho@@ xy@@ mor@@ ph@@ in@@ an ratio ) , 2@@ C@@ 9 ( war@@ far@@ in ) , 2@@ C@@ 19 ( om@@ ep@@ ra@@ z@@ ole ) , and 3@@ A4 ( de@@ x@@ tro@@ meth@@ orph@@ an ) .
Additionally , ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole did not show potential for alter@@ ing C@@ Y@@ P@@ 1@@ A@@ 2-@@ medi@@ ated metabolism in vit@@ ro .
Thus , ari@@ pip@@ ra@@ z@@ ole is un@@ likely to cause clin@@ ically important medic@@ inal product inter@@ actions medi@@ ated by these enz@@ y@@ mes .
When ari@@ pip@@ ra@@ z@@ ole was administ@@ ered con@@ com@@ it@@ antly with either val@@ pro@@ ate or li@@ th@@ ium , there was no clin@@ ically important change in val@@ pro@@ ate or li@@ th@@ ium concentr@@ ations .
4.@@ 6 Pre@@ gn@@ ancy and lac@@ tation
There are no adequate and well-@@ controlled trials of ari@@ pip@@ ra@@ z@@ ole in pregnant women .
Animal studies could not exclu@@ de potential develop@@ mental tox@@ ic@@ ity ( see section 5.@@ 3 ) .
Pati@@ ents should be advised to noti@@ fy their physi@@ cian if they become pregnant or intend to become pregnant during treatment with ari@@ pip@@ ra@@ z@@ ole .
Due to in@@ sufficient safety information in humans and concerns raised by animal re@@ productive studies , this medic@@ inal product should not be used in pregnancy unless the expected benefit clearly justi@@ fies the potential risk to the fo@@ etus .
A@@ rip@@ ip@@ ra@@ z@@ ole was ex@@ cre@@ ted in the milk of treated rats during lac@@ tation .
Pati@@ ents should be advised not to breast feed if they are taking ari@@ pip@@ ra@@ z@@ ole .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No studies on the effect on the ability to drive and use machines have been performed .
However , as with other anti@@ psycho@@ tics , patients should be cau@@ tioned about operating haz@@ ard@@ ous machines , including motor vehicles , until they are reason@@ ably certain that ari@@ pip@@ ra@@ z@@ ole does not affect them ad@@ ver@@ sely .
98 4.@@ 8 Un@@ des@@ irable effects
The following undes@@ irable effects occurred more often ( ≥ 1 / 100 ) than plac@@ eb@@ o , or were identified as possibly medi@@ cally relevant ad@@ verse reactions ( * ) in clinical trials with ari@@ pip@@ ra@@ z@@ ole solution for injection ( see section 5.1 ) :
The frequency listed below is defined using the following convention : common ( ≥ 1 / 100 , &lt; 1 / 10 ) and un@@ common ( ≥ 1 / 1,000 , &lt; 1 / 100 ) .
Cardi@@ ac disorders Un@@ common : t@@ ach@@ y@@ car@@ dia * N@@ erv@@ ous system disorders Common : som@@ n@@ ol@@ ence , di@@ zz@@ iness , head@@ ache , ak@@ ath@@ is@@ ia Gast@@ ro@@ int@@ est@@ inal disorders Common : nau@@ sea , v@@ om@@ iting Un@@ common : dry mouth * Vas@@ cular disorders Un@@ common : or@@ tho@@ static h@@ yp@@ ot@@ en@@ sion * , increased di@@ ast@@ olic blood pressure * General disorders and administration site conditions Un@@ common : f@@ ati@@ gue *
The following undes@@ irable effects occurred more often ( ≥ 1 / 100 ) than plac@@ eb@@ o , or were identified as possibly medi@@ cally relevant ad@@ verse reactions ( * ) in clinical trials with oral form@@ ulations of ari@@ pip@@ ra@@ z@@ ole ( see section 5.1 ) :
Cardi@@ ac disorders Un@@ common : t@@ ach@@ y@@ car@@ dia * N@@ erv@@ ous system disorders Common : extra@@ py@@ ram@@ id@@ al dis@@ order , ak@@ ath@@ is@@ ia , tre@@ m@@ or , di@@ zz@@ iness , som@@ n@@ ol@@ ence , se@@ dation , head@@ ache Eye disorders Common : bl@@ urred vision Gast@@ ro@@ int@@ est@@ inal disorders Common : dy@@ sp@@ ep@@ sia , v@@ om@@ iting , nau@@ sea , con@@ sti@@ p@@ ation , s@@ ali@@ vary hy@@ persec@@ re@@ tion Vas@@ cular disorders Un@@ common : or@@ tho@@ static h@@ yp@@ ot@@ en@@ sion * General disorders and administration site conditions Common : f@@ ati@@ gue Psych@@ iat@@ ric disorders Common : rest@@ less@@ ness , in@@ som@@ nia , an@@ xi@@ ety Un@@ common : depression *
Extra@@ py@@ ram@@ id@@ al symptoms ( EP@@ S ) :
Sch@@ iz@@ op@@ hr@@ en@@ ia - in a long term 5@@ 2-@@ week controlled trial , ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients had an over@@ all-@@ lower inci@@ dence ( 25.@@ 8 % ) of EP@@ S including par@@ kin@@ son@@ ism , ak@@ ath@@ is@@ ia , d@@ yst@@ onia and dy@@ sk@@ in@@ esia compared with those treated with hal@@ op@@ eri@@ do@@ l ( 5@@ 7.@@ 3 % ) .
In a long term 26@@ -@@ week plac@@ eb@@ o-@@ controlled trial , the inci@@ dence of EP@@ S was 19 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 13@@ .1 % for plac@@ eb@@ o-@@ treated patients .
In another long-term 26@@ -@@ week controlled trial , the inci@@ dence of EP@@ S was 14.@@ 8 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 15@@ .1 % for ol@@ anz@@ ap@@ ine-@@ treated patients .
Man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order - in a 12-@@ week controlled trial , the inci@@ dence of EP@@ S was 2@@ 3.5 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 5@@ 3.3 % for hal@@ op@@ eri@@ dol@@ -@@ treated patients .
In another 12-@@ week trial , the inci@@ dence of EP@@ S was 26.@@ 6 % for patients treated with ari@@ pip@@ ra@@ z@@ ole and 17.@@ 6 % for those treated with li@@ th@@ ium .
In the long term 26@@ -@@ week maintenance phase of a plac@@ eb@@ o-@@ controlled trial , the inci@@ dence of EP@@ S was 18.@@ 2 % for ari@@ pip@@ ra@@ z@@ ol@@ e-@@ treated patients and 15.@@ 7 % for plac@@ eb@@ o-@@ treated patients .
In plac@@ eb@@ o-@@ controlled trials , the inci@@ dence of ak@@ ath@@ is@@ ia in bi@@ pol@@ ar patients was 12.@@ 1 % with ari@@ pip@@ ra@@ z@@ ole and 3.2 % with plac@@ eb@@ o .
In sch@@ iz@@ op@@ hr@@ en@@ ia patients the inci@@ dence of ak@@ ath@@ is@@ ia was 6.2 % with ari@@ pip@@ ra@@ z@@ ole and 3.0 % with plac@@ eb@@ o .
99 Compar@@ is@@ ons between ari@@ pip@@ ra@@ z@@ ole and plac@@ eb@@ o in the propor@@ tions of patients experiencing potentially clin@@ ically significant changes in routine laboratory parameters revealed no medi@@ cally important differences .
Elev@@ ations of CP@@ K ( Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ ase ) , generally transi@@ ent and asy@@ mpt@@ omati@@ c , were observed in 3.5 % of ari@@ pip@@ ra@@ z@@ ole treated patients as compared to 2.0 % of patients who received plac@@ eb@@ o .
Other findings :
Un@@ des@@ irable effects known to be associated with anti@@ psycho@@ tic therapy and also reported during treatment with ari@@ pip@@ ra@@ z@@ ole include neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ drome , tar@@ dive dy@@ sk@@ in@@ esia , sei@@ z@@ ure , cer@@ eb@@ rov@@ as@@ cular ad@@ verse events and increased mort@@ ality in elderly dem@@ ented patients , hyper@@ gly@@ ca@@ emia and diabetes mel@@ lit@@ us ( see section 4.4 ) .
Po@@ st-@@ Marketing :
The following ad@@ verse events have been reported during post-@@ marketing surveillance .
The frequency of these events is considered not known ( cannot be estimated from the available data ) .
Inves@@ tig@@ ations :
increased Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ ase , blood glu@@ c@@ ose increased , blood glu@@ c@@ ose flu@@ c@@ tu@@ ation , gly@@ cos@@ yl@@ ated ha@@ em@@ og@@ lob@@ in increased
Cardi@@ ac disorders :
Q@@ T pro@@ long@@ ation , v@@ entri@@ cular ar@@ rhyth@@ mi@@ as , sudden un@@ explained death , cardi@@ ac arrest , tor@@ sa@@ des de poin@@ tes , bra@@ dy@@ car@@ dia
Blood and the ly@@ m@@ ph@@ atic system disorders :
leu@@ kop@@ en@@ ia , neut@@ rop@@ en@@ ia , thro@@ mbo@@ cy@@ top@@ en@@ ia
N@@ erv@@ ous system disorders :
speech dis@@ order , Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome ( N@@ MS ) , grand mal conv@@ ul@@ sion
Resp@@ ir@@ atory , thor@@ ac@@ ic and medi@@ ast@@ inal disorders :
or@@ op@@ har@@ yn@@ ge@@ al sp@@ as@@ m , lar@@ yn@@ g@@ osp@@ as@@ m , asp@@ ir@@ ation pneum@@ onia
Gast@@ ro@@ int@@ est@@ inal disorders :
pan@@ cre@@ ati@@ tis , dy@@ sph@@ ag@@ ia , ab@@ dom@@ inal dis@@ comfort , stomach dis@@ comfort , di@@ ar@@ r@@ ho@@ ea
Ren@@ al and ur@@ inary disorders :
ur@@ inary in@@ contin@@ ence , ur@@ inary re@@ tention
Skin and sub@@ cut@@ aneous tissue disorders :
r@@ ash , phot@@ os@@ ensi@@ tivity reaction , al@@ op@@ eci@@ a , hyper@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ etal and connec@@ tive tissue disorders :
r@@ hab@@ dom@@ y@@ oly@@ sis , my@@ al@@ gia , sti@@ ff@@ ness
En@@ doc@@ r@@ ine disorders :
hyper@@ gly@@ ca@@ emia , diabetes mel@@ lit@@ us , di@@ ab@@ etic k@@ eto@@ aci@@ do@@ sis , di@@ ab@@ etic hyper@@ os@@ mol@@ ar com@@ a
Met@@ aboli@@ sm and nutrition disorders :
weight gain , weight decreased , an@@ or@@ ex@@ ia , h@@ yp@@ on@@ at@@ rem@@ ia
Vas@@ cular disorders :
syn@@ cope , hyper@@ tension , thro@@ mbo@@ em@@ bo@@ lic events
General disorders and administration site conditions :
temperature regulation dis@@ order ( e. g. hypo@@ ther@@ m@@ ia , py@@ re@@ x@@ ia ) , chest pain , periph@@ eral o@@ e@@ de@@ ma
Im@@ m@@ une system disorders :
aller@@ gic reaction ( e. g. an@@ ap@@ hy@@ lac@@ tic reaction , an@@ gi@@ o@@ e@@ de@@ ma including sw@@ ollen tongue , tongue o@@ e@@ de@@ ma , face o@@ e@@ de@@ ma , pr@@ ur@@ it@@ us , or ur@@ tic@@ aria )
H@@ ep@@ at@@ o@@ bili@@ ary disorders :
j@@ a@@ un@@ dice , h@@ ep@@ ati@@ tis , increased Al@@ an@@ ine Amin@@ ot@@ ran@@ s@@ fer@@ ase ( AL@@ T ) , increased A@@ spart@@ ate Amin@@ ot@@ ran@@ s@@ fer@@ ase ( AS@@ T ) , increased G@@ amma Gl@@ ut@@ am@@ yl Transfer@@ ase ( G@@ GT ) , increased al@@ kal@@ ine phosph@@ at@@ ase
Re@@ productive system and breast disorders :
pri@@ ap@@ ism
Psych@@ iat@@ ric disorders :
ag@@ itation , ner@@ v@@ ousness ; suicide attempt , su@@ ic@@ id@@ al ide@@ ation , and completed suicide ( see section 4.4 )
4.@@ 9 Over@@ dose
In clinical trials and post-@@ marketing experience , acci@@ dental or inten@@ tional ac@@ ute over@@ dos@@ age of ari@@ pip@@ ra@@ z@@ ole alone was identified in adult patients with reported estimated d@@ oses up to 1,@@ 260 mg with no fat@@ alities .
The potentially medi@@ cally important signs and symptoms observed included le@@ th@@ ar@@ gy , increased blood pressure , som@@ n@@ ol@@ ence , t@@ ach@@ y@@ car@@ dia , nau@@ sea , v@@ om@@ iting and di@@ ar@@ r@@ ho@@ ea .
In addition , reports of acci@@ dental over@@ dose with ari@@ pip@@ ra@@ z@@ ole alone ( up to 195 mg ) in children have been received with no fat@@ alities .
The potentially medi@@ cally serious signs and symptoms reported included som@@ n@@ ol@@ ence , transi@@ ent loss of consciousness and extra@@ py@@ ram@@ id@@ al symptoms .
Management of over@@ dose should concentrate on sup@@ por@@ tive therapy , maintaining an adequate air@@ way , oxy@@ gen@@ ation and ventil@@ ation , and management of symptoms .
The possibility of multiple medic@@ inal product involvement should be considered .
Therefore cardi@@ ov@@ as@@ cular monitoring should be started immediately and should include continuous electro@@ cardi@@ ographic monitoring to detect possible ar@@ rhyth@@ mi@@ as .
Following any confirmed or susp@@ ected over@@ dose with ari@@ pip@@ ra@@ z@@ ole , close medical supervision and monitoring should continue until the patient re@@ covers .
Activ@@ ated char@@ coal ( 50 g ) , administ@@ ered one hour after ari@@ pip@@ ra@@ z@@ ole , decreased ari@@ pip@@ ra@@ z@@ ole C@@ max by about 41 % and AU@@ C by about 51 % , suggest@@ ing that char@@ coal may be effective in the treatment of over@@ dose .
Although there is no information on the effect of ha@@ emo@@ di@@ aly@@ sis in tre@@ ating an over@@ dose with ari@@ pip@@ ra@@ z@@ ole , ha@@ emo@@ di@@ aly@@ sis is un@@ likely to be useful in over@@ dose management since ari@@ pip@@ ra@@ z@@ ole is highly bound to plas@@ ma proteins .
5 .
PH@@ AR@@ MA@@ CO@@ LO@@ G@@ IC@@ AL PRO@@ PER@@ TI@@ ES
5.1 Ph@@ armac@@ o@@ dynamic properties
Ph@@ armac@@ o@@ therapeutic group : anti@@ psycho@@ tics , AT@@ C code :
N@@ 05@@ AX@@ 12
It has been proposed that ari@@ pip@@ ra@@ z@@ ole ’ s eff@@ ic@@ acy in sch@@ iz@@ op@@ hr@@ en@@ ia and Bi@@ pol@@ ar I Dis@@ order is medi@@ ated through a combination of partial agon@@ ism at d@@ op@@ am@@ ine D@@ 2 and ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ a rec@@ ept@@ ors and ant@@ agon@@ ism of ser@@ ot@@ on@@ in 5@@ HT@@ 2@@ a rec@@ ept@@ ors .
A@@ rip@@ ip@@ ra@@ z@@ ole exhib@@ ited ant@@ agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ ergi@@ c hyper@@ activity and agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ ergi@@ c hypo@@ activity .
A@@ rip@@ ip@@ ra@@ z@@ ole exhib@@ ited high binding aff@@ inity in vit@@ ro for d@@ op@@ am@@ ine D@@ 2 and D@@ 3 , ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ a and 5@@ HT@@ 2@@ a rec@@ ept@@ ors and moderate aff@@ inity for d@@ op@@ am@@ ine D@@ 4 , ser@@ ot@@ on@@ in 5@@ HT@@ 2@@ c and 5@@ HT@@ 7 , alp@@ ha@@ -1 ad@@ ren@@ ergi@@ c and hist@@ am@@ ine H@@ 1 rec@@ ept@@ ors .
A@@ rip@@ ip@@ ra@@ z@@ ole also exhib@@ ited moderate binding aff@@ inity for the ser@@ ot@@ on@@ in re@@ up@@ take site and no appreci@@ able aff@@ inity for mus@@ car@@ in@@ ic rec@@ ept@@ ors .
Inter@@ action with rec@@ ept@@ ors other than d@@ op@@ am@@ ine and ser@@ ot@@ on@@ in sub@@ types may explain some of the other clinical effects of ari@@ pip@@ ra@@ z@@ ole .
A@@ rip@@ ip@@ ra@@ z@@ ole d@@ oses ranging from 0.5 to 30 mg administ@@ ered once a day to healthy subjects for 2 weeks produced a dos@@ e-@@ dependent reduction in the binding of 11@@ C-@@ rac@@ lo@@ pride , a D@@ 2 / D@@ 3 recep@@ tor lig@@ and , to the cau@@ date and put@@ amen detected by pos@@ it@@ ron emission tom@@ ography .
101 Further information on clinical trials :
Ag@@ itation in sch@@ iz@@ op@@ hr@@ en@@ ia and Bi@@ pol@@ ar I Dis@@ order with ari@@ pip@@ ra@@ z@@ ole solution for injection :
In two short@@ - term ( 24-hour ) plac@@ eb@@ o-@@ controlled trials involving 5@@ 54 sch@@ iz@@ op@@ hr@@ en@@ ic patients presenting with ag@@ itation and distur@@ bed behavi@@ ours , ari@@ pip@@ ra@@ z@@ ole solution for injection was associated with statisti@@ cally significant greater improvements in ag@@ itation / behavi@@ our@@ al symptoms compared to plac@@ eb@@ o and was similar to hal@@ op@@ eri@@ do@@ l .
In one short-@@ term ( 24-hour ) plac@@ eb@@ o-@@ controlled trial involving 29@@ 1 patients with bi@@ pol@@ ar dis@@ order presenting with ag@@ itation and distur@@ bed behavi@@ ours , ari@@ pip@@ ra@@ z@@ ole solution for injection was associated with statisti@@ cally significant greater improvements in ag@@ itation / behavi@@ our@@ al symptoms compared to plac@@ eb@@ o and was similar to the reference arm lor@@ az@@ ep@@ am .
The observed mean improvement from bas@@ eline on the P@@ AN@@ SS Exc@@ it@@ ement Compon@@ ent score at the primary 2-@@ hour end@@ point was 5.@@ 8 for plac@@ eb@@ o , 9.@@ 6 for lor@@ az@@ ep@@ am , and 8.@@ 7 for ari@@ pip@@ ra@@ z@@ ole .
In sub@@ population analyses on patients with mixed episodes or on patients with severe ag@@ itation , a similar pattern of eff@@ ic@@ acy to the overall population was observed but statistical significance could not be established due to a reduced sample size .
Sch@@ iz@@ op@@ hr@@ en@@ ia with oral ari@@ pip@@ ra@@ z@@ ole :
In three short-@@ term ( 4 to 6 weeks ) plac@@ eb@@ o-@@ controlled trials involving 1,@@ 2@@ 28 sch@@ iz@@ op@@ hr@@ en@@ ic patients , presenting with positive or negative symptoms , oral ari@@ pip@@ ra@@ z@@ ole was associated with statisti@@ cally significantly greater improvements in psycho@@ tic symptoms compared to plac@@ eb@@ o .
AB@@ IL@@ IF@@ Y is effective in maintaining the clinical improvement during continu@@ ation therapy in patients who have shown an initial treatment response .
In a hal@@ op@@ eri@@ dol@@ -@@ controlled trial , the proportion of respon@@ der patients maintaining response to medic@@ inal product at 5@@ 2-@@ weeks was similar in both groups ( oral ari@@ pip@@ ra@@ z@@ ole 77 % and hal@@ op@@ eri@@ do@@ l 73 % ) .
The overall completion rate was significantly higher for patients on oral ari@@ pip@@ ra@@ z@@ ole ( 43 % ) than for oral hal@@ op@@ eri@@ do@@ l ( 30 % ) .
Ac@@ tual scores in rating sc@@ ales used as secondary end@@ points , including P@@ AN@@ SS and the Mont@@ g@@ om@@ er@@ y-@@ As@@ berg Depression Rating Sc@@ ale showed a significant improvement over hal@@ op@@ eri@@ do@@ l .
In a 26@@ -@@ week , plac@@ eb@@ o-@@ controlled trial in stabili@@ sed patients with chronic sch@@ iz@@ op@@ hr@@ en@@ ia , oral ari@@ pip@@ ra@@ z@@ ole had significantly greater reduction in rel@@ ap@@ se rate , 34 % in oral ari@@ pip@@ ra@@ z@@ ole group and 57 % in plac@@ eb@@ o .
Weight gain : in clinical trials oral ari@@ pip@@ ra@@ z@@ ole has not been shown to in@@ duce clin@@ ically relevant weight gain .
In a 26@@ -@@ week , ol@@ anz@@ ap@@ ine-@@ controlled , double-@@ blind , multi-@@ national study of sch@@ iz@@ op@@ hr@@ en@@ ia which included 3@@ 14 patients and where the primary end-@@ point was weight gain , significantly less patients had at least 7 % weight gain over bas@@ eline ( i@@ . e. a gain of at least 5.@@ 6 kg for a mean bas@@ eline weight of ~ 8@@ 0.5 kg ) on oral ari@@ pip@@ ra@@ z@@ ole ( N = 18 , or 13 % of evalu@@ able patients ) , compared to oral ol@@ anz@@ ap@@ ine ( N = 45 , or 33 % of evalu@@ able patients ) .
Man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order with oral ari@@ pip@@ ra@@ z@@ ole :
In two 3-@@ week , flexi@@ b@@ le-@@ dose , plac@@ eb@@ o-@@ controlled mon@@ o@@ therapy trials involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , ari@@ pip@@ ra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to plac@@ eb@@ o in reduction of man@@ ic symptoms over 3 weeks .
These trials included patients with or without psycho@@ tic features and with or without a rap@@ id-@@ cycling course .
In one 3-@@ week , fix@@ ed-@@ dose , plac@@ eb@@ o-@@ controlled mon@@ o@@ therapy trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , ari@@ pip@@ ra@@ z@@ ole failed to demonstrate superior eff@@ ic@@ acy to plac@@ eb@@ o .
In two 12-@@ week , plac@@ ebo@@ - and activ@@ e-@@ controlled mon@@ o@@ therapy trials in patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , with or without psycho@@ tic features , ari@@ pip@@ ra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to plac@@ eb@@ o at week 3 and a maintenance of effect comparable to li@@ th@@ ium or hal@@ op@@ eri@@ do@@ l at week 12 .
A@@ rip@@ ip@@ ra@@ z@@ ole also demonstrated a comparable proportion of patients in sympt@@ omati@@ c re@@ mission from man@@ ia as li@@ th@@ ium or hal@@ op@@ eri@@ do@@ l at week 12 .
In a 6-@@ week , plac@@ eb@@ o-@@ controlled trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ order , with or without psycho@@ tic features , who were partially non-@@ respon@@ sive to li@@ th@@ ium or val@@ pro@@ ate mon@@ o@@ therapy for 2 weeks at therapeutic ser@@ um levels , the addition of ari@@ pip@@ ra@@ z@@ ole as adj@@ unc@@ tive therapy resulted in superior eff@@ ic@@ acy in reduction of man@@ ic symptoms than li@@ th@@ ium or val@@ pro@@ ate mon@@ o@@ therapy .
102 In a 26@@ -@@ week , plac@@ eb@@ o-@@ controlled trial , followed by a 7@@ 4-@@ week extension , in man@@ ic patients who achieved re@@ mission on ari@@ pip@@ ra@@ z@@ ole during a stabili@@ zation phase prior to random@@ ization , ari@@ pip@@ ra@@ z@@ ole demonstrated su@@ peri@@ ority over plac@@ eb@@ o in preventing bi@@ pol@@ ar rec@@ ur@@ r@@ ence , primarily in preventing rec@@ ur@@ r@@ ence into man@@ ia but failed to demonstrate su@@ peri@@ ority over plac@@ eb@@ o in preventing rec@@ ur@@ r@@ ence into depression .
5.2 Ph@@ armac@@ ok@@ ine@@ tic properties
Ab@@ sor@@ ption :
A@@ rip@@ ip@@ ra@@ z@@ ole solution for injection administ@@ ered in@@ tr@@ am@@ us@@ cul@@ arly as a single-@@ dose to healthy subjects is well absor@@ bed and has an absolute bio@@ availability of 100 % .
The ari@@ pip@@ ra@@ z@@ ole AU@@ C in the first 2 hours after an in@@ tr@@ am@@ us@@ cular injection was 90 % greater than the AU@@ C after the same dose as a tablet ; system@@ ic exposure was generally similar between the 2 form@@ ulations .
In 2 studies in healthy subjects the medi@@ an times to the peak plas@@ ma concentr@@ ations were 1 and 3 hours after d@@ osing .
Distribution :
A@@ rip@@ ip@@ ra@@ z@@ ole is widely distributed throughout the body with an apparent volume of distribution of 4.@@ 9 l / kg , indic@@ ating extensive ex@@ trav@@ as@@ cular distribution .
At therapeutic concentr@@ ations , ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole are greater than 99 % bound to ser@@ um proteins , binding primarily to alb@@ um@@ in .
Met@@ aboli@@ sm :
A@@ rip@@ ip@@ ra@@ z@@ ole is exten@@ sively metaboli@@ sed by the liver primarily by three bi@@ ot@@ ran@@ s@@ formation path@@ ways : de@@ hydro@@ gen@@ ation , hydro@@ x@@ yl@@ ation , and N-@@ deal@@ k@@ yl@@ ation .
Based on in vit@@ ro studies , C@@ Y@@ P@@ 3@@ A4 and C@@ Y@@ P@@ 2@@ D@@ 6 enz@@ y@@ mes are responsible for de@@ hydro@@ gen@@ ation and hydro@@ x@@ yl@@ ation of ari@@ pip@@ ra@@ z@@ ole , and N-@@ deal@@ k@@ yl@@ ation is cat@@ aly@@ sed by C@@ Y@@ P@@ 3@@ A4 .
A@@ rip@@ ip@@ ra@@ z@@ ole is the pre@@ dominant medic@@ inal product mo@@ i@@ ety in system@@ ic circulation .
At ste@@ ady state , de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole , the active metaboli@@ te , represents about 40 % of ari@@ pip@@ ra@@ z@@ ole AU@@ C in plas@@ ma .
Eli@@ min@@ ation :
The mean elim@@ ination half-@@ lives for ari@@ pip@@ ra@@ z@@ ole are approximately 75 hours in extensive metaboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 and approximately 14@@ 6 hours in poor metaboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 .
The total body clear@@ ance of ari@@ pip@@ ra@@ z@@ ole is 0.@@ 7 ml / min / kg , which is primarily h@@ ep@@ atic .
Following a single oral dose of &#91; 14@@ C &#93; -@@ lab@@ elled ari@@ pip@@ ra@@ z@@ ole , approximately 27 % of the administ@@ ered radio@@ activity was recovered in the ur@@ ine and approximately 60 % in the fa@@ eces .
Less than 1 % of un@@ changed ari@@ pip@@ ra@@ z@@ ole was ex@@ cre@@ ted in the ur@@ ine and approximately 18 % was recovered un@@ changed in the fa@@ eces .
Ph@@ armac@@ ok@@ ine@@ tics in special patient groups
El@@ derly :
There are no differences in the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole between healthy elderly and younger adult subjects , nor is there any det@@ ec@@ table effect of age in a population ph@@ armac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hr@@ en@@ ic patients .
Gender :
There are no differences in the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole between healthy male and female subjects nor is there any det@@ ec@@ table effect of gender in a population ph@@ armac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hr@@ en@@ ic patients .
Smoking and Race :
Population ph@@ armac@@ ok@@ ine@@ tic evaluation has revealed no evidence of clin@@ ically significant rac@@ e-@@ related differences or effects from smoking upon the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole .
103 Ren@@ al Dis@@ ease :
The ph@@ armac@@ ok@@ ine@@ tic characteristics of ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole were found to be similar in patients with severe ren@@ al disease compared to young healthy subjects .
H@@ ep@@ atic Dis@@ ease :
A single-@@ dose study in subjects with var@@ ying degrees of liver cir@@ r@@ ho@@ sis ( Chil@@ d-@@ Pu@@ gh Cl@@ asses A , B , and C ) did not reveal a significant effect of h@@ ep@@ atic imp@@ air@@ ment on the ph@@ armac@@ ok@@ ine@@ tics of ari@@ pip@@ ra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pip@@ ra@@ z@@ ole , but the study included only 3 patients with Class C liver cir@@ r@@ ho@@ sis , which is in@@ sufficient to draw conclusions on their metaboli@@ c capacity .
5.@@ 3 Prec@@ lin@@ ical safety data
Administration of ari@@ pip@@ ra@@ z@@ ole solution for injection was well toler@@ ated and produced no direct target organ tox@@ ic@@ ity in rats or mon@@ keys after repeated d@@ osing at system@@ ic expos@@ ures ( AU@@ C ) that were 15 and 5 times , respectively , human exposure at the maximum recommended human dose of 30 mg in@@ tr@@ am@@ us@@ cular .
In in@@ tra@@ ven@@ ous re@@ productive tox@@ ic@@ ity studies , no new safety concerns were observed at mat@@ ern@@ al expos@@ ures up to 15 ( rat ) and 29 ( rab@@ bit ) times human exposure at 30 mg .
Non-@@ clinical safety data revealed no special haz@@ ard for humans based on conventional oral ari@@ pip@@ ra@@ z@@ ole studies of safety ph@@ armac@@ ology , repe@@ at-@@ dose tox@@ ic@@ ity , gen@@ ot@@ ox@@ ic@@ ity , car@@ cin@@ ogen@@ ic potential , and tox@@ ic@@ ity to reproduction .
To@@ x@@ ic@@ ologically significant effects were observed only at d@@ oses or expos@@ ures that were sufficiently in excess of the maximum human dose or exposure , indic@@ ating that these effects were limited or of no relev@@ ance to clinical use .
These included : dos@@ e-@@ dependent ad@@ ren@@ oc@@ or@@ tical tox@@ ic@@ ity ( li@@ po@@ f@@ us@@ c@@ in pig@@ ment accum@@ ulation and / or par@@ ench@@ y@@ mal cell loss ) in rats after 104 weeks at 20 to 60 mg / kg / day ( 3 to 10 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended human dose ) and increased ad@@ ren@@ oc@@ or@@ tical car@@ cin@@ omas and combined ad@@ ren@@ oc@@ or@@ tical aden@@ omas / car@@ cin@@ omas in female rats at 60 mg / kg / day ( 10 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended human dose ) .
The highest n@@ ont@@ um@@ orig@@ en@@ ic exposure in female rats was 7 times the human exposure at the recommended dose .
An additional finding was chol@@ eli@@ thi@@ asis as a consequence of precipitation of sul@@ ph@@ ate con@@ jug@@ ates of hydro@@ xy metaboli@@ tes of ari@@ pip@@ ra@@ z@@ ole in the b@@ ile of mon@@ keys after repeated oral d@@ osing at 25 to 125 mg / kg / day ( 1 to 3 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended clinical dose 2 or 16 to 81 times the maximum recommended human dose based on mg / m ) .
However , the concentr@@ ations of the sul@@ ph@@ ate con@@ jug@@ ates of hydro@@ xy ari@@ pip@@ ra@@ z@@ ole in human b@@ ile at the highest dose proposed , 30 mg per day , were no more than 6 % of the b@@ ile concentr@@ ations found in the mon@@ keys in the 3@@ 9-@@ week study and are well below ( 6 % ) their limits of in vit@@ ro sol@@ u@@ bility .
Based on results of a full range of standard gen@@ ot@@ ox@@ ic@@ ity tests , ari@@ pip@@ ra@@ z@@ ole was considered non-@@ gen@@ ot@@ ox@@ ic .
A@@ rip@@ ip@@ ra@@ z@@ ole did not imp@@ air fer@@ tility in re@@ productive tox@@ ic@@ ity studies .
Develop@@ mental tox@@ ic@@ ity , including dos@@ e-@@ dependent del@@ ayed fo@@ etal ossi@@ fication and possible ter@@ at@@ ogen@@ ic effects , were observed in rats at d@@ oses resulting in sub@@ therapeutic expos@@ ures ( based on AU@@ C ) and in rab@@ bits at d@@ oses resulting in expos@@ ures 3 and 11 times the mean ste@@ ad@@ y-@@ state AU@@ C at the maximum recommended clinical dose .
Mat@@ ern@@ al tox@@ ic@@ ity occurred at d@@ oses similar to those el@@ ic@@ iting develop@@ mental tox@@ ic@@ ity .
6 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL P@@ ART@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
Sul@@ f@@ ob@@ ut@@ y@@ le@@ ther β -@@ cyclo@@ de@@ x@@ tr@@ in ( S@@ BE@@ CD ) T@@ art@@ ari@@ c acid So@@ dium hydro@@ x@@ ide Water for injection
104 6.2 In@@ compati@@ bilities
Not applicable
6.@@ 3 Shel@@ f life
18 months Use product immediately after opening and disc@@ ard any un@@ used amount .
6.@@ 4 Special prec@@ au@@ tions for storage
Keep the vi@@ al in the outer cart@@ on in order to protect from light .
6.5 Nature and contents of container
Each cart@@ on contains one single-@@ use type I glass vi@@ al with a rubber but@@ yl stop@@ per and a &quot; fli@@ p-@@ off &quot; aluminium seal .
6.@@ 6 Special prec@@ au@@ tions for disposal and other handling
Any un@@ used product or waste material should be dispos@@ ed of in accordance with local requirements .
7 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
8 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION N@@ UM@@ BER ( S )
EU / 1 / 04 / 27@@ 6 / 0@@ 36
9 .
D@@ ATE OF F@@ IR@@ ST AU@@ TH@@ OR@@ IS@@ ATION / R@@ EN@@ EW@@ AL OF THE AU@@ TH@@ OR@@ IS@@ ATION
Date of first author@@ isation :
4 June 2004
10 .
D@@ ATE OF RE@@ V@@ IS@@ ION OF THE TE@@ XT
{ M@@ M / Y@@ Y@@ Y@@ Y }
Detailed information on this product is available on the website of the European Medic@@ ines Agency ( EM@@ EA ) http : / / ww@@ w. em@@ e@@ a. europ@@ a. eu /
105 AN@@ NE@@ X II
A MAN@@ UF@@ AC@@ T@@ UR@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER RES@@ P@@ ON@@ SI@@ B@@ LE FOR B@@ AT@@ CH RE@@ LE@@ AS@@ E
B CON@@ D@@ IT@@ ION@@ S OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION
106 A MAN@@ UF@@ AC@@ T@@ UR@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER RES@@ P@@ ON@@ SI@@ B@@ LE FOR B@@ AT@@ CH RE@@ LE@@ AS@@ E
Name and address of the manufacturer responsible for bat@@ ch release
Brist@@ ol@@ -@@ My@@ ers Squ@@ ib@@ b S@@ r@@ l Con@@ tra@@ da Font@@ ana Del Cer@@ as@@ o I-@@ 0@@ 30@@ 12 An@@ ag@@ ni@@ -F@@ ros@@ in@@ one Italy
B CON@@ D@@ IT@@ ION@@ S OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION
• CON@@ D@@ IT@@ ION@@ S OR RES@@ TR@@ IC@@ TI@@ ON@@ S RE@@ GAR@@ D@@ ING SU@@ P@@ PL@@ Y AND USE IM@@ PO@@ SE@@ D ON THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Medic@@ inal product subject to medical pres@@ cription .
• CON@@ D@@ IT@@ ION@@ S OR RES@@ TR@@ IC@@ TI@@ ON@@ S W@@ IT@@ H RE@@ G@@ ARD TO THE SA@@ F@@ E AND EF@@ F@@ EC@@ TI@@ VE USE OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
Not applicable .
• O@@ TH@@ ER CON@@ D@@ IT@@ ION@@ S
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd comm@@ its to provide a PS@@ UR at 6 monthly inter@@ vals unless otherwise decided by the CH@@ MP .
Ph@@ armac@@ ov@@ ig@@ il@@ ance system The MA@@ H must ensure that the system of ph@@ armac@@ ov@@ ig@@ il@@ ance , as described in version 1.0 presented in Module 1.@@ 8.@@ 1. of the Marketing Auth@@ or@@ isation , is in place and functioning before and whilst the product is on the market .
Risk Management Plan The MA@@ H comm@@ its to performing the studies and additional ph@@ armac@@ ov@@ ig@@ il@@ ance activities detailed in the Ph@@ armac@@ ov@@ ig@@ il@@ ance Plan , as agreed in version 3.0 of the Risk Management Plan ( R@@ MP ) presented in Module 1.@@ 8.@@ 2. of the Marketing Auth@@ or@@ isation and any subsequent updates of the R@@ MP agreed by the CH@@ MP .
As per the CH@@ MP Guid@@ eline on Risk Management Systems for medic@@ inal products for human use , the updated R@@ MP should be submitted at the same time as the next Peri@@ odi@@ c Safety Update Report ( PS@@ UR ) .
In addition , an updated R@@ MP should be submitted When new information is received that may impact on the current Safety Speci@@ fication , Ph@@ armac@@ ov@@ ig@@ il@@ ance Plan or risk minim@@ isation activities Within 60 days of an important ( ph@@ armac@@ ov@@ ig@@ il@@ ance or risk minim@@ isation ) mil@@ estone being reached At the request of the EM@@ EA
107 AN@@ NE@@ X III
LA@@ B@@ ELL@@ ING AND P@@ ACK@@ AG@@ E LE@@ AF@@ LE@@ T
108 A.
LA@@ B@@ ELL@@ ING
109 P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON THE O@@ UT@@ ER P@@ ACK@@ AG@@ ING
O@@ UT@@ ER CAR@@ T@@ ON
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 5 mg tablets ari@@ pip@@ ra@@ z@@ ole
2 .
ST@@ AT@@ EM@@ ENT OF AC@@ TI@@ VE SU@@ B@@ ST@@ AN@@ CE
Each tablet contains 5 mg of ari@@ pip@@ ra@@ z@@ ole .
3 .
L@@ IST OF EX@@ C@@ IP@@ I@@ EN@@ TS
Also contains : l@@ act@@ ose mon@@ oh@@ ydr@@ ate .
4 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL FOR@@ M AND CON@@ TEN@@ TS
14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets
5 .
M@@ ET@@ HO@@ D AND RO@@ U@@ TE ( S ) OF AD@@ MIN@@ IS@@ TR@@ ATION
Read the package le@@ af@@ let before use .
Or@@ al use .
6 .
SP@@ EC@@ I@@ AL WAR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT OF THE RE@@ ACH AND S@@ IG@@ HT OF CH@@ IL@@ DR@@ EN
Keep out of the reach and sight of children .
7 .
O@@ TH@@ ER SP@@ EC@@ I@@ AL WAR@@ N@@ ING ( S ) , I@@ F N@@ EC@@ ES@@ S@@ AR@@ Y
8 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
9 .
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ ION@@ S
Store in the original package in order to protect from moisture .
110 10 .
SP@@ EC@@ I@@ AL PRE@@ CA@@ U@@ TI@@ ON@@ S FOR D@@ ISPO@@ SA@@ L OF UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS OR W@@ AS@@ TE MAT@@ ER@@ I@@ AL@@ S DER@@ IV@@ ED F@@ ROM SU@@ CH ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS , I@@ F AP@@ PRO@@ PR@@ I@@ ATE
11 .
N@@ AME AND AD@@ DR@@ ESS OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION N@@ UM@@ BER ( S )
EU / 1 / 04 / 27@@ 6 / 001 14 x 1 tablets EU / 1 / 04 / 27@@ 6 / 00@@ 2 28 x 1 tablets EU / 1 / 04 / 27@@ 6 / 00@@ 3 49 x 1 tablets EU / 1 / 04 / 27@@ 6 / 00@@ 4 56 x 1 tablets EU / 1 / 04 / 27@@ 6 / 00@@ 5 98 x 1 tablets
13 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
14 .
GEN@@ ER@@ AL CL@@ AS@@ S@@ IF@@ IC@@ ATION FOR SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical pres@@ cription .
15 .
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON USE
16 .
IN@@ FOR@@ M@@ ATION IN BRA@@ IL@@ LE
AB@@ IL@@ IF@@ Y 5 mg
111 MIN@@ IM@@ UM P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON BL@@ IS@@ TER@@ S OR ST@@ R@@ IP@@ S
BL@@ IS@@ TER@@ S
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 5 mg tablets ari@@ pip@@ ra@@ z@@ ole
2 .
N@@ AME OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
3 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
4 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
5 .
O@@ TH@@ ER
112 P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON THE O@@ UT@@ ER P@@ ACK@@ AG@@ ING
O@@ UT@@ ER CAR@@ T@@ ON
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 10 mg tablets ari@@ pip@@ ra@@ z@@ ole
2 .
ST@@ AT@@ EM@@ ENT OF AC@@ TI@@ VE SU@@ B@@ ST@@ AN@@ CE
Each tablet contains 10 mg of ari@@ pip@@ ra@@ z@@ ole .
3 .
L@@ IST OF EX@@ C@@ IP@@ I@@ EN@@ TS
Also contains : l@@ act@@ ose mon@@ oh@@ ydr@@ ate .
4 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL FOR@@ M AND CON@@ TEN@@ TS
14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets
5 .
M@@ ET@@ HO@@ D AND RO@@ U@@ TE ( S ) OF AD@@ MIN@@ IS@@ TR@@ ATION
Read the package le@@ af@@ let before use .
Or@@ al use .
6 .
SP@@ EC@@ I@@ AL WAR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT OF THE RE@@ ACH AND S@@ IG@@ HT OF CH@@ IL@@ DR@@ EN
Keep out of the reach and sight of children .
7 .
O@@ TH@@ ER SP@@ EC@@ I@@ AL WAR@@ N@@ ING ( S ) , I@@ F N@@ EC@@ ES@@ S@@ AR@@ Y
8 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
9 .
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ ION@@ S
Store in the original package in order to protect from moisture .
113 10 .
SP@@ EC@@ I@@ AL PRE@@ CA@@ U@@ TI@@ ON@@ S FOR D@@ ISPO@@ SA@@ L OF UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS OR W@@ AS@@ TE MAT@@ ER@@ I@@ AL@@ S DER@@ IV@@ ED F@@ ROM SU@@ CH ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS , I@@ F AP@@ PRO@@ PR@@ I@@ ATE
11 .
N@@ AME AND AD@@ DR@@ ESS OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION N@@ UM@@ BER ( S )
EU / 1 / 04 / 27@@ 6 / 00@@ 6 14 x 1 tablets EU / 1 / 04 / 27@@ 6 / 00@@ 7 28 x 1 tablets EU / 1 / 04 / 27@@ 6 / 00@@ 8 49 x 1 tablets EU / 1 / 04 / 27@@ 6 / 00@@ 9 56 x 1 tablets EU / 1 / 04 / 27@@ 6 / 0@@ 10 98 x 1 tablets
13 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
14 .
GEN@@ ER@@ AL CL@@ AS@@ S@@ IF@@ IC@@ ATION FOR SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical pres@@ cription .
15 .
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON USE
16 .
IN@@ FOR@@ M@@ ATION IN BRA@@ IL@@ LE
AB@@ IL@@ IF@@ Y 10 mg
114 MIN@@ IM@@ UM P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON BL@@ IS@@ TER@@ S OR ST@@ R@@ IP@@ S
BL@@ IS@@ TER@@ S
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 10 mg tablets ari@@ pip@@ ra@@ z@@ ole
2 .
N@@ AME OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
3 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
4 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
5 .
O@@ TH@@ ER
115 P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON THE O@@ UT@@ ER P@@ ACK@@ AG@@ ING
O@@ UT@@ ER CAR@@ T@@ ON
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 15 mg tablets ari@@ pip@@ ra@@ z@@ ole
2 .
ST@@ AT@@ EM@@ ENT OF AC@@ TI@@ VE SU@@ B@@ ST@@ AN@@ CE
Each tablet contains 15 mg of ari@@ pip@@ ra@@ z@@ ole .
3 .
L@@ IST OF EX@@ C@@ IP@@ I@@ EN@@ TS
Also contains : l@@ act@@ ose mon@@ oh@@ ydr@@ ate .
4 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL FOR@@ M AND CON@@ TEN@@ TS
14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets
5 .
M@@ ET@@ HO@@ D AND RO@@ U@@ TE ( S ) OF AD@@ MIN@@ IS@@ TR@@ ATION
Read the package le@@ af@@ let before use .
Or@@ al use .
6 .
SP@@ EC@@ I@@ AL WAR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT OF THE RE@@ ACH AND S@@ IG@@ HT OF CH@@ IL@@ DR@@ EN
Keep out of the reach and sight of children .
7 .
O@@ TH@@ ER SP@@ EC@@ I@@ AL WAR@@ N@@ ING ( S ) , I@@ F N@@ EC@@ ES@@ S@@ AR@@ Y
8 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
9 .
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ ION@@ S
Store in the original package in order to protect from moisture .
116 10 .
SP@@ EC@@ I@@ AL PRE@@ CA@@ U@@ TI@@ ON@@ S FOR D@@ ISPO@@ SA@@ L OF UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS OR W@@ AS@@ TE MAT@@ ER@@ I@@ AL@@ S DER@@ IV@@ ED F@@ ROM SU@@ CH ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS , I@@ F AP@@ PRO@@ PR@@ I@@ ATE
11 .
N@@ AME AND AD@@ DR@@ ESS OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION N@@ UM@@ BER ( S )
EU / 1 / 04 / 27@@ 6 / 0@@ 11 14 x 1 tablets EU / 1 / 04 / 27@@ 6 / 0@@ 12 28 x 1 tablets EU / 1 / 04 / 27@@ 6 / 0@@ 13 49 x 1 tablets EU / 1 / 04 / 27@@ 6 / 0@@ 14 56 x 1 tablets EU / 1 / 04 / 27@@ 6 / 0@@ 15 98 x 1 tablets
13 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
14 .
GEN@@ ER@@ AL CL@@ AS@@ S@@ IF@@ IC@@ ATION FOR SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical pres@@ cription .
15 .
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON USE
16 .
IN@@ FOR@@ M@@ ATION IN BRA@@ IL@@ LE
AB@@ IL@@ IF@@ Y 15 mg
117 MIN@@ IM@@ UM P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON BL@@ IS@@ TER@@ S OR ST@@ R@@ IP@@ S
BL@@ IS@@ TER@@ S
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 15 mg tablets ari@@ pip@@ ra@@ z@@ ole
2 .
N@@ AME OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
3 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
4 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
5 .
O@@ TH@@ ER
118 P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON THE O@@ UT@@ ER P@@ ACK@@ AG@@ ING
O@@ UT@@ ER CAR@@ T@@ ON
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 30 mg tablets ari@@ pip@@ ra@@ z@@ ole
2 .
ST@@ AT@@ EM@@ ENT OF AC@@ TI@@ VE SU@@ B@@ ST@@ AN@@ CE
Each tablet contains 30 mg of ari@@ pip@@ ra@@ z@@ ole .
3 .
L@@ IST OF EX@@ C@@ IP@@ I@@ EN@@ TS
Also contains : l@@ act@@ ose mon@@ oh@@ ydr@@ ate .
4 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL FOR@@ M AND CON@@ TEN@@ TS
14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets
5 .
M@@ ET@@ HO@@ D AND RO@@ U@@ TE ( S ) OF AD@@ MIN@@ IS@@ TR@@ ATION
Read the package le@@ af@@ let before use .
Or@@ al use .
6 .
SP@@ EC@@ I@@ AL WAR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT OF THE RE@@ ACH AND S@@ IG@@ HT OF CH@@ IL@@ DR@@ EN
Keep out of the reach and sight of children .
7 .
O@@ TH@@ ER SP@@ EC@@ I@@ AL WAR@@ N@@ ING ( S ) , I@@ F N@@ EC@@ ES@@ S@@ AR@@ Y
8 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
9 .
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ ION@@ S
Store in the original package in order to protect from moisture .
119 10 .
SP@@ EC@@ I@@ AL PRE@@ CA@@ U@@ TI@@ ON@@ S FOR D@@ ISPO@@ SA@@ L OF UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS OR W@@ AS@@ TE MAT@@ ER@@ I@@ AL@@ S DER@@ IV@@ ED F@@ ROM SU@@ CH ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS , I@@ F AP@@ PRO@@ PR@@ I@@ ATE
11 .
N@@ AME AND AD@@ DR@@ ESS OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION N@@ UM@@ BER ( S )
EU / 1 / 04 / 27@@ 6 / 0@@ 16 14 x 1 tablets EU / 1 / 04 / 27@@ 6 / 0@@ 17 28 x 1 tablets EU / 1 / 04 / 27@@ 6 / 0@@ 18 49 x 1 tablets EU / 1 / 04 / 27@@ 6 / 0@@ 19 56 x 1 tablets EU / 1 / 04 / 27@@ 6 / 0@@ 20 98 x 1 tablets
13 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
14 .
GEN@@ ER@@ AL CL@@ AS@@ S@@ IF@@ IC@@ ATION FOR SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical pres@@ cription .
15 .
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON USE
16 .
IN@@ FOR@@ M@@ ATION IN BRA@@ IL@@ LE
AB@@ IL@@ IF@@ Y 30 mg
120 MIN@@ IM@@ UM P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON BL@@ IS@@ TER@@ S OR ST@@ R@@ IP@@ S
BL@@ IS@@ TER@@ S
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 30 mg tablets ari@@ pip@@ ra@@ z@@ ole
2 .
N@@ AME OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
3 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
4 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
5 .
O@@ TH@@ ER
121 P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON THE O@@ UT@@ ER P@@ ACK@@ AG@@ ING
O@@ UT@@ ER CAR@@ T@@ ON
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 10 mg or@@ o@@ disp@@ er@@ sible tablets ari@@ pip@@ ra@@ z@@ ole
2 .
ST@@ AT@@ EM@@ ENT OF AC@@ TI@@ VE SU@@ B@@ ST@@ AN@@ CE
Each tablet contains 10 mg of ari@@ pip@@ ra@@ z@@ ole .
3 .
L@@ IST OF EX@@ C@@ IP@@ I@@ EN@@ TS
4 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL FOR@@ M AND CON@@ TEN@@ TS
14 x 1 or@@ o@@ disp@@ er@@ sible tablets 28 x 1 or@@ o@@ disp@@ er@@ sible tablets 49 x 1 or@@ o@@ disp@@ er@@ sible tablets
5 .
M@@ ET@@ HO@@ D AND RO@@ U@@ TE ( S ) OF AD@@ MIN@@ IS@@ TR@@ ATION
Read the package le@@ af@@ let before use .
Or@@ al use .
6 .
SP@@ EC@@ I@@ AL WAR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT OF THE RE@@ ACH AND S@@ IG@@ HT OF CH@@ IL@@ DR@@ EN
Keep out of the reach and sight of children .
7 .
O@@ TH@@ ER SP@@ EC@@ I@@ AL WAR@@ N@@ ING ( S ) , I@@ F N@@ EC@@ ES@@ S@@ AR@@ Y
Con@@ tains as@@ part@@ ame .
See le@@ af@@ let for further information .
8 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
122 9 .
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ ION@@ S
Store in the original package in order to protect from moisture .
10 .
SP@@ EC@@ I@@ AL PRE@@ CA@@ U@@ TI@@ ON@@ S FOR D@@ ISPO@@ SA@@ L OF UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS OR W@@ AS@@ TE MAT@@ ER@@ I@@ AL@@ S DER@@ IV@@ ED F@@ ROM SU@@ CH ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS , I@@ F AP@@ PRO@@ PR@@ I@@ ATE
11 .
N@@ AME AND AD@@ DR@@ ESS OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION N@@ UM@@ BER ( S )
EU / 1 / 04 / 27@@ 6 / 0@@ 24 14 x 1 or@@ o@@ disp@@ er@@ sible tablets EU / 1 / 04 / 27@@ 6 / 0@@ 25 28 x 1 or@@ o@@ disp@@ er@@ sible tablets EU / 1 / 04 / 27@@ 6 / 0@@ 26 49 x 1 or@@ o@@ disp@@ er@@ sible tablets
13 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
14 .
GEN@@ ER@@ AL CL@@ AS@@ S@@ IF@@ IC@@ ATION FOR SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical pres@@ cription .
15 .
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON USE
16 .
IN@@ FOR@@ M@@ ATION IN BRA@@ IL@@ LE
AB@@ IL@@ IF@@ Y 10 mg
123 MIN@@ IM@@ UM P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON BL@@ IS@@ TER@@ S OR ST@@ R@@ IP@@ S
BL@@ IS@@ TER@@ S
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 10 mg or@@ o@@ disp@@ er@@ sible tablets ari@@ pip@@ ra@@ z@@ ole
2 .
N@@ AME OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
3 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
4 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
5 .
O@@ TH@@ ER
124 P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON THE O@@ UT@@ ER P@@ ACK@@ AG@@ ING
O@@ UT@@ ER CAR@@ T@@ ON
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 15 mg or@@ o@@ disp@@ er@@ sible tablets ari@@ pip@@ ra@@ z@@ ole
2 .
ST@@ AT@@ EM@@ ENT OF AC@@ TI@@ VE SU@@ B@@ ST@@ AN@@ CE
Each tablet contains 15 mg of ari@@ pip@@ ra@@ z@@ ole .
3 .
L@@ IST OF EX@@ C@@ IP@@ I@@ EN@@ TS
4 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL FOR@@ M AND CON@@ TEN@@ TS
14 x 1 or@@ o@@ disp@@ er@@ sible tablets 28 x 1 or@@ o@@ disp@@ er@@ sible tablets 49 x 1 or@@ o@@ disp@@ er@@ sible tablets
5 .
M@@ ET@@ HO@@ D AND RO@@ U@@ TE ( S ) OF AD@@ MIN@@ IS@@ TR@@ ATION
Read the package le@@ af@@ let before use .
Or@@ al use .
6 .
SP@@ EC@@ I@@ AL WAR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT OF THE RE@@ ACH AND S@@ IG@@ HT OF CH@@ IL@@ DR@@ EN
Keep out of the reach and sight of children .
7 .
O@@ TH@@ ER SP@@ EC@@ I@@ AL WAR@@ N@@ ING ( S ) , I@@ F N@@ EC@@ ES@@ S@@ AR@@ Y
Con@@ tains as@@ part@@ ame .
See le@@ af@@ let for further information .
8 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
125 9 .
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ ION@@ S
Store in the original package in order to protect from moisture .
10 .
SP@@ EC@@ I@@ AL PRE@@ CA@@ U@@ TI@@ ON@@ S FOR D@@ ISPO@@ SA@@ L OF UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS OR W@@ AS@@ TE MAT@@ ER@@ I@@ AL@@ S DER@@ IV@@ ED F@@ ROM SU@@ CH ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS , I@@ F AP@@ PRO@@ PR@@ I@@ ATE
11 .
N@@ AME AND AD@@ DR@@ ESS OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION N@@ UM@@ BER ( S )
EU / 1 / 04 / 27@@ 6 / 0@@ 27 14 x 1 or@@ o@@ disp@@ er@@ sible tablets EU / 1 / 04 / 27@@ 6 / 0@@ 28 28 x 1 or@@ o@@ disp@@ er@@ sible tablets EU / 1 / 04 / 27@@ 6 / 0@@ 29 49 x 1 or@@ o@@ disp@@ er@@ sible tablets
13 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
14 .
GEN@@ ER@@ AL CL@@ AS@@ S@@ IF@@ IC@@ ATION FOR SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical pres@@ cription .
15 .
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON USE
16 .
IN@@ FOR@@ M@@ ATION IN BRA@@ IL@@ LE
AB@@ IL@@ IF@@ Y 15 mg
126 MIN@@ IM@@ UM P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON BL@@ IS@@ TER@@ S OR ST@@ R@@ IP@@ S
BL@@ IS@@ TER@@ S
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 15 mg or@@ o@@ disp@@ er@@ sible tablets ari@@ pip@@ ra@@ z@@ ole
2 .
N@@ AME OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
3 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
4 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
5 .
O@@ TH@@ ER
127 P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON THE O@@ UT@@ ER P@@ ACK@@ AG@@ ING
O@@ UT@@ ER CAR@@ T@@ ON
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 30 mg or@@ o@@ disp@@ er@@ sible tablets ari@@ pip@@ ra@@ z@@ ole
2 .
ST@@ AT@@ EM@@ ENT OF AC@@ TI@@ VE SU@@ B@@ ST@@ AN@@ CE
Each tablet contains 30 mg of ari@@ pip@@ ra@@ z@@ ole .
3 .
L@@ IST OF EX@@ C@@ IP@@ I@@ EN@@ TS
4 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL FOR@@ M AND CON@@ TEN@@ TS
14 x 1 or@@ o@@ disp@@ er@@ sible tablets 28 x 1 or@@ o@@ disp@@ er@@ sible tablets 49 x 1 or@@ o@@ disp@@ er@@ sible tablets
5 .
M@@ ET@@ HO@@ D AND RO@@ U@@ TE ( S ) OF AD@@ MIN@@ IS@@ TR@@ ATION
Read the package le@@ af@@ let before use .
Or@@ al use .
6 .
SP@@ EC@@ I@@ AL WAR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT OF THE RE@@ ACH AND S@@ IG@@ HT OF CH@@ IL@@ DR@@ EN
Keep out of the reach and sight of children .
7 .
O@@ TH@@ ER SP@@ EC@@ I@@ AL WAR@@ N@@ ING ( S ) , I@@ F N@@ EC@@ ES@@ S@@ AR@@ Y
Con@@ tains as@@ part@@ ame .
See le@@ af@@ let for further information .
8 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
128 9 .
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ ION@@ S
Store in the original package in order to protect from moisture .
10 .
SP@@ EC@@ I@@ AL PRE@@ CA@@ U@@ TI@@ ON@@ S FOR D@@ ISPO@@ SA@@ L OF UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS OR W@@ AS@@ TE MAT@@ ER@@ I@@ AL@@ S DER@@ IV@@ ED F@@ ROM SU@@ CH ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS , I@@ F AP@@ PRO@@ PR@@ I@@ ATE
11 .
N@@ AME AND AD@@ DR@@ ESS OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION N@@ UM@@ BER ( S )
EU / 1 / 04 / 27@@ 6 / 0@@ 30 14 x 1 or@@ o@@ disp@@ er@@ sible tablets EU / 1 / 04 / 27@@ 6 / 0@@ 31 28 x 1 or@@ o@@ disp@@ er@@ sible tablets EU / 1 / 04 / 27@@ 6 / 0@@ 32 49 x 1 or@@ o@@ disp@@ er@@ sible tablets
13 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
14 .
GEN@@ ER@@ AL CL@@ AS@@ S@@ IF@@ IC@@ ATION FOR SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical pres@@ cription .
15 .
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON USE
16 .
IN@@ FOR@@ M@@ ATION IN BRA@@ IL@@ LE
AB@@ IL@@ IF@@ Y 30 mg
129 MIN@@ IM@@ UM P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON BL@@ IS@@ TER@@ S OR ST@@ R@@ IP@@ S
BL@@ IS@@ TER@@ S
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 30 mg or@@ o@@ disp@@ er@@ sible tablets ari@@ pip@@ ra@@ z@@ ole
2 .
N@@ AME OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
3 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
4 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
5 .
O@@ TH@@ ER
130 P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON THE O@@ UT@@ ER P@@ ACK@@ AG@@ ING AND THE IM@@ ME@@ DI@@ ATE P@@ ACK@@ AG@@ ING
O@@ UT@@ ER CAR@@ T@@ ON AND BO@@ TT@@ LE LA@@ B@@ EL
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 1 mg / ml oral solution ari@@ pip@@ ra@@ z@@ ole
2 .
ST@@ AT@@ EM@@ ENT OF AC@@ TI@@ VE SU@@ B@@ ST@@ AN@@ CE
Each ml contains 1 mg of ari@@ pip@@ ra@@ z@@ ole .
3 .
L@@ IST OF EX@@ C@@ IP@@ I@@ EN@@ TS
Con@@ tains fru@@ c@@ t@@ ose , su@@ c@@ rose , E@@ 2@@ 18 , and E@@ 2@@ 16 .
4 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL FOR@@ M AND CON@@ TEN@@ TS
50 ml oral solution 150 ml oral solution 4@@ 80 ml oral solution
5 .
M@@ ET@@ HO@@ D AND RO@@ U@@ TE ( S ) OF AD@@ MIN@@ IS@@ TR@@ ATION
Read the package le@@ af@@ let before use .
Or@@ al use .
6 .
SP@@ EC@@ I@@ AL WAR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT OF THE RE@@ ACH AND S@@ IG@@ HT OF CH@@ IL@@ DR@@ EN
Keep out of the reach and sight of children .
7 .
O@@ TH@@ ER SP@@ EC@@ I@@ AL WAR@@ N@@ ING ( S ) , I@@ F N@@ EC@@ ES@@ S@@ AR@@ Y
8 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P Use within 6 months after first opening .
9 .
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ ION@@ S
131 10 .
SP@@ EC@@ I@@ AL PRE@@ CA@@ U@@ TI@@ ON@@ S FOR D@@ ISPO@@ SA@@ L OF UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS OR W@@ AS@@ TE MAT@@ ER@@ I@@ AL@@ S DER@@ IV@@ ED F@@ ROM SU@@ CH ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS , I@@ F AP@@ PRO@@ PR@@ I@@ ATE
11 .
N@@ AME AND AD@@ DR@@ ESS OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
O@@ uter cart@@ on :
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION N@@ UM@@ BER ( S )
EU / 1 / 04 / 27@@ 6 / 0@@ 33 - 50 ml bottle EU / 1 / 04 / 27@@ 6 / 0@@ 34 - 150 ml bottle EU / 1 / 04 / 27@@ 6 / 0@@ 35 - 4@@ 80 ml bottle
13 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
14 .
GEN@@ ER@@ AL CL@@ AS@@ S@@ IF@@ IC@@ ATION FOR SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical pres@@ cription .
15 .
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON USE
16 .
IN@@ FOR@@ M@@ ATION IN BRA@@ IL@@ LE
O@@ uter cart@@ on :
AB@@ IL@@ IF@@ Y 1 mg / ml
132 P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON THE O@@ UT@@ ER P@@ ACK@@ AG@@ ING
O@@ UT@@ ER CAR@@ T@@ ON
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T
AB@@ IL@@ IF@@ Y 7.5 mg / ml solution for injection ari@@ pip@@ ra@@ z@@ ole
2 .
ST@@ AT@@ EM@@ ENT OF AC@@ TI@@ VE SU@@ B@@ ST@@ AN@@ CE ( S )
Each ml contains 7.5 mg of ari@@ pip@@ ra@@ z@@ ole .
A vi@@ al provides 9.@@ 75 mg in 1.3 ml
3 .
L@@ IST OF EX@@ C@@ IP@@ I@@ EN@@ TS
Also contains sul@@ f@@ ob@@ ut@@ y@@ le@@ ther b-@@ cyclo@@ de@@ x@@ tr@@ in , t@@ art@@ ari@@ c acid , so@@ dium hydro@@ x@@ ide , and water for injection .
4 .
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL FOR@@ M AND CON@@ TEN@@ TS
Solution for injection 1 vi@@ al
5 .
M@@ ET@@ HO@@ D AND RO@@ U@@ TE ( S ) OF AD@@ MIN@@ IS@@ TR@@ ATION
In@@ tr@@ am@@ us@@ cular use Read the package le@@ af@@ let before use .
6 .
SP@@ EC@@ I@@ AL WAR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT OF THE RE@@ ACH AND S@@ IG@@ HT OF CH@@ IL@@ DR@@ EN
Keep out of the reach and sight of children .
7 .
O@@ TH@@ ER SP@@ EC@@ I@@ AL WAR@@ N@@ ING ( S ) , I@@ F N@@ EC@@ ES@@ S@@ AR@@ Y
8 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
9 .
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ ION@@ S
Keep the vi@@ al in the outer cart@@ on in order to protect from light .
133 10 .
SP@@ EC@@ I@@ AL PRE@@ CA@@ U@@ TI@@ ON@@ S FOR D@@ ISPO@@ SA@@ L OF UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS OR W@@ AS@@ TE MAT@@ ER@@ I@@ AL@@ S DER@@ IV@@ ED F@@ ROM SU@@ CH ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ TS , I@@ F AP@@ PRO@@ PR@@ I@@ ATE
11 .
N@@ AME AND AD@@ DR@@ ESS OF THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION H@@ OL@@ DER
Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12 .
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ ATION N@@ UM@@ BER ( S )
EU / 1 / 04 / 27@@ 6 / 0@@ 36
13 .
MAN@@ UF@@ AC@@ T@@ UR@@ ER ’ S B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
14 .
GEN@@ ER@@ AL CL@@ AS@@ S@@ IF@@ IC@@ ATION FOR SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical pres@@ cription .
15 .
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON USE
16 .
IN@@ FOR@@ M@@ ATION IN BRA@@ IL@@ LE
As AB@@ IL@@ IF@@ Y 7.5 mg / ml solution for injection is only intended for administration by health care professionals , no information will be included in Bra@@ ille .
134 MIN@@ IM@@ UM P@@ ART@@ IC@@ UL@@ AR@@ S TO AP@@ PE@@ AR ON SM@@ ALL IM@@ ME@@ DI@@ ATE P@@ ACK@@ AG@@ ING UN@@ IT@@ S
VI@@ AL LA@@ B@@ EL
1 .
N@@ AME OF THE ME@@ D@@ IC@@ IN@@ AL PRO@@ D@@ UC@@ T AND RO@@ U@@ TE ( S ) OF AD@@ MIN@@ IS@@ TR@@ ATION
AB@@ IL@@ IF@@ Y 7.5 mg / ml solution for injection ari@@ pip@@ ra@@ z@@ ole In@@ tr@@ am@@ us@@ cular use
2 .
M@@ ET@@ HO@@ D OF AD@@ MIN@@ IS@@ TR@@ ATION
Read the package le@@ af@@ let before use .
3 .
EX@@ P@@ IR@@ Y D@@ ATE
EX@@ P
4 .
B@@ AT@@ CH N@@ UM@@ BER
L@@ ot
5 .
CON@@ TEN@@ TS B@@ Y WE@@ IG@@ HT , B@@ Y V@@ OL@@ UM@@ E OR B@@ Y UN@@ IT
9.@@ 75 mg ( 1.@@ 3@@ ml )
6 .
O@@ TH@@ ER
135 B.
P@@ ACK@@ AG@@ E LE@@ AF@@ LE@@ T
136 P@@ ACK@@ AG@@ E LE@@ AF@@ LE@@ T :
IN@@ FOR@@ M@@ ATION FOR THE US@@ ER
AB@@ IL@@ IF@@ Y 5 mg tablets ari@@ pip@@ ra@@ z@@ ole
Read all of this le@@ af@@ let carefully before you start taking this medicine .
Keep this le@@ af@@ let .
You may need to read it again .
If you have any further questions , ask your doctor or ph@@ armac@@ ist .
This medicine has been prescri@@ bed for you .
Do not pass it on to others .
It may harm them , even if their symptoms are the same as your@@ s .
If any of the side effects gets serious , or if you notice any side effects not listed in this le@@ af@@ let , please tell your doctor or ph@@ armac@@ ist .
In this le@@ af@@ let :
1 .
What AB@@ IL@@ IF@@ Y is and what it is used for 2 .
Before you take AB@@ IL@@ IF@@ Y 3 .
How to take AB@@ IL@@ IF@@ Y 4 .
Pos@@ sible side effects 5 How to store AB@@ IL@@ IF@@ Y 6 .
Further information
1 .
WH@@ AT AB@@ IL@@ IF@@ Y IS AND WH@@ AT IT IS US@@ ED FOR
AB@@ IL@@ IF@@ Y is one of a group of medicines called anti@@ psycho@@ tics .
It is used to treat adults who suffer from a disease characterised by symptoms such as hearing , seeing or sen@@ sing things which are not there , susp@@ ici@@ ousness , mist@@ aken beliefs , in@@ coher@@ ent speech and behaviour and emotional fl@@ at@@ ness .
People with this condition may also feel de@@ pressed , guil@@ ty , an@@ x@@ ious or ten@@ se .
AB@@ IL@@ IF@@ Y is used to treat adults who suffer from a condition with symptoms such as feeling &quot; high &quot; , having excessive amounts of energy , ne@@ eding much less sleep than usual , talking very quickly with racing ideas and sometimes severe ir@@ rit@@ ability .
It also prevents this condition from returning in patients who have responded to the treatment with AB@@ IL@@ IF@@ Y .
2 .
B@@ EF@@ OR@@ E YO@@ U T@@ AK@@ E AB@@ IL@@ IF@@ Y
Do not take AB@@ IL@@ IF@@ Y if you are aller@@ gic ( hyper@@ sensitive ) to ari@@ pip@@ ra@@ z@@ ole or any of the other ingredients of AB@@ IL@@ IF@@ Y .
Take special care with AB@@ IL@@ IF@@ Y Before treatment with AB@@ IL@@ IF@@ Y , tell your doctor if you suffer from High blood sugar or family history of diabetes Sei@@ z@@ ure In@@ voluntary , ir@@ regular muscle movements , especially in the face Cardi@@ ov@@ as@@ cular diseases , family history of cardi@@ ov@@ as@@ cular disease , stroke or &quot; mini &quot; stroke , ab@@ normal blood pressure
If you notice you are gaining weight , experience any difficulty in swal@@ lowing or aller@@ gic symptoms , please tell your doctor .
If you are an elderly patient suffering from de@@ men@@ tia ( loss of memory and other mental abilities ) , you or your car@@ er / relative should tell your doctor if you have ever had a stroke or &quot; mini &quot; stroke .
Tell your doctor immediately if you are having any thoughts or feelings about hur@@ ting yourself .
Su@@ ic@@ id@@ al thoughts and behavi@@ ours have been reported during ari@@ pip@@ ra@@ z@@ ole treatment .
137 Tell your doctor immediately if you suffer from muscle sti@@ ff@@ ness or inf@@ lexi@@ bility with high f@@ ever , swe@@ ating , alter@@ ed mental status , or very rapid or ir@@ regular heart beat .
Children and ad@@ ol@@ esc@@ ents AB@@ IL@@ IF@@ Y is not for use in children and ad@@ ol@@ esc@@ ents as it has not been studied in patients under 18 years .
Ask your doctor or ph@@ armac@@ ist for advice before taking AB@@ IL@@ IF@@ Y .
T@@ aking other medicines Please tell your doctor or ph@@ armac@@ ist if you are taking or have recently taken any other medicines , including medicines obtained without a pres@@ cription .
Blood pres@@ su@@ re-@@ lo@@ wering medicines :
AB@@ IL@@ IF@@ Y may increase the effect of medicines used to lower the blood pressure .
Be sure to tell your doctor if you take a medicine to keep your blood pressure under control .
T@@ aking AB@@ IL@@ IF@@ Y with some medicines may need to change your dose of AB@@ IL@@ IF@@ Y .
It is especially important to mention the following to your doctor :
Medic@@ ines to correct heart rhythm Anti@@ de@@ pres@@ s@@ ants or her@@ bal re@@ me@@ dy used to treat depression and an@@ xi@@ ety Anti@@ fung@@ al agents Cer@@ tain medicines to treat HIV infection Anti@@ conv@@ ul@@ s@@ ants used to treat ep@@ il@@ ep@@ sy
T@@ aking AB@@ IL@@ IF@@ Y with food and drink AB@@ IL@@ IF@@ Y can be taken regardless of meals .
Al@@ co@@ hol should be avoided when taking AB@@ IL@@ IF@@ Y .
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding You should not take AB@@ IL@@ IF@@ Y if you are pregnant unless you have discussed this with your doctor .
Be sure to tell your doctor immediately if you are pregnant , think you may be pregnant , or if you are planning to become pregnant .
Bre@@ ast@@ -@@ feeding mo@@ thers should not take AB@@ IL@@ IF@@ Y .
Be sure to tell your doctor immediately if you are bre@@ ast@@ -@@ feeding .
Dri@@ ving and using machines Do not drive or use any tools or machines , until you know how AB@@ IL@@ IF@@ Y affects you .
Important information about some of the ingredients of AB@@ IL@@ IF@@ Y If you have been told by your doctor that you have an int@@ oler@@ ance to some su@@ gar@@ s , contact your doctor before taking this medicine .
3 .
HO@@ W TO T@@ AK@@ E AB@@ IL@@ IF@@ Y
Always take AB@@ IL@@ IF@@ Y exactly as your doctor has told you .
You should check with your doctor or ph@@ armac@@ ist if you are not sure .
The usual dose is 15 mg once a day .
However your doctor may prescri@@ be a lower or higher dose to a maximum of 30 mg once a day .
If you have the impression that the effect of AB@@ IL@@ IF@@ Y is too strong or too weak , talk to your doctor or ph@@ armac@@ ist .
Try to take the AB@@ IL@@ IF@@ Y tablet at the same time each day .
It does not matter whether you take it with or without food .
Always take the tablet with water and swal@@ low it whole .
138 Even if you feel better , do not alter or dis@@ continue the daily dose of AB@@ IL@@ IF@@ Y without first consulting your doctor .
If you take more AB@@ IL@@ IF@@ Y than you should If you realise you have taken more AB@@ IL@@ IF@@ Y tablets than your doctor has recommended ( or if someone else has taken some of your AB@@ IL@@ IF@@ Y tablets ) , contact your doctor right away .
If you cannot reach your doctor , go to the nearest hospital and take the pack with you .
If you forget to take AB@@ IL@@ IF@@ Y If you miss a dose , take the missed dose as soon as you remember but do not take two d@@ oses in one day .
If you have any further questions on the use of this product , ask your doctor or ph@@ armac@@ ist .
4 .
PO@@ SS@@ IB@@ LE SI@@ DE EF@@ F@@ EC@@ TS
Like all medicines , AB@@ IL@@ IF@@ Y can cause side effects , although not everybody gets them .
Common side effects ( greater than 1 in 100 , less than 1 in 10 patients ) Un@@ contro@@ ll@@ able tw@@ it@@ ching or jer@@ king movements , head@@ ache , ti@@ red@@ ness , nau@@ sea , v@@ om@@ iting , an un@@ comfortable feeling in the stomach , con@@ sti@@ p@@ ation , increased production of s@@ ali@@ va , ligh@@ t-@@ he@@ ade@@ dness , trouble sleeping , rest@@ less@@ ness , feeling an@@ x@@ ious , sle@@ ep@@ iness , sh@@ aking and bl@@ urred vision .
Un@@ common side effects ( greater than 1 in 1,000 , less than 1 in 100 patients ) Some people may feel di@@ zz@@ y , especially when getting up from a lying or sitting position , or may experience a fast heart rate .
Some people may feel de@@ pressed .
Other inf@@ requ@@ ently reported side effects :
Changes in the levels of some blood cells ; unusual heart beat , sudden un@@ explained death , heart attack ; aller@@ gic reaction ( e. g. sw@@ elling in the mouth , tongue , face and thro@@ at , it@@ ching , r@@ ash ) ; high blood sugar , on@@ set or wor@@ sen@@ ing of diabetes , k@@ eto@@ aci@@ do@@ sis ( k@@ et@@ ones in the blood and ur@@ ine ) or com@@ a , low so@@ dium level in the blood ; weight gain , weight loss , an@@ or@@ ex@@ ia ; ner@@ v@@ ousness , ag@@ itation , feeling an@@ x@@ ious ; thoughts of suicide , suicide attempt and suicide ; speech dis@@ order , sei@@ z@@ ure , combination of f@@ ever , muscle sti@@ ff@@ ness , faster breath@@ ing , swe@@ ating , reduced consciousness and sudden changes in blood pressure and heart rate ; f@@ ain@@ ting , high blood pressure , block@@ age of a blood vessel by a blood c@@ lot formed elsewhere in the body ; sp@@ as@@ m of the muscles around the voice box , acci@@ dental inhal@@ ation of food with risk of pneum@@ onia , difficulty in swal@@ lowing ; infl@@ amm@@ ation of the pan@@ cre@@ as ; infl@@ amm@@ ation of the liver , y@@ el@@ lowing of the skin and white part of eyes , reports of ab@@ normal liver test values , ab@@ dom@@ inal and stomach dis@@ comfort , di@@ ar@@ r@@ ho@@ ea ; skin r@@ ash and sensitivity to light , unusual hair loss or th@@ inning , excessive swe@@ ating ; sti@@ ff@@ ness or cr@@ amps , muscle pain , weak@@ ness ; invol@@ untary loss of ur@@ ine , difficulty in passing ur@@ ine ; pro@@ long@@ ed and / or painful er@@ ection ; difficulty controlling core body temperature or over@@ heating , chest pain , and sw@@ elling of hands , an@@ kl@@ es or feet .
In elderly patients with de@@ men@@ tia , more fat@@ al cases have been reported while taking ari@@ pip@@ ra@@ z@@ ole .
In addition , cases of stroke or &quot; mini &quot; stroke have been reported .
If any of the side effects gets serious , or if you notice any side effects not listed in this le@@ af@@ let , please tell your doctor or ph@@ armac@@ ist .
5 .
HO@@ W TO ST@@ OR@@ E AB@@ IL@@ IF@@ Y
Keep out of the reach and sight of children .
Do not use AB@@ IL@@ IF@@ Y after the exp@@ iry date which is stated on the bli@@ ster and on the cart@@ on .
139 Store in the original package in order to protect from moisture .
Medic@@ ines should not be dispos@@ ed of via wast@@ e@@ water or household waste .
Ask your ph@@ armac@@ ist how to disp@@ ose of medicines no longer required .
These measures will help to protect the environment .
6 .
F@@ UR@@ TH@@ ER IN@@ FOR@@ M@@ ATION
What AB@@ IL@@ IF@@ Y contains The active substance is ari@@ pip@@ ra@@ z@@ ole .
Each tablet contains 5 mg of ari@@ pip@@ ra@@ z@@ ole .
The other ingredients are l@@ act@@ ose mon@@ oh@@ ydr@@ ate , ma@@ ize star@@ ch , micro@@ cryst@@ all@@ ine cell@@ ul@@ ose , hydro@@ xy@@ prop@@ yl cell@@ ul@@ ose , magn@@ esium st@@ ear@@ ate , in@@ dig@@ o car@@ mine aluminium lake ( E@@ 132 ) .
What AB@@ IL@@ IF@@ Y looks like and contents of the pack AB@@ IL@@ IF@@ Y 5 mg tablets are rect@@ angular and blue , marked with A-@@ 00@@ 7 and 5 on one side .
They are supplied in per@@ for@@ ated unit dose bli@@ sters packed in cart@@ ons containing 14 , 28 , 49 , 56 , or 98 tablets .
Not all pack sizes may be mark@@ eted .
Marketing Auth@@ or@@ isation Hol@@ der Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
Manufacturer Brist@@ ol@@ -@@ My@@ ers Squ@@ ib@@ b S. r. l .
Con@@ tra@@ da Font@@ ana del Cer@@ as@@ o I-@@ 0@@ 30@@ 12 An@@ ag@@ ni@@ -F@@ ros@@ in@@ one - Italy
For any information about this medicine , please contact the local representative of the Marketing Auth@@ or@@ isation Hol@@ der :
Belgi@@ que / Belgi@@ ë / Belgien BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B B@@ EL@@ GI@@ UM S. A. / N. V.
T@@ é@@ l / Tel : + 32 2 352 74 60
Luxembourg / Luxemburg BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B B@@ EL@@ GI@@ UM S. A. / N. V.
T@@ é@@ l / Tel : + 32 2 352 74 60
Б@@ ъ@@ л@@ г@@ а@@ р@@ и@@ я BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ MI K@@ FT .
Te@@ л . : + 35@@ 9 800 12 400
Mag@@ yar@@ or@@ sz@@ á@@ g BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ MI K@@ FT .
Tel . : + 36 1 30@@ 1 9@@ 700
Č esk@@ á republi@@ ka BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B SP@@ O@@ L .
S R. O.
Tel : + 420 2@@ 21 0@@ 16 111
Malta BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B S. R. L.
Tel : + 39 06 50 39 61
Dan@@ mark BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B T@@ l@@ f : + 45 45 93 05 06
Ne@@ der@@ land BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B B@@ V Tel : + 31 34 8@@ 57 42 22
Deutschland BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B GM@@ B@@ H &amp; CO .
K@@ G@@ AA Tel : + 49 89 121 4@@ 2-@@ 0
Nor@@ ge BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B N@@ OR@@ W@@ A@@ Y LT@@ D T@@ l@@ f : + 47 67 55 53 50
140 E@@ est@@ i Österreich BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ MI K@@ FT .
Tel : + 3@@ 72 6@@ 40 13@@ 01
BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B GES@@ MB@@ H Tel : + 43 1 60 14 30
Ε@@ λ@@ λ@@ ά@@ δ@@ α BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B A. E.
Τ@@ η@@ λ : + 30 210 60@@ 74@@ 300
Pol@@ ska BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B P@@ OL@@ SK@@ A SP .
Z O. O.
Tel . : + 48 22 57@@ 9@@ 66@@ 66
Españ@@ a BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B , S. A.
Tel : + 34 91 4@@ 56 53 00
Portugal BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B F@@ AR@@ M@@ AC@@ Ê@@ UT@@ ICA POR@@ TU@@ GU@@ ESA , S. A.
Tel : + 35@@ 1 21 4@@ 40 70 00
France BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B S@@ AR@@ L T@@ é@@ l : + 33 ( 0 ) 8@@ 10 4@@ 10 500
Rom@@ â@@ nia BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ MI K@@ FT .
Tel : + 40 ( 0 ) 21 27@@ 2 16 00
Ireland BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S LT@@ D Tel : + 35@@ 3 ( 1 800 ) 7@@ 49 7@@ 49
Sloven@@ i@@ ja BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B SP@@ O@@ L .
S R. O.
Tel : + 38@@ 6 1 23@@ 6 47 00
Í@@ s@@ land V@@ IS@@ TO@@ R HF S@@ í@@ mi : + 35@@ 4 5@@ 35 7@@ 000
Slov@@ ens@@ k@@ á republi@@ ka BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B SP@@ O@@ L .
S R. O.
Tel : + 4@@ 21 2 59@@ 29@@ 84@@ 11
Italia BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B S. R. L.
Tel : + 39 06 50 39 61
Su@@ om@@ i / Finland O@@ Y BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B ( FIN@@ LAN@@ D ) AB Pu@@ h / Tel : + 35@@ 8 9 25@@ 1 21 230
Κ@@ ύ@@ π@@ ρ@@ ο@@ ς Α@@ Κ@@ Η@@ Σ Π@@ Α@@ Ν@@ Α@@ Γ@@ Ι@@ Ω@@ Τ@@ Ο@@ Υ &amp; Υ@@ Ι@@ Ο@@ Σ Ε .@@ Π .@@ Ε@@ .
Τ@@ η@@ λ : + 35@@ 7 22 67@@ 70@@ 38
S@@ ver@@ ige BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B AB Tel : + 46 8 7@@ 04 71 00
Lat@@ vi@@ ja BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ MI K@@ FT .
Tel : + 3@@ 71 67 50 21 85
United Kingdom BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S LT@@ D Tel : + 44 ( 0@@ 800 ) 7@@ 31 17@@ 36
Li@@ et@@ u@@ va BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ MI K@@ FT .
Tel : + 3@@ 70 5 27@@ 90 7@@ 62
This le@@ af@@ let was last approved in
Detailed information on this medicine is available on the European Medic@@ ines Agency ( EM@@ EA ) web site : http : / / ww@@ w. em@@ e@@ a. europ@@ a. eu /
14@@ 1 P@@ ACK@@ AG@@ E LE@@ AF@@ LE@@ T :
IN@@ FOR@@ M@@ ATION FOR THE US@@ ER
AB@@ IL@@ IF@@ Y 10 mg tablets ari@@ pip@@ ra@@ z@@ ole
Read all of this le@@ af@@ let carefully before you start taking this medicine .
Keep this le@@ af@@ let .
You may need to read it again .
If you have any further questions , ask your doctor or ph@@ armac@@ ist .
This medicine has been prescri@@ bed for you .
Do not pass it on to others .
It may harm them , even if their symptoms are the same as your@@ s .
If any of the side effects gets serious , or if you notice any side effects not listed in this le@@ af@@ let , please tell your doctor or ph@@ armac@@ ist .
In this le@@ af@@ let :
1 .
What AB@@ IL@@ IF@@ Y is and what it is used for 2 .
Before you take AB@@ IL@@ IF@@ Y 3 .
How to take AB@@ IL@@ IF@@ Y 4 .
Pos@@ sible side effects 5 How to store AB@@ IL@@ IF@@ Y 6 .
Further information
1 .
WH@@ AT AB@@ IL@@ IF@@ Y IS AND WH@@ AT IT IS US@@ ED FOR
AB@@ IL@@ IF@@ Y is one of a group of medicines called anti@@ psycho@@ tics .
It is used to treat adults who suffer from a disease characterised by symptoms such as hearing , seeing or sen@@ sing things which are not there , susp@@ ici@@ ousness , mist@@ aken beliefs , in@@ coher@@ ent speech and behaviour and emotional fl@@ at@@ ness .
People with this condition may also feel de@@ pressed , guil@@ ty , an@@ x@@ ious or ten@@ se .
AB@@ IL@@ IF@@ Y is used to treat adults who suffer from a condition with symptoms such as feeling &quot; high &quot; , having excessive amounts of energy , ne@@ eding much less sleep than usual , talking very quickly with racing ideas and sometimes severe ir@@ rit@@ ability .
It also prevents this condition from returning in patients who have responded to the treatment with AB@@ IL@@ IF@@ Y .
2 .
B@@ EF@@ OR@@ E YO@@ U T@@ AK@@ E AB@@ IL@@ IF@@ Y
Do not take AB@@ IL@@ IF@@ Y if you are aller@@ gic ( hyper@@ sensitive ) to ari@@ pip@@ ra@@ z@@ ole or any of the other ingredients of AB@@ IL@@ IF@@ Y .
Take special care with AB@@ IL@@ IF@@ Y Before treatment with AB@@ IL@@ IF@@ Y , tell your doctor if you suffer from High blood sugar or family history of diabetes Sei@@ z@@ ure In@@ voluntary , ir@@ regular muscle movements , especially in the face Cardi@@ ov@@ as@@ cular diseases , family history of cardi@@ ov@@ as@@ cular disease , stroke or &quot; mini &quot; stroke , ab@@ normal blood pressure
If you notice you are gaining weight , experience any difficulty in swal@@ lowing or aller@@ gic symptoms , please tell your doctor .
If you are an elderly patient suffering from de@@ men@@ tia ( loss of memory and other mental abilities ) , you or your car@@ er / relative should tell your doctor if you have ever had a stroke or &quot; mini &quot; stroke .
Tell your doctor immediately if you are having any thoughts or feelings about hur@@ ting yourself .
Su@@ ic@@ id@@ al thoughts and behavi@@ ours have been reported during ari@@ pip@@ ra@@ z@@ ole treatment .
142 Tell your doctor immediately if you suffer from muscle sti@@ ff@@ ness or inf@@ lexi@@ bility with high f@@ ever , swe@@ ating , alter@@ ed mental status , or very rapid or ir@@ regular heart beat .
Children and ad@@ ol@@ esc@@ ents AB@@ IL@@ IF@@ Y is not for use in children and ad@@ ol@@ esc@@ ents as it has not been studied in patients under 18 years .
Ask your doctor or ph@@ armac@@ ist for advice before taking AB@@ IL@@ IF@@ Y .
T@@ aking other medicines Please tell your doctor or ph@@ armac@@ ist if you are taking or have recently taken any other medicines , including medicines obtained without a pres@@ cription .
Blood pres@@ su@@ re-@@ lo@@ wering medicines :
AB@@ IL@@ IF@@ Y may increase the effect of medicines used to lower the blood pressure .
Be sure to tell your doctor if you take a medicine to keep your blood pressure under control .
T@@ aking AB@@ IL@@ IF@@ Y with some medicines may need to change your dose of AB@@ IL@@ IF@@ Y .
It is especially important to mention the following to your doctor :
Medic@@ ines to correct heart rhythm Anti@@ de@@ pres@@ s@@ ants or her@@ bal re@@ me@@ dy used to treat depression and an@@ xi@@ ety Anti@@ fung@@ al agents Cer@@ tain medicines to treat HIV infection Anti@@ conv@@ ul@@ s@@ ants used to treat ep@@ il@@ ep@@ sy
T@@ aking AB@@ IL@@ IF@@ Y with food and drink AB@@ IL@@ IF@@ Y can be taken regardless of meals .
Al@@ co@@ hol should be avoided when taking AB@@ IL@@ IF@@ Y .
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding You should not take AB@@ IL@@ IF@@ Y if you are pregnant unless you have discussed this with your doctor .
Be sure to tell your doctor immediately if you are pregnant , think you may be pregnant , or if you are planning to become pregnant .
Bre@@ ast@@ -@@ feeding mo@@ thers should not take AB@@ IL@@ IF@@ Y .
Be sure to tell your doctor immediately if you are bre@@ ast@@ -@@ feeding .
Dri@@ ving and using machines Do not drive or use any tools or machines , until you know how AB@@ IL@@ IF@@ Y affects you .
Important information about some of the ingredients of AB@@ IL@@ IF@@ Y If you have been told by your doctor that you have an int@@ oler@@ ance to some su@@ gar@@ s , contact your doctor before taking this medicine .
3 .
HO@@ W TO T@@ AK@@ E AB@@ IL@@ IF@@ Y
Always take AB@@ IL@@ IF@@ Y exactly as your doctor has told you .
You should check with your doctor or ph@@ armac@@ ist if you are not sure .
The usual dose is 15 mg once a day .
However your doctor may prescri@@ be a lower or higher dose to a maximum of 30 mg once a day .
If you have the impression that the effect of AB@@ IL@@ IF@@ Y is too strong or too weak , talk to your doctor or ph@@ armac@@ ist .
Try to take the AB@@ IL@@ IF@@ Y tablet at the same time each day .
It does not matter whether you take it with or without food .
Always take the tablet with water and swal@@ low it whole .
14@@ 3 Even if you feel better , do not alter or dis@@ continue the daily dose of AB@@ IL@@ IF@@ Y without first consulting your doctor .
If you take more AB@@ IL@@ IF@@ Y than you should If you realise you have taken more AB@@ IL@@ IF@@ Y tablets than your doctor has recommended ( or if someone else has taken some of your AB@@ IL@@ IF@@ Y tablets ) , contact your doctor right away .
If you cannot reach your doctor , go to the nearest hospital and take the pack with you .
If you forget to take AB@@ IL@@ IF@@ Y If you miss a dose , take the missed dose as soon as you remember but do not take two d@@ oses in one day .
If you have any further questions on the use of this product , ask your doctor or ph@@ armac@@ ist .
4 .
PO@@ SS@@ IB@@ LE SI@@ DE EF@@ F@@ EC@@ TS
Like all medicines , AB@@ IL@@ IF@@ Y can cause side effects , although not everybody gets them .
Common side effects ( greater than 1 in 100 , less than 1 in 10 patients ) Un@@ contro@@ ll@@ able tw@@ it@@ ching or jer@@ king movements , head@@ ache , ti@@ red@@ ness , nau@@ sea , v@@ om@@ iting , an un@@ comfortable feeling in the stomach , con@@ sti@@ p@@ ation , increased production of s@@ ali@@ va , ligh@@ t-@@ he@@ ade@@ dness , trouble sleeping , rest@@ less@@ ness , feeling an@@ x@@ ious , sle@@ ep@@ iness , sh@@ aking and bl@@ urred vision .
Un@@ common side effects ( greater than 1 in 1,000 , less than 1 in 100 patients ) Some people may feel di@@ zz@@ y , especially when getting up from a lying or sitting position , or may experience a fast heart rate .
Some people may feel de@@ pressed .
Other inf@@ requ@@ ently reported side effects :
Changes in the levels of some blood cells ; unusual heart beat , sudden un@@ explained death , heart attack ; aller@@ gic reaction ( e. g. sw@@ elling in the mouth , tongue , face and thro@@ at , it@@ ching , r@@ ash ) ; high blood sugar , on@@ set or wor@@ sen@@ ing of diabetes , k@@ eto@@ aci@@ do@@ sis ( k@@ et@@ ones in the blood and ur@@ ine ) or com@@ a , low so@@ dium level in the blood ; weight gain , weight loss , an@@ or@@ ex@@ ia ; ner@@ v@@ ousness , ag@@ itation , feeling an@@ x@@ ious ; thoughts of suicide , suicide attempt and suicide ; speech dis@@ order , sei@@ z@@ ure , combination of f@@ ever , muscle sti@@ ff@@ ness , faster breath@@ ing , swe@@ ating , reduced consciousness and sudden changes in blood pressure and heart rate ; f@@ ain@@ ting , high blood pressure , block@@ age of a blood vessel by a blood c@@ lot formed elsewhere in the body ; sp@@ as@@ m of the muscles around the voice box , acci@@ dental inhal@@ ation of food with risk of pneum@@ onia , difficulty in swal@@ lowing ; infl@@ amm@@ ation of the pan@@ cre@@ as ; infl@@ amm@@ ation of the liver , y@@ el@@ lowing of the skin and white part of eyes , reports of ab@@ normal liver test values , ab@@ dom@@ inal and stomach dis@@ comfort , di@@ ar@@ r@@ ho@@ ea ; skin r@@ ash and sensitivity to light , unusual hair loss or th@@ inning , excessive swe@@ ating ; sti@@ ff@@ ness or cr@@ amps , muscle pain , weak@@ ness ; invol@@ untary loss of ur@@ ine , difficulty in passing ur@@ ine ; pro@@ long@@ ed and / or painful er@@ ection ; difficulty controlling core body temperature or over@@ heating , chest pain , and sw@@ elling of hands , an@@ kl@@ es or feet .
In elderly patients with de@@ men@@ tia , more fat@@ al cases have been reported while taking ari@@ pip@@ ra@@ z@@ ole .
In addition , cases of stroke or &quot; mini &quot; stroke have been reported .
If any of the side effects gets serious , or if you notice any side effects not listed in this le@@ af@@ let , please tell your doctor or ph@@ armac@@ ist .
5 .
HO@@ W TO ST@@ OR@@ E AB@@ IL@@ IF@@ Y
Keep out of the reach and sight of children .
Do not use AB@@ IL@@ IF@@ Y after the exp@@ iry date which is stated on the bli@@ ster and on the cart@@ on .
144 Store in the original package in order to protect from moisture .
Medic@@ ines should not be dispos@@ ed of via wast@@ e@@ water or household waste .
Ask your ph@@ armac@@ ist how to disp@@ ose of medicines no longer required .
These measures will help to protect the environment .
6 .
F@@ UR@@ TH@@ ER IN@@ FOR@@ M@@ ATION
What AB@@ IL@@ IF@@ Y contains The active substance is ari@@ pip@@ ra@@ z@@ ole .
Each tablet contains 10 mg of ari@@ pip@@ ra@@ z@@ ole .
The other ingredients are l@@ act@@ ose mon@@ oh@@ ydr@@ ate , ma@@ ize star@@ ch , micro@@ cryst@@ all@@ ine cell@@ ul@@ ose , hydro@@ xy@@ prop@@ yl cell@@ ul@@ ose , magn@@ esium st@@ ear@@ ate , red iron oxide ( E@@ 17@@ 2 ) .
What AB@@ IL@@ IF@@ Y looks like and contents of the pack AB@@ IL@@ IF@@ Y 10 mg tablets are rect@@ angular and pink , marked with A-@@ 00@@ 8 and 10 on one side .
They are supplied in per@@ for@@ ated unit dose bli@@ sters packed in cart@@ ons containing 14 , 28 , 49 , 56 , or 98 tablets .
Not all pack sizes may be mark@@ eted .
Marketing Auth@@ or@@ isation Hol@@ der Ot@@ su@@ ka Ph@@ armaceutical Europe Ltd .
Hun@@ ton House High@@ bridge Business Park , Oxford Road U@@ x@@ bridge - Mid@@ d@@ les@@ ex U@@ B@@ 8 1@@ H@@ U - United Kingdom
Manufacturer Brist@@ ol@@ -@@ My@@ ers Squ@@ ib@@ b S. r. l .
Con@@ tra@@ da Font@@ ana del Cer@@ as@@ o I-@@ 0@@ 30@@ 12 An@@ ag@@ ni@@ -F@@ ros@@ in@@ one - Italy
For any information about this medicine , please contact the local representative of the Marketing Auth@@ or@@ isation Hol@@ der :
Belgi@@ que / Belgi@@ ë / Belgien BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B B@@ EL@@ GI@@ UM S. A. / N. V.
T@@ é@@ l / Tel : + 32 2 352 74 60
Luxembourg / Luxemburg BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B B@@ EL@@ GI@@ UM S. A. / N. V.
T@@ é@@ l / Tel : + 32 2 352 74 60
Б@@ ъ@@ л@@ г@@ а@@ р@@ и@@ я BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ MI K@@ FT .
Te@@ л . : + 35@@ 9 800 12 400
Mag@@ yar@@ or@@ sz@@ á@@ g BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ MI K@@ FT .
Tel . : + 36 1 30@@ 1 9@@ 700
Č esk@@ á republi@@ ka BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B SP@@ O@@ L .
S R. O.
Tel : + 420 2@@ 21 0@@ 16 111
Malta BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B S. R. L.
Tel : + 39 06 50 39 61
Dan@@ mark BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B T@@ l@@ f : + 45 45 93 05 06
Ne@@ der@@ land BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B B@@ V Tel : + 31 34 8@@ 57 42 22
Deutschland BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B GM@@ B@@ H &amp; CO .
K@@ G@@ AA Tel : + 49 89 121 4@@ 2-@@ 0
Nor@@ ge BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B N@@ OR@@ W@@ A@@ Y LT@@ D T@@ l@@ f : + 47 67 55 53 50
145 E@@ est@@ i Österreich BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ MI K@@ FT .
Tel : + 3@@ 72 6@@ 40 13@@ 01
BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B GES@@ MB@@ H Tel : + 43 1 60 14 30
Ε@@ λ@@ λ@@ ά@@ δ@@ α BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B A. E.
Τ@@ η@@ λ : + 30 210 60@@ 74@@ 300
Pol@@ ska BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B P@@ OL@@ SK@@ A SP .
Z O. O.
Tel . : + 48 22 57@@ 9@@ 66@@ 66
Españ@@ a BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B , S. A.
Tel : + 34 91 4@@ 56 53 00
Portugal BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B F@@ AR@@ M@@ AC@@ Ê@@ UT@@ ICA POR@@ TU@@ GU@@ ESA , S. A.
Tel : + 35@@ 1 21 4@@ 40 70 00
France BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B S@@ AR@@ L T@@ é@@ l : + 33 ( 0 ) 8@@ 10 4@@ 10 500
Rom@@ â@@ nia BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ MI K@@ FT .
Tel : + 40 ( 0 ) 21 27@@ 2 16 00
Ireland BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S LT@@ D Tel : + 35@@ 3 ( 1 800 ) 7@@ 49 7@@ 49
Sloven@@ i@@ ja BR@@ IS@@ TO@@ L-@@ M@@ Y@@ ER@@ S SQ@@ U@@ IB@@ B SP@@ O@@ L .
S R. O.
Tel : + 38@@ 6 1 23@@ 6 47 00
